Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
fba7d30510659b049ef7201bd5022aa1e35f5c858ae96496aff631e6cc2d654e.png
complex
<table><tr><td>Key challenges</td><td>Solutions</td><td>Future implications</td></tr><tr><td colspan="3">1) Identification of centres willing/able to participate in the study</td></tr><tr><td>&#8226; Identifying centres with interest/capacity to participate in research and the correct people to discuss participation with proved difficult via conventional means (unsolicited mail/email).&#8226; Limitations in dedicating time or resources to external research projects due to clinical workloads and lack of designated support staff were common reasons for non-participation cited by centres. Levels of remuneration provided to centres for participation in the study were considered insufficient by some centres.&#8226; Availability of NHS staff participating in research having completed Good Clinical Practice (GCP) training.</td><td>&#8226; The ZQOL study was accepted into the National Institute for Health Research Clinical Research Network (NIHR CRN) portfolio. NIHR were able to offer wide range of support services including:o Access to existing networks of centres with interests in participating in research.o Provision of support to centres interesting in participating in research.o Exploring centre eligibility for additional remuneration for participation in NIHR CRN-approved studies.o Delivering GCP training to centres interesting in participating in studies.</td><td>&#8226; Experiences indicate the need for greater links between commissioners of research and primary/secondary care centres.&#8226; A refocusing of targets for primary care centres, to provide staff with opportunities and incentives for partaking in research is needed.&#8226; Current R&amp;D approval process makes no concessions for non-interventional research. R&amp;D requirements should be proportionate to the risks associated with patient participation in such studies.</td></tr><tr><td colspan="3">2) Obtaining Ethics and Research &amp; Development (R&amp;D) Management Approval</td></tr><tr><td>&#8226; Information and documentation required to support R&amp;D applications was a barrier to participation for a number of centres.&#8226; Significant variation in timelines for R&amp;D approval at a local and regional level (i.e. England, Scotland, Wales &amp; Northern Ireland) led to significant delays in the study.&#8226; R&amp;D approval process requires that extensive tri-partite agreements between the study sponsor, co-ordinating CRO and R&amp;D department be agreed and signed. However, there is no standard template available for such agreements.</td><td>&#8226; ZQOL study organisers implemented a number of practical solutions including:o Minimising the number of R&amp;D approvals by seeking participation of clusters of centres in the same NHS trust.o Implemented a staged study roll-out such that R&amp;D applications for key centres were prioritised and R&amp;D applications could occur in parallel to patient recruitment.&#8226; NIHR CRN can also provide assistance:o As a NIHR-CRN portfolio adopted study, more likely to be considered for priority review by R&amp;D depts.o NIHR CRN local research network teams are able to offer support and guidance to co-ordinating CROs throughout England.</td><td>&#8226; Current R&amp;D approval process makes no concessions for non-interventional research. R&amp;D requirements should be proportionate to the risks associated with patient participation in such studies.&#8226; A move to standardise R&amp;D approval process across NHS trusts in England would reduce burden (and barriers) to research for study organisers and NHS staff interested in participating in research.</td></tr><tr><td colspan="3">3) Recruitment of Study Participants</td></tr><tr><td>&#8226; Recruitment of HZ patients in primary care was slower than envisaged, a likely result of practical and organisational factors:o As an acute condition, HZ patients had to be recruited on initial presentation to physicians and did not allow searches of eligible participants via patient medical records.o At the time of the study there will only limited opportunities for notifications and reminders to be incorporated into electronic-record systems on presentation of incident cases.&#8226; Lack of unique identifiers or codes in electronic-record systems made it difficult to identify PHN patients for participation in the ZQOL study.</td><td>&#8226; To ensure that study recruitment quotas were met, additional centres were recruited for participation in the study and study timelines were extended.&#8226; NIHR CRN local research networks and the co-ordinating CRO were in regular contact with centre staff so to ensure to provide support where needed.</td><td>&#8226; Standardisation of medical record keeping and greater integration of record and monitoring systems would be to the benefit of facilitating real-world research.&#8226; Centres having systems in place to confirm the feasibility of recruitment numbers and having opportunity to work alongside study organisers could facilitate the development of study inclusion/exclusion criteria that are less restrictive to recruitment in real-world practice.</td></tr></table>
2f062a70b091f54d8289c9342e834672ce0a02b5026d812349e9692f38af4269.png
complex
<table><tr><td></td><td colspan="2">Overall survival</td><td colspan="2">Disease specific survival</td></tr><tr><td>Covariate</td><td>Hazard ratio (95% CI)</td><td>p value</td><td>Hazard ratio (95% CI)</td><td>p value</td></tr><tr><td>Age</td><td>0.99 (0.97-1.01)</td><td>0.26</td><td>0.99 (097&#8211;1.01)</td><td>0.16</td></tr><tr><td>Female gender</td><td>0.71 (0.42-1.20)</td><td>0.20</td><td>0.61 (0.34-1.11)</td><td>0.11</td></tr><tr><td>First Nations (vs Non)</td><td>4.20 (1.43-12.27</td><td>0.01</td><td>4.57 (1.31-15.92)</td><td>0.02</td></tr><tr><td>Smoking (vs non-smoker)</td><td>1.29 (0.65-2.58)</td><td>0.47</td><td>1.41 (0.65-3.10)</td><td>0.39</td></tr><tr><td>Alcohol use</td><td>0.65 (0.31-1.36)</td><td>0.25</td><td>0.63 (0.27-1.45)</td><td>0.27</td></tr><tr><td>Treatment</td><td></td><td></td><td></td><td></td></tr><tr><td>S + CRT (ref)</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>S + RT</td><td>0.72 (0.26-1.94)</td><td>0.51</td><td>0.76 (0.21-2.71)</td><td>0.67</td></tr><tr><td>CRT</td><td>2.01 (0.39-10.96)</td><td>0.39</td><td>1.94 (0.20-19.04)</td><td>0.57</td></tr><tr><td>RT</td><td>4.45 (1.22-16.31)</td><td>0.02</td><td>8.43 (1.89-37.63)</td><td>0.01</td></tr><tr><td>S</td><td>1.43 (0.42-4.91)</td><td>0.57</td><td>1.42 (0.65-3.11)</td><td>0.52</td></tr><tr><td>TNM stage advanced</td><td>1.34 (0.58-3.10)</td><td>0.49</td><td>0.98 (0.39-2.47)</td><td>0.97</td></tr></table>
88233c77798cc8510603047cb8479353891423e55041c112a400431bfdc51b0b.png
simple
<table><tr><td>Case</td><td>Case summary</td><td>Examination type</td><td>Performing department</td><td>Allegation</td></tr><tr><td>1</td><td>Middle-aged female presented with calf pain. Ultrasound study reported to be negative. Patient had fatal pulmonary embolism. (2012 WL 1100657 [Ohio App. 7 Dist])</td><td>DVT</td><td>Radiology</td><td>Failure to perform complete examination</td></tr><tr><td>2</td><td>Teen-aged female presented with calf pain, palpitations and pre-syncope. EKG and chest x-ray normal. Patient died of massive pulmonary embolism. (2012 WL 1605709 (La.App. 5 Cir.), 11&#8211;1006 [La.App. 5 Cir. 5/8/12])</td><td>DVT</td><td>Not performed</td><td>Failure to perform</td></tr><tr><td>3</td><td>Teen-aged boy presented after motor vehicle collision. No abdominal imaging was performed. Patient was discharged and died that night at home with liver laceration and hemoperitoneum. (721 S.E.2d 238)</td><td>FAST</td><td>Not performed</td><td>Failure to perform</td></tr><tr><td>4</td><td>Adult female presented with abdominal pain. Right upper quadrant ultrasound scheduled next day. Positive for cholecystitis. Alleged delay in diagnosis prolonging hospitalization and causing complications. (2009 WL 2473514)</td><td>RUQ</td><td>Radiology</td><td>Failure to perform in a timely manner</td></tr><tr><td>5</td><td>Adolescent male 8 days status post knee arthroscopy presented with chest pain. Diagnosed with pleurisy and discharged. Patient subsequently died of bilateral pulmonary emboli. (2012 WL 5910796)</td><td>DVT</td><td>Not performed</td><td>Failure to perform</td></tr></table>
21c082d40317d7c31ab868d2ed39bc74669ac2543c4a6f62c143de42796685f6.png
complex
<table><tr><td rowspan="2"><i>Variables</i></td><td><i>Utilization </i><i>(HP visits)</i></td><td> </td><td rowspan="2"><i>Crude OR </i><i>(95% </i><i>CI)</i></td><td rowspan="2"><i>Adjusted OR </i><i>(95% </i><i>CI)</i></td></tr><tr><td>Yes</td><td>No</td></tr><tr><td>Mothers&#8217; occupation</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Housewife</td><td>837</td><td>204</td><td>1.0</td><td>1.0</td></tr><tr><td>Farmers and others</td><td>197</td><td>80</td><td>0.600 (0.444, 0.811)</td><td>0.920 (0.494, 1.715)</td></tr><tr><td>Family Income</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>562 and below</td><td>228</td><td>103</td><td>1.0</td><td>1.0</td></tr><tr><td>563-760</td><td>253</td><td>77</td><td>1.484 (1.051, 2.096)</td><td>1.189 (0.774, 1.827)</td></tr><tr><td>761-960</td><td>277</td><td>76</td><td>1.647 (1.167, 2.323)</td><td>1.275 (0.817, 1.989)</td></tr><tr><td>961 and above</td><td>276</td><td>28</td><td>4.453 (2.831, 7.005)</td><td>3.867 (1.630, 5.040)*</td></tr><tr><td>Heard about HEP</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>51</td><td>56</td><td>1.0</td><td>1.0</td></tr><tr><td>Yes</td><td>983</td><td>228</td><td>4.734 (3.155, 7.104)</td><td>1.198 (.604, 2.377)</td></tr><tr><td>Understanding HEP</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>284</td><td>144</td><td>1.0</td><td>1.0</td></tr><tr><td>Yes</td><td>750</td><td>140</td><td>2.716 (2.074, 3.557)</td><td>1.573 (1.056, 2.343)**</td></tr><tr><td>Perception on quality of services in HP</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Bad</td><td>35</td><td>39</td><td>1.0</td><td>1.0</td></tr><tr><td>Good</td><td>999</td><td>245</td><td>4.544 (2.819, 7.323)</td><td>0.634 (0.356, 1.127)</td></tr><tr><td>Perception about the conduct of HEWs</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Bad</td><td>38</td><td>32</td><td>1.0</td><td>1.0</td></tr><tr><td>Good</td><td>996</td><td>252</td><td>3.328 (2.039, 5.434)</td><td>0.804 (0.455, 1.421)</td></tr><tr><td>Frequency of home visits</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No visits or less frequent visits</td><td>450</td><td>173</td><td>1.0</td><td>1.0</td></tr><tr><td>More frequent visits</td><td>584</td><td>111</td><td>2.023 (1.547, 2.645)</td><td>1.289 (1.028, 1.826)**</td></tr><tr><td>Household graduation status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Not graduated</td><td>203</td><td>109</td><td>1.0</td><td>1.0</td></tr><tr><td>1-2 years s</td><td>509</td><td>127</td><td>2.152 (1.589, 2.914)</td><td>1.310 (0.780, 1.830)</td></tr><tr><td>3 years</td><td>212</td><td>26</td><td>4.378 (2.739, 6.999)</td><td>2.150 (1.058, 4.365)**</td></tr><tr><td>4-5 years</td><td>110</td><td>22</td><td>2.685 (1.607, 4.487)</td><td>1.666 (0.736, 3.771)</td></tr></table>
ad36c9a628248746636c2e216e8dc3ad934ea7e5317eb4d920091cf7cd90edb1.png
complex
<table><tr><td rowspan="2">Group</td><td rowspan="2">n</td><td rowspan="2">Before Treatment</td><td rowspan="2">After Treatment</td><td colspan="2">Comparison</td></tr><tr><td>F</td><td>P</td></tr><tr><td>Moxibustion Group</td><td>15</td><td>28.27 &#177; 6.64</td><td>9.00 &#177; 4.05</td><td>417.009</td><td>&lt;0.001</td></tr><tr><td>Control Group</td><td>13</td><td>27.38 &#177; 3.95</td><td>21.46 &#177; 4.31</td><td>45.260</td><td>&lt;0.001</td></tr><tr><td>Total Amount</td><td>28</td><td>27.86 &#177; 27.86</td><td>14.79 &#177; 7.54</td><td>373.207</td><td>&lt;0.001</td></tr><tr><td>Comparison between groups</td><td>F</td><td>0.175</td><td>62.040</td><td></td><td></td></tr><tr><td></td><td>P</td><td>0.679</td><td>&lt;0.001</td><td></td><td></td></tr></table>
6e4d63941c5fe1e762d05074a65b4b99174b48537c4e14c22a7b834d4fa064fd.png
simple
<table><tr><td></td><td>ARDS patients</td><td>Age- and sex-matched reference values</td><td><i>P</i> value</td></tr><tr><td></td><td>Mean (SD)</td><td>Mean (SD)</td><td></td></tr><tr><td>EQ5D index at 6 months</td><td></td><td></td><td></td></tr><tr><td>Patients under 65</td><td>0.55 (0.37)</td><td>0.85 (0.06)</td><td>&lt;0.001</td></tr><tr><td>Patients 65 and above</td><td>0.62 (0.37)</td><td>0.77 (0.02)</td><td>0.003</td></tr><tr><td>EQ5D at 12 months</td><td></td><td></td><td></td></tr><tr><td>Patients under 65</td><td>0.58 (0.35)</td><td>0.85 (0.06)</td><td>&lt;0.001</td></tr><tr><td>Patients 65 and above</td><td>0.58 (0.38)</td><td>0.77 (0.02)</td><td>&lt;0.001</td></tr></table>
b7c693bc89e255d2cb78e3c21e094a45cb7a3a2e0539aea940185027054294e0.png
complex
<table><tr><td></td><td>Total sample</td><td>Respondents</td><td>Non-respondents</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>N</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>P-value*</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Male</i></td><td>48 910</td><td>48.9</td><td>23 240</td><td>46.8</td><td>23 407</td><td>51.4</td><td rowspan="2">&lt;0.001</td></tr><tr><td><i>Female</i></td><td>51 090</td><td>51.1</td><td>26 466</td><td>53.2</td><td>22 140</td><td>48.6</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>20</i>&#8211;<i>39</i></td><td>27 706</td><td>27.7</td><td>12 251</td><td>24.6</td><td>15 455</td><td>30.7</td><td rowspan="4">&lt;0.001</td></tr><tr><td><i>40</i>&#8211;<i>59</i></td><td>37 106</td><td>37.1</td><td>20 305</td><td>40.9</td><td>16 801</td><td>33.4</td></tr><tr><td><i>60</i>&#8211;<i>79</i></td><td>28 868</td><td>28.9</td><td>15 748</td><td>31.7</td><td>13 120</td><td>26.1</td></tr><tr><td><i>80-</i></td><td>6 320</td><td>6.3</td><td>1 402</td><td>2.8</td><td>4 918</td><td>9.8</td></tr><tr><td>Marital status<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Single</i></td><td>31 140</td><td>32.8</td><td>12 475</td><td>25.1</td><td>18 665</td><td>41.2</td><td rowspan="2">&lt;0.001</td></tr><tr><td><i>Married/living together</i></td><td>63 807</td><td>67.2</td><td>37 140</td><td>74.9</td><td>26 667</td><td>58.8</td></tr><tr><td>Educational level<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Low</i></td><td>24 770</td><td>27.2</td><td>9 540</td><td>19.7</td><td>15 230</td><td>35.6</td><td rowspan="3">&lt;0.001</td></tr><tr><td><i>Medium</i></td><td>40 659</td><td>44.6</td><td>22 155</td><td>45.8</td><td>18 504</td><td>43.3</td></tr><tr><td><i>High</i></td><td>25 752</td><td>28.2</td><td>16 724</td><td>34.5</td><td>9 028</td><td>21.1</td></tr><tr><td>Income level<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Low</i></td><td>22 440</td><td>23.6</td><td>8 072</td><td>16.3</td><td>14 368</td><td>31.7</td><td rowspan="3">&lt;0.001</td></tr><tr><td><i>Medium</i></td><td>48 126</td><td>50.7</td><td>25 712</td><td>41.8</td><td>22 414</td><td>49.4</td></tr><tr><td><i>High</i></td><td>24 382</td><td>25.7</td><td>24 382</td><td>31.9</td><td>8 551</td><td>18.9</td></tr><tr><td>Employment status<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Workning</i></td><td>59 961</td><td>63.1</td><td>33 961</td><td>68.4</td><td>26 000</td><td>57.3</td><td rowspan="3">&lt;0.001</td></tr><tr><td><i>Pensioners</i></td><td>23 193</td><td>24.4</td><td>11 294</td><td>22.7</td><td>11 899</td><td>26.2</td></tr><tr><td><i>Out of workforce</i></td><td>11 911</td><td>12.5</td><td>4 410</td><td>8.9</td><td>7 501</td><td>16.5</td></tr><tr><td>Ethnic groups<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Danish</i></td><td>86 248</td><td>90.8</td><td>46 543</td><td>93.8</td><td>39 705</td><td>87.6</td><td rowspan="3">&lt;0.001</td></tr><tr><td><i>Immigrants</i></td><td>8 038</td><td>8.5</td><td>2 858</td><td>5.8</td><td>5 180</td><td>11.4</td></tr><tr><td><i>Descendants of Immigrants</i></td><td>661</td><td>0.7</td><td>214</td><td>0.4</td><td>447</td><td>1.0</td></tr><tr><td>GP contacts<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Average contacts to GP in 2011</i></td><td>8.1</td><td></td><td>7.6</td><td></td><td>8.5</td><td></td><td>&lt;0.001</td></tr></table>
fdabdf00e092e1980317bede17509cca0a127932486e4bbd8d7acbe26289a399.png
simple
<table><tr><td>Variable</td><td>25th percentile</td><td>50th percentile</td><td>75th percentile</td><td>Standard deviation</td></tr><tr><td>GC</td><td>0.298</td><td>0.318</td><td>0.353</td><td>0.041</td></tr><tr><td>RHI</td><td>0.218</td><td>0.233</td><td>0.260</td><td>0.033</td></tr><tr><td>80/20 ratio</td><td>5.550</td><td>6.570</td><td>8.155</td><td>1.965</td></tr><tr><td>All-cause mortality rate (/100,000)</td><td>378.5</td><td>416.3</td><td>441.7</td><td>48.8</td></tr><tr><td>Community population</td><td>165,980.8</td><td>280,277.0</td><td>363,011.0</td><td>143,540.9</td></tr><tr><td>Percent of over 65 years in community population (%)</td><td>8.9</td><td>10.8</td><td>13.8</td><td>4.1</td></tr><tr><td>Ratio of social welfare expenditure (%)</td><td>23.9</td><td>30.9</td><td>44.6</td><td>12.2</td></tr><tr><td>Number of physicians (/1,000)</td><td>1.6</td><td>2.0</td><td>2.8</td><td>2.5</td></tr><tr><td>Smoking rate (%)</td><td>22.0</td><td>24.0</td><td>25.0</td><td>2.7</td></tr><tr><td>Drinking rate (%)</td><td>56.0</td><td>59.0</td><td>61.0</td><td>4.9</td></tr></table>
13a463b899d6457181b9a2fe30fe807b339e0c7b62c5a4838624e8422f4e676f.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">2016</td><td colspan="4">2017</td><td colspan="4">2018</td><td colspan="4">2019</td></tr><tr><td>Q2</td><td>Q3</td><td>Q4</td><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td></tr><tr><td>Protocol development</td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Training of research coordinators and physicians</td><td>X</td><td></td><td>X</td><td>X</td><td></td><td></td><td></td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Training of nurses for motivational counseling (yearly refresher training)</td><td></td><td>X</td><td></td><td></td><td>X</td><td></td><td></td><td></td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Obtaining informed consent, recruitment, and baseline interview</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Auditing and site visit monitoring (every 2 weeks)</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Trial supervision</td><td></td><td></td><td>X</td><td></td><td></td><td></td><td>X</td><td></td><td></td><td></td><td>X</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Monthly Trial Management Committee meeting</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Telephone follow-up by nurses (monthly until 3 months and then every 3 months)</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Follow-up by clinical research coordinators (every 4 months by telephone; annually on site)</td><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Data Safety and Monitoring Board meeting (every 6 months)</td><td></td><td>X</td><td></td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td></tr><tr><td>Trial Steering Committee Meeting (every 6 months)</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Quality assessment</td><td></td><td></td><td>X</td><td></td><td></td><td>X</td><td></td><td></td><td>X</td><td></td><td></td><td>X</td><td></td><td></td><td>X</td></tr><tr><td>Progress or interim report</td><td></td><td></td><td></td><td></td><td></td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Data analysis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Manuscript writing</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Final report</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>X</td><td>X</td></tr></table>
ececf72ab574ef6b8c69da349f8dffb2de47d7e5d157e748bc929d5f21705847.png
complex
<table><tr><td rowspan="2"> </td><td colspan="2">I</td><td colspan="2">II</td><td rowspan="2">% change</td><td rowspan="2">Cohen's <i>d</i></td></tr><tr><td>Mean &#177; SD</td><td>(95% CI)</td><td>Mean &#177; SD</td><td>(95% CI)</td></tr><tr><td><i>Lower body WAnT</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Maximal power (W)</td><td>722 &#177; 113<sup>&#8743;</sup></td><td>657&#8211;788</td><td>751 &#177; 124<sup><i>&#8727;</i>&#8743;</sup></td><td>679&#8211;822</td><td>4.0</td><td>0.24</td></tr><tr><td> Mean power (W)</td><td>562 &#177; 73<sup>&#8743;</sup></td><td>520&#8211;605</td><td>577 &#177; 80<sup>&#8743;</sup></td><td>531&#8211;624</td><td>2,7</td><td>0.19</td></tr><tr><td> Relative peak power (W/kg)</td><td>10.6 &#177; 0.8<sup>&#8743;</sup></td><td>10.1&#8211;11.1</td><td>11.0 &#177; 1.0<sup><i>&#8727;</i></sup></td><td>10.4&#8211;11.5</td><td>3.8</td><td>0.44</td></tr><tr><td> Relative mean power (W/kg)</td><td>8.2 &#177; 0.5<sup>&#8743;</sup></td><td>8.0&#8211;8.5</td><td>8.4 &#177; 0.5<sup>&#8743;</sup></td><td>8.2&#8211;8.7</td><td>2.4</td><td>0.40</td></tr><tr><td>Fatigue index (%)</td><td>25.6 &#177; 6.5</td><td>21.8&#8211;29.4</td><td>26.2 &#177; 5.9</td><td>22.8&#8211;29.6</td><td>2.3</td><td>0.09</td></tr><tr><td><i>Upper body WAnT</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Maximal power (W)</td><td>575 &#177; 123</td><td>504&#8211;647</td><td>586 &#177; 120</td><td>517&#8211;656</td><td>1.9</td><td>0.09</td></tr><tr><td> Mean Power (W)</td><td>444 &#177; 84</td><td>395&#8211;493</td><td>464 &#177; 86<sup>&#8224;</sup></td><td>414&#8211;513</td><td>4.5</td><td>0.23</td></tr><tr><td> Relative peak power (W/kg)</td><td>8.4 &#177; 1.3</td><td>7.7&#8211;9.2</td><td>8.6 &#177; 1.3</td><td>7.8&#8211;9.2</td><td>2.4</td><td>0.15</td></tr><tr><td> Relative mean power (W/kg)</td><td>6.5 &#177; 0.8</td><td>6.0&#8211;7.0</td><td>6.8 &#177; 0.9<sup>&#8224;</sup></td><td>6.2&#8211;7.3</td><td>4.6</td><td>0.35</td></tr><tr><td>Fatigue index (%)</td><td>27.7 &#177; 6.0</td><td>24.2&#8211;31.1</td><td>24.2 &#177; 5.7<sup><i>&#8727;</i></sup></td><td>20.9&#8211;27.5</td><td>&#8722;12.6</td><td>0.59</td></tr></table>
ffd6f5f4203f7bba6d6912252207d2e528889662c181d07b7b0164f138b75bbf.png
simple
<table><tr><td>Trait</td><td>OR (95% CI)</td><td><i>p</i></td></tr><tr><td>Total serum IgE</td><td>1.60 (1.24, 2.07)</td><td>&lt; 0.0001</td></tr><tr><td>Atopy</td><td>3.09 (1.39, 6.87)</td><td>0.006</td></tr><tr><td>Food allergen test positive</td><td>2.04 (0.99, 4.20)</td><td>0.053</td></tr><tr><td>Eosinophilia</td><td>3.56 (1.30, 9.73)</td><td>0.013</td></tr></table>
6b5ca4b9f6f7ed514611ee1b109381980fec7a327b66022651e0844a97392163.png
complex
<table><tr><td></td><td colspan="4">Controls</td><td colspan="4">Patients</td></tr><tr><td></td><td>Scene</td><td>Object</td><td>Face</td><td>Total</td><td>Scene</td><td>Object</td><td>Face</td><td>Total</td></tr><tr><td colspan="9">(A) MEAN ERROR RATE (PERCENTAGE ERROR)</td></tr><tr><td>Color</td><td>0.67</td><td>0.50</td><td>1.33</td><td>0.83</td><td>9.10</td><td>5.38</td><td>12.05</td><td>8.85</td></tr><tr><td>Grayscale</td><td>1.00</td><td>0.50</td><td>1.67</td><td>1.06</td><td>10.51</td><td>6.79</td><td>16.28</td><td>11.20</td></tr><tr><td>Total</td><td>0.83</td><td>0.50</td><td>1.50</td><td>0.94</td><td>9.81</td><td>6.09</td><td>14.17</td><td>10.02</td></tr><tr><td colspan="9">(B) HARMONIC MEAN RESPONSE TIMES (s)</td></tr><tr><td>Color</td><td>1.03</td><td>0.97</td><td>1.03</td><td>1.01</td><td>1.90</td><td>1.73</td><td>1.62</td><td>1.75</td></tr><tr><td>Grayscale</td><td>1.00</td><td>0.94</td><td>0.98</td><td>0.97</td><td>1.99</td><td>1.69</td><td>1.57</td><td>1.75</td></tr><tr><td>Total</td><td>1.01</td><td>0.95</td><td>1.01</td><td>0.99</td><td>1.94</td><td>1.71</td><td>1.59</td><td>1.75</td></tr></table>
4b7201a730a2f78c8694e25eba1877f025887cebabb3dd56e104f52b6ac3b8a5.png
simple
<table><tr><td>Diets</td><td>Intestine</td><td>Liver</td><td>Muscle</td><td>Brain</td></tr><tr><td>HD</td><td></td><td></td><td></td><td></td></tr><tr><td>LD</td><td></td><td></td><td></td><td><i>fabp7b</i></td></tr><tr><td>LND</td><td><i>fabp1b.1, fabp7b</i></td><td></td><td><i>fabp7a</i></td><td></td></tr><tr><td>LFD</td><td></td><td><i>fabp7a</i></td><td><i>fabp11a</i></td><td></td></tr></table>
555b9a4e8fbebe678bf40c222641488063ab1ba992a52de233d9e51ecb007b6d.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>OR</td><td>95% CI for OR</td><td><i>p</i></td><td>OR</td><td>95% CI for OR</td><td><i>P</i></td></tr><tr><td colspan="7">Total cholesterol: high (<i>n</i> = 93) vs normal (<i>n</i> = 178)</td></tr><tr><td> Overweight/obese at study entry</td><td>1.760</td><td>1.032&#8211;3.003</td><td>0.0379</td><td>1.764</td><td>1.013&#8211;3.073</td><td>0.0451</td></tr><tr><td> Age at study entry</td><td>2.101</td><td>1.467&#8211;3.010</td><td>&lt;0.0001</td><td>2.093</td><td>1.461&#8211;2.997</td><td>&lt;0.0001</td></tr><tr><td>&#8804; 40</td><td>1</td><td>-</td><td></td><td></td><td></td><td rowspan="4"></td></tr><tr><td>41&#8211;45</td><td>1.490</td><td>0.494&#8211;4.489</td><td>0.4789</td><td></td><td></td></tr><tr><td>46&#8211;50</td><td>3.838</td><td>1.397&#8211;10.548</td><td>0.0091</td><td></td><td></td></tr><tr><td>&gt; 50</td><td>7.020</td><td>1.989&#8211;24.772</td><td>0.0025</td><td></td><td></td></tr><tr><td colspan="7">LDL cholesterol: high (<i>n</i> = 152) vs normal (<i>n</i> = 115)</td></tr><tr><td> Received corticosteroid premedication during chemotherapy</td><td>7.576</td><td>1.724&#8211;33.33</td><td>0.0074</td><td>5.747</td><td>1.264&#8211;26.32</td><td>0.0236</td></tr><tr><td> Received adjuvant tamoxifen</td><td>0.388</td><td>0.209&#8211;0.720</td><td>0.0027</td><td>0.342</td><td>0.179&#8211;0.656</td><td>0.0012</td></tr><tr><td> Overweight/obese at study entry</td><td>2.468</td><td>1.407&#8211;4.330</td><td>0.0016</td><td>2.560</td><td>1.410&#8211;4.649</td><td>0.0020</td></tr><tr><td> Age at study entry</td><td>1.626</td><td>1.192&#8211;2.217</td><td>0.0021</td><td>1.625</td><td>1.165&#8211;2.266</td><td>0.0042</td></tr><tr><td>&#8804; 40</td><td>1</td><td>-</td><td></td><td></td><td></td><td rowspan="4"></td></tr><tr><td>41&#8211;45</td><td>0.963</td><td>0.420&#8211;2.212</td><td>0.9298</td><td></td><td></td></tr><tr><td>46&#8211;50</td><td>1.763</td><td>0.813&#8211;3.823</td><td>0.1510</td><td></td><td></td></tr><tr><td>&gt; 50</td><td>5.383</td><td>1.493&#8211;19.407</td><td>0.0101</td><td></td><td></td></tr><tr><td colspan="7">HDL cholesterol: low (<i>n</i> = 18) vs. normal (<i>n</i> = 251)</td></tr><tr><td> Ever smoker</td><td>4.357</td><td>0.836&#8211;22.707</td><td>0.0806</td><td>7.772</td><td>1.102&#8211;54.827</td><td>0.0397</td></tr><tr><td> Post/peri- menopausal at study entry</td><td>3.881</td><td>1.243&#8211;12.114</td><td>0.0196</td><td>3.629</td><td>1.144&#8211;11.509</td><td>0.0286</td></tr><tr><td> Overweight/obese at study entry</td><td>8.193</td><td>1.845&#8211;36.372</td><td>0.0057</td><td>7.786</td><td>1.742&#8211;34.795</td><td>0.0072</td></tr><tr><td colspan="7">Triglyceride: high (<i>n</i> = 62) vs. normal (<i>n</i> = 209)</td></tr><tr><td> Adjuvant taxane-containing chemotherapy</td><td>2.040</td><td>1.124&#8211;3.704</td><td>0.0192</td><td>2.552</td><td>1.317&#8211;4.944</td><td>0.0055</td></tr><tr><td> Weight gain &gt;2%</td><td>2.258</td><td>1.171&#8211;4.355</td><td>0.0150</td><td>2.213</td><td>1.084&#8211;4.517</td><td>0.0292</td></tr><tr><td> Overweight/obese at study entry</td><td>2.306</td><td>1.282&#8211;4.149</td><td>0.0053</td><td>2.775</td><td>1.446&#8211;5.325</td><td>0.0021</td></tr><tr><td> Age at study entry</td><td>1.641</td><td>1.118&#8211;2.410</td><td>0.0114</td><td>1.969</td><td>1.285&#8211;3.017</td><td>0.0019</td></tr><tr><td>&#8804; 40</td><td>1</td><td>-</td><td></td><td></td><td></td><td rowspan="4"></td></tr><tr><td>41&#8211;45</td><td>1.355</td><td>0.401&#8211;4.573</td><td>0.6246</td><td></td><td></td></tr><tr><td>46&#8211;50</td><td>2.558</td><td>0.842&#8211;7.773</td><td>0.0978</td><td></td><td></td></tr><tr><td>&gt; 50</td><td>3.733</td><td>0.964&#8211;14.461</td><td>0.0566</td><td></td><td></td></tr></table>
3e362cd09d5bf9c1a6324d80a428c86507afaeeeef86bfd05a25cb8fd216c77a.png
complex
<table><tr><td> </td><td colspan="3">Midwives</td><td colspan="3">Child health nurses</td><td colspan="3">Dental hygienists/dental nurses</td></tr><tr><td> </td><td colspan="2">Raising the topic with more than half or all pregnant women (%)</td><td>Wilcoxon Signed Rank Test</td><td colspan="2">Raising the topic with more than half or all parents (%)</td><td>Wilcoxon Signed Rank Test</td><td colspan="2">Raising the topic with more than half or all clients (%)</td><td>Wilcoxon Signed Rank Test</td></tr><tr><td>Topic</td><td>Pre</td><td>Post</td><td>p-value</td><td>Pre</td><td>Post</td><td>p-value</td><td>Pre</td><td>Post</td><td>p-value</td></tr><tr><td>Psychosocial health</td><td>73</td><td>86</td><td>.048</td><td>47</td><td>64</td><td>.053</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Men&#8217;s violence against women/children</td><td>59</td><td>82</td><td>.010</td><td>11</td><td>36</td><td>.000</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Tobacco</td><td>91</td><td>96</td><td>.581</td><td>72</td><td>89</td><td>.059</td><td>79</td><td>84</td><td>.690</td></tr><tr><td>Alcohol</td><td>91</td><td>96</td><td>.414</td><td>64</td><td>81</td><td>.109</td><td>0</td><td>21</td><td>.026</td></tr><tr><td>Drugs</td><td>91</td><td>82</td><td>.269</td><td>19</td><td>36</td><td>.004</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Weight/BMI</td><td>76</td><td>86</td><td>.107</td><td>11</td><td>13</td><td>.169</td><td>5</td><td>26</td><td>.006</td></tr><tr><td>Discretionary foods</td><td>59</td><td>41</td><td>.790</td><td>23</td><td>43</td><td>.005</td><td>47</td><td>100</td><td>.001</td></tr><tr><td>Regular meals</td><td>59</td><td>46</td><td>.941</td><td>34</td><td>55</td><td>.035</td><td>53</td><td>100</td><td>.001</td></tr><tr><td>Beverage intake</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>63</td><td>100</td><td>.000</td></tr><tr><td>5 fruits and vegetables a day</td><td>67</td><td>82</td><td>.191</td><td>21</td><td>53</td><td>.000</td><td>32</td><td>100</td><td>.000</td></tr><tr><td>30 min daily physical activity</td><td>59</td><td>68</td><td>.129</td><td>11</td><td>36</td><td>.000</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Parenthood/parent relationships</td><td>77</td><td>77</td><td>.623</td><td>64</td><td>83</td><td>.107</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Tooth brushing/dental health (child)</td><td>-</td><td>-</td><td>-</td><td>55</td><td>89</td><td>.001</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Weight/BMI (child)</td><td>-</td><td>-</td><td>-</td><td>77</td><td>81</td><td>.805</td><td>-</td><td>-</td><td>-</td></tr><tr><td>5 fruits and vegetables a day (child)</td><td>-</td><td>-</td><td>-</td><td>45</td><td>66</td><td>.002</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Regular meals (child)</td><td>-</td><td>-</td><td>-</td><td>83</td><td>85</td><td>.907</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Discretionary foods (child)</td><td>-</td><td>-</td><td>-</td><td>55</td><td>68</td><td>.026</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Physical activity (child)</td><td>-</td><td>-</td><td>-</td><td>72</td><td>87</td><td>.068</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Psychosocial health (child)</td><td>-</td><td>-</td><td>-</td><td>79</td><td>87</td><td>.337</td><td>-</td><td>-</td><td>-</td></tr></table>
a97ccb600637da16d04470e93201dc4c3c39a2057b8ced35371318540372849c.png
complex
<table><tr><td rowspan="2">Characteristics</td><td rowspan="2">No. patients(%)</td><td colspan="2">ZC3H15 immunoreactivity*</td><td rowspan="2">P value</td></tr><tr><td>High</td><td>Low</td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td>230(88.12)</td><td>125</td><td>105</td><td>0.1017</td></tr><tr><td> Female</td><td>31(11.88)</td><td>12</td><td>19</td><td></td></tr><tr><td colspan="5">Age (yrs)</td></tr><tr><td> &lt;40</td><td>38(14.55)</td><td>20</td><td>18</td><td>0.6719</td></tr><tr><td> 40-60</td><td>166(63.60)</td><td>90</td><td>76</td><td></td></tr><tr><td> &gt;60</td><td>57(21.84)</td><td>27</td><td>30</td><td></td></tr><tr><td colspan="5">AFP</td></tr><tr><td> &#8804;20 (ng/mL)</td><td>98(37.69)</td><td>41</td><td>57</td><td>0.0064</td></tr><tr><td> &gt;20</td><td>163(62.31)</td><td>97</td><td>66</td><td></td></tr><tr><td colspan="5">HBV</td></tr><tr><td> Negative</td><td>33(12.64)</td><td>14</td><td>19</td><td>0.2154</td></tr><tr><td> Positive</td><td>228(87.36)</td><td>123</td><td>105</td><td></td></tr><tr><td colspan="5">Histological grading</td></tr><tr><td> Well</td><td>1(0.36)</td><td>0</td><td>1</td><td>0.0705</td></tr><tr><td> Moderate</td><td>25(10.51)</td><td>8</td><td>17</td><td></td></tr><tr><td> Poorly</td><td>234(88.77)</td><td>129</td><td>105</td><td></td></tr><tr><td colspan="5">Largest tumor size</td></tr><tr><td> &lt;3cm</td><td>70(26.82)</td><td>39</td><td>31</td><td>0.6355</td></tr><tr><td> 3-10cm</td><td>152(58.24)</td><td>76</td><td>76</td><td></td></tr><tr><td> &gt;10cm</td><td>39(14.94)</td><td>22</td><td>17</td><td></td></tr><tr><td colspan="5">Presence of satellite nodules</td></tr><tr><td> Negative</td><td>73(27.97)</td><td>33</td><td>40</td><td>0.1419</td></tr><tr><td> Positive</td><td>188(72.03)</td><td>104</td><td>84</td><td></td></tr><tr><td colspan="5">Vascular invasion</td></tr><tr><td> Negative</td><td>109(41.76)</td><td>46</td><td>63</td><td>0.0049</td></tr><tr><td> Positive</td><td>152(58.23)</td><td>91</td><td>61</td><td></td></tr><tr><td colspan="5">HbeAg</td></tr><tr><td> Negative</td><td>202(77.39)</td><td>102</td><td>100</td><td>0.2323</td></tr><tr><td> Positive</td><td>59(22.61)</td><td>35</td><td>24</td><td></td></tr><tr><td colspan="5">Tumorous number</td></tr><tr><td> 1</td><td>208(79.69)</td><td>108</td><td>100</td><td>0.7162</td></tr><tr><td> &gt;=2</td><td>53(20.30)</td><td>29</td><td>24</td><td></td></tr><tr><td colspan="5">Child-Pugh Classification</td></tr><tr><td> Child-A</td><td>237(90.80)</td><td>123</td><td>114</td><td>0.5542</td></tr><tr><td> Child-B</td><td>24(9.20)</td><td>11</td><td>13</td><td></td></tr><tr><td colspan="5">UICC stage</td></tr><tr><td> I+II</td><td>204(78.16)</td><td>106</td><td>98</td><td>0.7458</td></tr><tr><td> III+IV</td><td>57(21.84)</td><td>31</td><td>26</td><td></td></tr></table>
15ab7187da7b3cecdf245a36453c5258fe26bfb6f048f8a6acdb7ece3b63d90e.png
simple
<table><tr><td></td><td>Severe (<i>n</i> = 12)</td><td>Mild (<i>n</i> = 5)</td><td></td></tr><tr><td>Birth Weight (g)</td><td>2500(2400&#8211;3000)<sup>a</sup></td><td>3100 (3000&#8211;3600)</td><td><i>p</i> = 0.04</td></tr><tr><td>Day of illness at hospital presentation</td><td>2.5 (2&#8211;3.5)</td><td>5 (5&#8211;5)</td><td>p = 0.02</td></tr><tr><td>Incubation period (days)</td><td>7 (7&#8211;10)</td><td>6 (5&#8211;7)</td><td>p = 0.04</td></tr></table>
120d18f7d340e1719d202f0152263fa72e8cf64cfde12d60840ce096335923b7.png
complex
<table><tr><td rowspan="2">HLA alleles</td><td rowspan="2">Risk allele (RA)</td><td colspan="3">Risk allele frequency</td><td rowspan="2"><i>P</i>-value</td><td rowspan="2">OR</td><td rowspan="2">CD groups</td></tr><tr><td>Indian</td><td>African</td><td>European</td></tr><tr><td rowspan="2">HLA-DQ2.2 (rs2395182)</td><td rowspan="2">T</td><td rowspan="2">0.83</td><td rowspan="2">0.73</td><td rowspan="2">0.76</td><td>1.06 &#215; 10<sup>&#8722;5</sup></td><td>2.72 [1.74&#8211;4.25]</td><td>Pediatric</td></tr><tr><td>6.26 &#215; 10<sup>&#8722;5</sup></td><td>1.99 [1.42&#8211;2.79]</td><td>Adult</td></tr><tr><td rowspan="2">HLA-DQ2.2 (rs7775228)</td><td rowspan="2">T</td><td rowspan="2">0.73</td><td rowspan="2">0.83</td><td rowspan="2">0.85</td><td>1.14 &#215; 10<sup>&#8722;4</sup></td><td>1.89 [1.36&#8211;2.63]</td><td>Pediatric</td></tr><tr><td>5.08 &#215; 10<sup>&#8722;7</sup></td><td>2.12 [1.58&#8211;2.84]</td><td>Adult</td></tr><tr><td rowspan="2">HLA-DQ2.5 (rs2187668)</td><td rowspan="2">A</td><td rowspan="2">0.16</td><td rowspan="2">0.06</td><td rowspan="2">0.10</td><td>3.46 &#215; 10<sup>&#8722;28</sup></td><td>6.03 [4.38&#8211;8.30]</td><td>Pediatric</td></tr><tr><td>2.45 &#215; 10<sup>&#8722;34</sup></td><td>5.99 [4.49&#8211;7.98]</td><td>Adult</td></tr><tr><td rowspan="2">HLA-DQ8 (rs7454108)</td><td rowspan="2">T</td><td rowspan="2">0.94</td><td rowspan="2">0.97</td><td rowspan="2">0.89</td><td>0.08</td><td>1.72 [0.93&#8211;3.18]</td><td>Pediatric</td></tr><tr><td>0.20</td><td>1.37 [0.84&#8211;2.22]</td><td>Adult</td></tr><tr><td rowspan="2">HLA-DQ4 (rs4713586)</td><td rowspan="2">T</td><td rowspan="2">0.98</td><td rowspan="2">0.92</td><td rowspan="2">0.94</td><td>0.03</td><td>9.05 [1.18&#8211;69.50]</td><td>Pediatric</td></tr><tr><td>0.03</td><td>3.71 [1.18&#8211;11.78]</td><td>Adult</td></tr></table>
3cdb98a362cf19819f349b2fb1628f00aaa8ab0fff94d52809e860456a26a478.png
simple
<table><tr><td>Outcomes</td><td>Conventional period<i>n</i> = 79 (%)</td><td>MALDI-TOF period<i>n</i> = 75 (%)</td><td><i>P</i> Value&#8224;</td></tr><tr><td>Time to pathogen identification (hours)</td><td>86.9 &#177; 30.4</td><td>62.5 &#177; 23.1</td><td>&lt; 0.001</td></tr><tr><td>Time to effective therapy (hours)</td><td>27.8 &#177; 32.4</td><td>17.1 &#177; 25.7</td><td>0.031</td></tr><tr><td>30-day all-cause mortality</td><td>7 (8.9)</td><td>5 (6.7)</td><td>0.612</td></tr><tr><td>Time to microbiological clearance (days)</td><td>4.1 &#177; 3.0</td><td>3.4 &#177; 2.0</td><td>0.081</td></tr><tr><td>Length of ICU stay (days)</td><td>14.1 &#177; 26.0</td><td>11.7 &#177; 12.8</td><td>0.719</td></tr><tr><td>30-day Recurrence of same BSI</td><td>2 (2.5)</td><td>0 (0.0)</td><td>0.497</td></tr></table>
03fff6c3446a1a5275044e9b919382e70331fbbaa8fa7b75a3d7e35ee283a721.png
simple
<table><tr><td>NaHS (&#956;mol/L)</td><td>5&#8242;- GMP (&#956;mol/L)</td><td><i>P</i></td></tr><tr><td>Basal (0)</td><td>0.45 &#177; 0.08</td><td></td></tr><tr><td>3</td><td>0.31 &#177; 0.09</td><td>0.27</td></tr><tr><td>50</td><td>0.15 &#177; 0.04 **</td><td>0.01</td></tr><tr><td>300</td><td>0.21 &#177; 0.06*</td><td>0.03</td></tr></table>
c5ae0bd0624b411f6e3c50a7189468e9b02e0394a7b8a4abeb74b181f30784c9.png
complex
<table><tr><td>Mouse primers</td><td></td><td>Oligonucleotide sequences (5&#8217;&#8722;3&#8217;)</td></tr><tr><td rowspan="2"><i>Aldh1a1</i><sup>-/-</sup></td><td>Forward</td><td>TGAGCAAATCCTCCACAGCCCTGTTC</td></tr><tr><td>Reverse</td><td>CTGCTAAAGCGCATGCTCCAGACTG</td></tr><tr><td rowspan="2"><i>Aldh1a3</i> flox</td><td>Forward</td><td>TCTCTGACCAGCTTTCCAACCTTCAG</td></tr><tr><td>Reverse</td><td>CTCAAACCAGCACCACCTCCATATTG</td></tr><tr><td rowspan="2"><i>Sox9</i> flox</td><td>Forward</td><td>TCAGCAAGACTCTGGGCAAGCTCT</td></tr><tr><td>Reverse</td><td>CTCAAAATCTGAGCCACTCCCTC</td></tr><tr><td rowspan="2"><i>Tyr</i>-Cre, <i>Pax6</i>-&#945;-Cre</td><td>Forward</td><td>CCTGGAAAATGCTTCTGTCCGT</td></tr><tr><td>Reverse</td><td>GTGTCCACATAGTCATTGGCAGAGTG</td></tr><tr><td rowspan="2"><i>Sox9</i>-Tg, <i>Kdr</i>-BAC-EGFP</td><td>Forward</td><td>AGCTGACCCTGAAGTTCATCTG</td></tr><tr><td>Reverse</td><td>GTCGTCCTTGAAGAAGATGGTG</td></tr><tr><td rowspan="2"><i>Flt1</i>-BAC-tdsRed</td><td>Forward</td><td>GCTGCAGGCGCGGAGAAGGGCTCTC</td></tr><tr><td>Reverse</td><td>CTTCACGTACACCTTGGAGC</td></tr><tr><td rowspan="2">IL2 (internal control)</td><td>Forward</td><td>GCCTAGAAGATGAACTTGGACCTCTG</td></tr><tr><td>Reverse</td><td>GTGGAAGGATTCACTTGCACAGTGAC</td></tr><tr><td>Human RPE primers</td><td></td><td></td></tr><tr><td rowspan="2"><i>Sox9</i></td><td>Forward</td><td>CGTACCCGCACTTGCACAAC</td></tr><tr><td>Reverse</td><td>TCTCGCTCTCGTTCAGAAGTC</td></tr><tr><td rowspan="2"><i>Vegfa</i></td><td>Forward</td><td>TGCCCGCTGCTGTCTAAT</td></tr><tr><td>Reverse</td><td>TCTCCGCTCTGAGCAAGG</td></tr><tr><td rowspan="2">&#946;-<i>actin</i></td><td>Forward</td><td>CCAACCGCGAGAAGATGA</td></tr><tr><td>Reverse</td><td>CCAGAGGCGTACAGGGATAG</td></tr></table>
9262d100e3a03a6fd3d2bdc7ecf8aad302681e015dcb7f1094242197a6f9a2d5.png
complex
<table><tr><td rowspan="2">Survey items</td><td rowspan="2">Overall (<i>n</i>=48)</td><td colspan="2">Completely achieved ILP goals and objectives</td></tr><tr><td>&#8216;No&#8217; (<i>n</i>=25)</td><td>&#8216;Yes&#8217; (<i>n</i>=23)</td></tr><tr><td colspan="4">ILP helpful in structuring ACE learning objectives (Rate 1&#8211;5), no. (%)</td></tr><tr><td> 1-3 ratings</td><td>12 (25 %)</td><td>10 (40 %)</td><td>2 (9 %)</td></tr><tr><td> 4-5 ratings</td><td>36 (75 %)</td><td>15 (60 %)</td><td>21 (91 %)</td></tr><tr><td colspan="4">ILP helpful in organizing goals for career (Rate 1&#8211;5), no. (%)</td></tr><tr><td> 1-3 ratings</td><td>19 (40 %)</td><td>15 (60 %)</td><td>4 (17 %)</td></tr><tr><td> 4-5 ratings</td><td>29 (60 %)</td><td>10 (40 %)</td><td>19 (83 %)</td></tr></table>
5d2470e477259cc6ca13f19d8ef253df91de766ab97ae58113a5c2e1b1af2fca.png
simple
<table><tr><td>Variable</td><td>CF1</td><td>CF2</td><td>CF3</td></tr><tr><td>As</td><td>&#8722;0.06</td><td>0.00</td><td>0.95</td></tr><tr><td>Cd</td><td>0.02</td><td>0.85</td><td>0.16</td></tr><tr><td>Cr</td><td>0.86</td><td>0.12</td><td>&#8722;0.13</td></tr><tr><td>Cu</td><td>0.83</td><td>0.09</td><td>&#8722;0.30</td></tr><tr><td>Hg</td><td>0.54</td><td>0.14</td><td>0.20</td></tr><tr><td>Ni</td><td>0.88</td><td>0.00</td><td>0.09</td></tr><tr><td>Pb</td><td>0.25</td><td>0.78</td><td>&#8722;0.19</td></tr><tr><td>Zn</td><td>0.91</td><td>0.19</td><td>&#8722;0.14</td></tr><tr><td>Eigenvalue</td><td>3.36</td><td>1.40</td><td>1.14</td></tr><tr><td>% Total variance</td><td>42.02</td><td>17.55</td><td>14.21</td></tr><tr><td>Cumulative % variance</td><td>42.02</td><td>59.56</td><td>73.78a</td></tr></table>
2860e932ddd053962e7712fb4a835cf98cee309bd17b43142434a96c6984c1a3.png
simple
<table><tr><td>Variable</td><td>HE group (<i>n =</i> 58)</td><td>Control group (<i>n =</i> 59)</td><td><i>P</i>-value</td></tr><tr><td>Historical information</td><td></td><td></td><td></td></tr><tr><td> Esophageal varices</td><td>60%</td><td>66%</td><td>0.518</td></tr><tr><td> Variceal bleeding</td><td>21%</td><td>24%</td><td>0.693</td></tr><tr><td> Variceal band ligation</td><td>24%</td><td>24%</td><td>0.952</td></tr><tr><td>Medications</td><td></td><td></td><td></td></tr><tr><td> Non-selective beta blockers</td><td>36%</td><td>44%</td><td>0.386</td></tr><tr><td> Narcotics</td><td>14%</td><td>8%</td><td>0.394</td></tr><tr><td> Centrally acting medications<sup>a</sup></td><td>41%</td><td>15%</td><td>0.002</td></tr><tr><td> Diuretics<sup>b</sup></td><td>88%</td><td>63%</td><td>0.002</td></tr><tr><td>Laboratory tests</td><td></td><td></td><td></td></tr><tr><td> Na &lt;135 mmol/L</td><td>69%</td><td>68%</td><td>0.892</td></tr><tr><td> Creatinine &gt; 1 mg/dL</td><td>31%</td><td>29%</td><td>0.793</td></tr><tr><td>CT scan findings</td><td></td><td></td><td></td></tr><tr><td> Liver antero-posterior diameter &#8804;6 cm</td><td>91%</td><td>68%</td><td>0.001</td></tr><tr><td> Liver cranio-caudal diameter &#8804;16 cm</td><td>69%</td><td>58%</td><td>0.203</td></tr><tr><td> Spleen diameter &#8805;16 cm</td><td>47%</td><td>53%</td><td>0.517</td></tr><tr><td> Nodular liver</td><td>86%</td><td>68%</td><td>0.018</td></tr><tr><td> Caudate lobe hypertrophy</td><td>55%</td><td>64%</td><td>0.308</td></tr><tr><td> Paraesophageal varices</td><td>67%</td><td>63%</td><td>0.608</td></tr><tr><td> Splenorenal varices</td><td>72%</td><td>83%</td><td>0.166</td></tr><tr><td> Umbilical vein recanalization</td><td>60%</td><td>58%</td><td>0.765</td></tr><tr><td> Presence of ascites</td><td>55%</td><td>49%</td><td>0.515</td></tr><tr><td> Portal vein diameter &#8804;12 mm</td><td>58%</td><td>28%</td><td>0.001</td></tr><tr><td>Duplex ultrasound findings</td><td></td><td></td><td></td></tr><tr><td> Portal vein flow velocity &lt;16 cm/s</td><td>26%</td><td>20%</td><td>0.475</td></tr><tr><td> Hepatofugal flow</td><td>16%</td><td>7%</td><td>0.132</td></tr><tr><td> Hepatic artery resistive index &#8805;0.75</td><td>33%</td><td>39%</td><td>0.527</td></tr></table>
4d1b2bf070929e030becc07c336b6dff379d5d9cd467112a2b09b69de76173d4.png
complex
<table><tr><td rowspan="2">Male</td><td rowspan="2">Control (mg/kg)</td><td colspan="3"><i>Alstonia scholaris</i> Extract Dose (mg/kg)</td></tr><tr><td>250</td><td>500</td><td>1000</td></tr><tr><td>TP (g/L)</td><td>67.21 &#177; 3.34</td><td>65.34 &#177; 4.5</td><td>70.32 &#177; 2.3</td><td>69.73 &#177; 1.52</td></tr><tr><td>Albumin (g/L)</td><td>28.40 &#177; 2.21</td><td>29.42 &#177; 0.46</td><td>32.37 &#177; 0.22</td><td>32.15 &#177; 1.40</td></tr><tr><td>Globulin (g/L)</td><td>38.24 &#177; 1.29</td><td>41.00 &#177; 3.03</td><td>39.62 &#177; 0.51</td><td>42.63 &#177; 2.50</td></tr><tr><td>ALP (IU/L)</td><td>113.3 &#177; 4.5</td><td>114.7 &#177; 14.7</td><td>121.7 &#177; 11.3 *</td><td>117.67 &#177; 6.9 *</td></tr><tr><td>Bilirubin (mol/L)</td><td>2.13 &#177; 0.59</td><td>2.70 &#177; 0.73</td><td>2.39 &#177; 0.47</td><td>2.84 &#177; 0.36</td></tr><tr><td>AST (IU/L)</td><td>221.32 &#177; 12.4</td><td>246.5 &#177; 21.3</td><td>257.3 &#177; 21.4 **</td><td>248.67 &#177; 16.6 *</td></tr><tr><td>ALT (IU/L)</td><td>49.0 &#177; 3.61</td><td>59.33 &#177; 1.86 *</td><td>54.67 &#177; 2.19 *</td><td>57.33 &#177; 3.76 *</td></tr></table>
311fa422b200a2760751b86532b9268ee8d589543277ff72ec895aff139d9555.png
simple
<table><tr><td>Variable</td><td>n</td><td>%</td></tr><tr><td>Surgical approach</td><td> </td><td> </td></tr><tr><td> Laparoscopic, completely closed</td><td>20</td><td>90</td></tr><tr><td> Hand-assisted laparoscopic</td><td>1</td><td>4.5</td></tr><tr><td> Lap converted to open</td><td>1</td><td>4.5</td></tr><tr><td>No. of metastases resected</td><td>45</td><td> </td></tr><tr><td> 1</td><td>14</td><td>64</td></tr><tr><td> 2</td><td>3</td><td>14</td></tr><tr><td> &#8805; 3</td><td>5</td><td>23</td></tr><tr><td>Segment of liver resected</td><td> </td><td> </td></tr><tr><td> Combined segment 2 and 3</td><td>2</td><td>9</td></tr><tr><td> Segment 3</td><td>8</td><td>36</td></tr><tr><td> Segment 5</td><td>2</td><td>9</td></tr><tr><td> Segment 6</td><td>8</td><td>36</td></tr><tr><td> Segment 7</td><td>1</td><td>4.5</td></tr><tr><td> Segment 8</td><td>1</td><td>4.5</td></tr><tr><td>Size (cm) of tumor resected (mean/median (range))</td><td>3.4/3 (0.3-8)</td><td> </td></tr><tr><td>Operative specifics (mean/median (range))</td><td> </td><td> </td></tr><tr><td> Intraoperative blood loss (mL)</td><td>256/100 (50&#8211;1400)</td><td> </td></tr><tr><td> Operative time (minutes)</td><td>194/193 (90&#8211;305)</td><td> </td></tr><tr><td> Use of pringle</td><td>3</td><td>14</td></tr><tr><td> Parenchymal transection with ultrasonic device</td><td>21</td><td>95</td></tr><tr><td> Parenchymal transection with endovascular stapler</td><td>15</td><td>68</td></tr><tr><td>Duration of hospitalization (days) (mean/median (range))</td><td>4/3 (1&#8211;10)</td><td> </td></tr><tr><td>Postoperative complication</td><td>3</td><td>14</td></tr><tr><td> Bile leak</td><td>1</td><td>4.5</td></tr><tr><td> Rapid atrial fibrillation</td><td>1</td><td>4.5</td></tr><tr><td> Colitis</td><td>1</td><td>4.5</td></tr></table>
508c7ff686544f19782ad2b10bd4ca66a1effa420824eeb95808fcc38c71bf18.png
simple
<table><tr><td>Protein 1</td><td>Protein 2</td><td>VAST</td><td>DALI</td><td>CE</td><td>FATCAT</td><td>Yang &amp; Tung's</td><td>de Brevern et al.'s</td><td>Our SA</td></tr><tr><td>1fxia</td><td>1ubq</td><td>48(2.10)</td><td>60(2.60)</td><td>64(3.80)</td><td>63(3.01)</td><td>59(2.76)</td><td>76(2.89)</td><td>58(2.64)</td></tr><tr><td>1ten</td><td>3hhrb</td><td>78(1.60)</td><td>86(1.90)</td><td>87(1.90)</td><td>87(1.90)</td><td>57(2.57)</td><td>73(2.31)</td><td>90(2.24)</td></tr><tr><td>3hlab</td><td>2rhe_</td><td>-</td><td>63(2.50)</td><td>85(3.50)</td><td>79(2.81)</td><td>54(2.65)</td><td>78(3.01)</td><td>79(2.87)</td></tr><tr><td>2azaa</td><td>1paz_</td><td>74(2.20)</td><td>81(2.50)</td><td>85(2.90)</td><td>87(3.01)</td><td>70(2.34)</td><td>57(2.23)</td><td>87(2.40)</td></tr><tr><td>1cewi</td><td>1mola</td><td>71(1.9)</td><td>81(2.30)</td><td>69(1.90)</td><td>83(2.44)</td><td>52(2.37)</td><td>53(2.35)</td><td>61(1.83)</td></tr><tr><td>1cid_</td><td>2rhe_</td><td>85(2.20)</td><td>95(3.30)</td><td>94(2.70)</td><td>100(3.11)</td><td>54(2.75)</td><td>53(2.49)</td><td>55(2.08)</td></tr><tr><td>1crl_</td><td>1ede</td><td>-</td><td>211(3.40)</td><td>187(3.20)</td><td>269(3.55)</td><td>167(3.35)</td><td>120(3.47)</td><td>187(3.25)</td></tr><tr><td>2sim_</td><td>1nsba</td><td>284(3.80)</td><td>286(3.80)</td><td>264(3.00)</td><td>286(3.07)</td><td>121(2.75)</td><td>121(2.96)</td><td>137(3.2)</td></tr><tr><td>1bgea</td><td>2gmfa</td><td>74(2.50)</td><td>98(3.50)</td><td>94(4.10)</td><td>100(3.19)</td><td>27(3.34)</td><td>77(2.8)</td><td>78(2.72)</td></tr><tr><td>1tie_</td><td>4fgf_</td><td>82(1.70)</td><td>108(2.00)</td><td>116(2.90)</td><td>117(3.05)</td><td>91(3.15)</td><td>62(3.45)</td><td>115(3.05)</td></tr><tr><td>Average RMSD/aligned-residues</td><td></td><td>0.0226</td><td>0.0238</td><td>0.0261</td><td>0.0229</td><td>0.0373</td><td>0.0363</td><td>0.0278</td></tr></table>
f63de1d6f464171fdab77976293dc4ca907ad1d5bd220f195ea94c61b0526cd8.png
simple
<table><tr><td>ORF Clusters features</td><td>MFL x MHP*</td><td>MFL x MHR*</td><td>MFL x MHP x MHR*</td></tr><tr><td>OCs 100% conserved</td><td>44</td><td>17</td><td>12</td></tr><tr><td>OCs Partially conserved</td><td>44</td><td>35</td><td>33</td></tr><tr><td>OCs Without conservation</td><td>29</td><td>62</td><td>-</td></tr></table>
569bda90e5779a53345aef42f2ceda715f9a4d477aea122c57a0e46e4ad1932e.png
simple
<table><tr><td>Conceptualization</td><td>Description</td></tr><tr><td>Revolution</td><td>&#8226; Health&#8217;s increasing role in foreign policy is transformative of the health-foreign policy nexus&#8226; Health collapses the traditional distinction between high and low politics and creates a new political space in which health isan overriding normative value and the ultimate goal of foreign policy&#8226; Health is broadly conceived and encompasses the social determinants of health&#8226; Is consistent with health discourses that focus on health as a human right and the &#8220;health for all&#8221; ideal</td></tr><tr><td>Remediation</td><td>&#8226; Health&#8217;s rise as foreign policy issue reflects the continued persistence of the traditional hierarchy of foreign policy functions&#8226; Health has become another issue that needs to be addressed through traditional approaches to foreign policy, or as astrategic vehicle through which traditional foreign policy goals can be achieved&#8226; Foreign policy attention on health is focused when disease crises appear and fades when crises drop off the political spotlight&#8226;Provides the strongest explanation for why health has risen as a foreign policy issue</td></tr><tr><td>Regression</td><td>&#8226; Health&#8217;s integration into foreign policy is a regressive development &#8211; an indicator that health problems are getting worse&#8226; The increasing attention paid to health across the functions of foreign policy signifies the failure of public health efforts&#8226; Connecting health with the high politics of foreign policy threatens to tarnish long-standing associations of health withnormative values&#8226; Public health&#8217;s wish for health to become more politically prominent may have come true but in a way that threatens whatwas special about health in the first place</td></tr></table>
fab5d5bf24682538b3e1b730f299aec0ccc2fc468d971025cfd9ba49fcd52605.png
complex
<table><tr><td></td><td>EU</td><td>Australia</td><td>Japan</td><td>WHO</td><td>Canada</td><td>Korea, India, Singapore, Malaysia</td></tr><tr><td>Synonym</td><td>Biosimilars</td><td>Biosimilars</td><td>Follow-on Biologics</td><td>Similar Biotherapeutic Product</td><td>Subsequent Entry Biologic</td><td>Biosimilars</td></tr><tr><td>Scope</td><td colspan="2">Mainly recombinant protein drugs</td><td colspan="4">Recombinant protein drugs</td></tr><tr><td rowspan="5">Principles</td><td colspan="6">&#8226; Generic approach is not appropriate for SEB.</td></tr><tr><td colspan="6">&#8226; SEB should be similar to the reference biologic with respect to quality, safety and efficacy.</td></tr><tr><td colspan="6">&#8226; Step-wise comparability approach: the reduction of non-clinical and clinical data required will only be considered after the similarity of the SEB and reference biologic is proven in terms of quality.</td></tr><tr><td colspan="6">&#8226; Case by case approach for different classes of products.</td></tr><tr><td colspan="6">&#8226; Pharmacovigilance is stressed.</td></tr><tr><td>Reference product</td><td colspan="2">Authorized in the EU</td><td>Authorized in Japan</td><td colspan="3">Authorized in a region with a well-established regulatory framework</td></tr><tr><td rowspan="2">Manufacture</td><td colspan="6">&#8226; Same standards required by the national regulatory agency for originator products.</td></tr><tr><td colspan="6">&#8226; Full chemistry and manufacture data package.</td></tr><tr><td rowspan="2">Physio-chemical</td><td colspan="6">&#8226; Primary and higher-order structure.</td></tr><tr><td colspan="6">&#8226; Post translational modifications.</td></tr><tr><td>Purity</td><td colspan="6">&#8226; Process-related and product-related impurities.</td></tr><tr><td>Non clinical</td><td colspan="6">&#8226; In-vitro such as cell-based assays and receptor-binding studies.</td></tr><tr><td>Stability</td><td colspan="2">Accelerated degradation studies and studied under various stress conditions</td><td>Not necessary</td><td colspan="3">Accelerated degradation studies and studied under various stress conditions</td></tr><tr><td rowspan="4">Pharmacokinetic study design &amp; criteria</td><td colspan="6">&#8226; Single dose, steady-state studies or repeated determinations of pharmacokinetics</td></tr><tr><td colspan="6">&#8226; Cross over or parallel.</td></tr><tr><td colspan="6">&#8226; Include absorption and elimination characteristics.</td></tr><tr><td colspan="6">&#8226; Use the traditional 80-125% equivalence range.</td></tr><tr><td>PD</td><td colspan="6">Pharmacodynamic (PD) markers should be selected and comparative PK/PD studies may be appropriate</td></tr><tr><td>Efficacy</td><td colspan="3">Comparability margins should be pre-specified and justified</td><td colspan="2">Observer or double-blinded. Equivalence or non-inferiority</td><td>Equivalence</td></tr><tr><td rowspan="3">Safety/pharmacovigilance</td><td colspan="6">&#8226; Pre-licensing safety data and risk management plan. Post authorization safety and/or efficacy studies may be required.</td></tr><tr><td colspan="6">&#8226; Adverse reactions must be reported.</td></tr><tr><td colspan="6">&#8226; Same rules apply to reference biologic and SEB.</td></tr><tr><td>INN vs. new generic name</td><td>INN</td><td>Unique generic name</td><td>Suffix &#8220;BS&#8221; added to INN</td><td>INN with biological qualifier (proposed)</td><td>INN but will follow WHO guidance</td><td>INN</td></tr><tr><td rowspan="2">Extrapolation of indications</td><td colspan="6">&#8226; Assessed on a case-by-case basis.</td></tr><tr><td colspan="6">&#8226; At least one clinical study required in the most sensitive population measuring the clinical endpoints likely to show a difference.</td></tr></table>
a673e609cd362ea388a6f7a511c64e5e24bf611c89acfb5db8aa0f46de154954.png
complex
<table><tr><td colspan="7">Pharmacovigilance area of interest</td></tr><tr><td>Activity type</td><td>Adverse events</td><td>Counterfeit drugs</td><td>Drug quality assurance</td><td>PV NOS</td><td>N/A</td><td>Total</td></tr><tr><td> Behaviour change communication</td><td></td><td>6 (85.7)</td><td>1 (14.3)</td><td></td><td></td><td>7 (2.4)</td></tr><tr><td> Improve regulatory system</td><td>1 (3.1)</td><td>6 (18.8)</td><td>14 (53.1)</td><td>11 (34.4)</td><td></td><td>32 (11.1)</td></tr><tr><td> Improving supply chain</td><td></td><td>1 (6.7)</td><td>7 (46.7)</td><td>7 (46.7)</td><td></td><td>15 (5.2)</td></tr><tr><td> Laboratory supplies and training</td><td></td><td>6 (15.4)</td><td>27 (69.2)</td><td>6 (15.4)</td><td></td><td>39 (13.5)</td></tr><tr><td> Operations research</td><td>2 (66.7)</td><td></td><td>1 (33.3)</td><td></td><td></td><td>3 (1.0)</td></tr><tr><td> Surveillance</td><td>3 (8.3)</td><td>10 (27.8)</td><td>21 (58.3)</td><td>2 (5.6)</td><td></td><td>36 (12.5)</td></tr><tr><td> Training/capacity building</td><td></td><td>1 (9.1)</td><td>6 (54.5)</td><td>4 (36.4)</td><td></td><td>11 (3.8)</td></tr><tr><td> Pharmacovigilance NOS</td><td>2 (6.3)</td><td>1 (3.1)</td><td>23 (71.9)</td><td>6 (18.8)</td><td></td><td>32 (11.1)</td></tr><tr><td> Pharmacovigilance NOS-unfunded</td><td></td><td></td><td>26 (100)</td><td></td><td></td><td>26 (9.0)</td></tr><tr><td> Surveillance-not funded</td><td>5 (100)</td><td></td><td></td><td></td><td></td><td>5 (1.7)</td></tr><tr><td> Context only<sup>a</sup></td><td></td><td></td><td></td><td></td><td>39 (100)</td><td>39 (13.5)</td></tr><tr><td> Historical activity<sup>b</sup></td><td></td><td>12 (17.4)</td><td>37 (53.6)</td><td>17 (24.6)</td><td>3 (4.4)</td><td>69 (24.0)</td></tr><tr><td> Total</td><td>14 (4.9)</td><td>40 (13.9)</td><td>154 (53.5)</td><td>49 (17.0)</td><td>42 (14.6)</td><td></td></tr></table>
f2cb5f8d06226bd847fe7bae835f83d323be25427adc330ad4e1111701cc64d7.png
simple
<table><tr><td>Schizophrenic Patient Variables</td><td>Values</td></tr><tr><td>Schizophrenia Severity</td><td>Severe/Other</td></tr><tr><td>Schizophrenia Heavy Alcohol Use</td><td>Yes/No</td></tr><tr><td>Schizophrenia Heavy Drug Use</td><td>Yes/No</td></tr><tr><td>Schizophrenia</td><td>Paranoid/Undiff</td></tr><tr><td>Schizophrenia Sudden Death</td><td>Yes/No</td></tr><tr><td>Schizophrenia Suicide</td><td>Yes/No</td></tr><tr><td>Schizophrenia Lifetime Antipsychotics &gt;45,000</td><td>Yes/No</td></tr><tr><td>Schizophrenia Antichollnergic</td><td>Yes/No</td></tr><tr><td>Schizophrenia Antidepressants</td><td>Yes/No</td></tr><tr><td>Schizophrenia Stabilizer</td><td>Yes/No</td></tr><tr><td>Schizophrenia Lithium</td><td>Yes/No</td></tr><tr><td>Schizophrenia Valproate</td><td>Yes/No</td></tr></table>
6d9e3504e076aaec82c7896e50e2d9afdb7c0486ee4dbc9aa3847bec84e9f5c0.png
simple
<table><tr><td>Reads</td><td>Assembler</td><td>Contig</td><td>Scaffold</td><td>Transf</td><td>Untransf</td><td>Shared</td><td>Masked</td></tr><tr><td>Sim</td><td>allp</td><td>57</td><td>7</td><td>21</td><td>1</td><td>18</td><td>12</td></tr><tr><td>Sim</td><td>sga_m75</td><td>504</td><td>463</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Sim</td><td>sga_m77</td><td>513</td><td>479</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Sim</td><td>soap_K69</td><td>1481</td><td>698</td><td>255</td><td>451</td><td>137</td><td>44</td></tr><tr><td>Sim</td><td>soap_K71</td><td>1469</td><td>769</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Bs-1</td><td>allp</td><td>66</td><td>9</td><td>35</td><td>0</td><td>23</td><td>15</td></tr><tr><td>Bs-1</td><td>sga_m75</td><td>899</td><td>711</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Bs-1</td><td>sga_m77</td><td>871</td><td>687</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Bs-1</td><td>soap_K69</td><td>1916</td><td>670</td><td>365</td><td>429</td><td>210</td><td>95</td></tr><tr><td>Bs-1</td><td>soap_K71</td><td>1909</td><td>692</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr></table>
0d3d9b2703fc48780db3c9dd002a4bab3cbcd49e82fdfd321b2c71c653707ac5.png
simple
<table><tr><td></td><td>Total</td><td>Diagnosis</td><td>Clinical therapy &amp; drug resistance</td><td>Case reports</td><td>Vaccine development</td><td>Epidemiology</td><td>Health education</td><td>Interventions and control</td><td>Others</td></tr><tr><td>HIV/AIDS</td><td>24025 (100%)</td><td>1229 (5.1%)</td><td>2706 (11.3%)</td><td>2105 (8.7%)</td><td>561 (2.3%)</td><td>6243 (26.0%)</td><td>696 (2.9%)</td><td>1135 (4.7%)</td><td>9350 (39.0%)</td></tr><tr><td>Parasites</td><td>14911 (100%)</td><td>1354 (9.1%)</td><td>1928 (12.9%)</td><td>2201 (14.7%)</td><td>132 (0.9%)</td><td>3667 (24.6%)</td><td>101 (0.7%)</td><td>835 (5.6%)</td><td>4693 (31.5%)</td></tr></table>
6b9e9acdcc53d8ab492502d2b3c6b474b68b49bae0b79432202e6803a28486bb.png
simple
<table><tr><td>Variable</td><td></td><td>Control(<i>n </i>= 91)</td><td>Intervention(<i>n </i>= 92)</td></tr><tr><td>Age</td><td>mean (sd)</td><td>57.5 (15.1)</td><td>57.2 (17.0)</td></tr><tr><td>Gender</td><td>%</td><td>M: 61</td><td>M: 62</td></tr><tr><td>APACHE II</td><td>mean (sd)</td><td>19.5 (7.2)</td><td>19.4 (12.6)</td></tr><tr><td>MV hours</td><td>mean (sd)</td><td>135 (117)</td><td>142 (159)</td></tr><tr><td></td><td>median<sup>c </sup>(IQR)</td><td>91 (48-179)</td><td>76 (41-180)</td></tr><tr><td>ICU LOS days</td><td>mean (sd)</td><td>8.6 (7.5)</td><td>9.4 (8.7)</td></tr><tr><td></td><td>median (IQR)</td><td>6 (4-10.5)</td><td>6 (4-11)</td></tr><tr><td>Hospital LOS days</td><td>mean (sd)</td><td>23.2 (16.9)</td><td>24.8 (20.4)</td></tr><tr><td></td><td>median (IQR)</td><td>18.5 (12-27.5)</td><td>18.5 (12-30)</td></tr><tr><td>SF-36 PF<sup>a</sup></td><td>mean (sd)</td><td>28.8 (10.2)</td><td>27.1 (12.3)</td></tr><tr><td>6MWT distance metres<sup>a</sup></td><td>mean (sd)</td><td>324 (143)</td><td>291 (129)</td></tr><tr><td>SF-36 PCS<sup>b</sup></td><td>mean (sd)</td><td>32.7 (8.6)</td><td>31.7 (10.0)</td></tr><tr><td>SF-36 MCS<sup>b</sup></td><td>mean (sd)</td><td>39.8 (13.5)</td><td>36.7 (15.1)</td></tr></table>
e8bfb91939513ac170e8f95010eeb466dd1189ad6e36f59aaa6f3114ebd39b30.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="4">Beclin 1 expression</td></tr><tr><td>All Cases</td><td>Low</td><td>High</td><td><i>p</i> Value</td></tr><tr><td>HER2 expression in total cases(41)</td><td></td><td></td><td></td><td>0.008</td></tr><tr><td>Negative</td><td>26</td><td>21(80.8%)</td><td>5(19.2%)</td><td></td></tr><tr><td>Positive</td><td>15</td><td>6(40.0%)</td><td>9(60.0%)</td><td></td></tr><tr><td>HER2 expression in ER positive cases(25)</td><td></td><td></td><td></td><td>0.002</td></tr><tr><td>Negative</td><td>18</td><td>16(88.9%)</td><td>2(11.1%)</td><td></td></tr><tr><td>Positive</td><td>7</td><td>1(14.3%)</td><td>6(85.7%)</td><td></td></tr><tr><td>HER2 expression in ER negative cases(16)</td><td></td><td></td><td></td><td>1.000</td></tr><tr><td>Negative</td><td>8</td><td>5(62.5%)</td><td>3(37.5%)</td><td></td></tr><tr><td>Positive</td><td>8</td><td>5(62.5%)</td><td>3(37.5%)</td><td></td></tr></table>
2048b8b103ef988508a22ec60cbf83a2b636fb66f10d889e1466e0036ca3ac79.png
complex
<table><tr><td></td><td colspan="2">MALL expression</td><td></td></tr><tr><td></td><td>Negative</td><td>Positive</td><td></td></tr><tr><td>Variables</td><td>(<i>n</i> = 58)</td><td>(<i>n</i> = 145)</td><td><i>P</i>-value</td></tr><tr><td>Age (y)</td><td></td><td></td><td>0.319</td></tr><tr><td>&lt;65</td><td>20 (34.5)</td><td>61 (42.1)</td><td></td></tr><tr><td>&#8805;65</td><td>38 (65.5)</td><td>84 (57.9)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>0.151</td></tr><tr><td>Male</td><td>20 (34.5)</td><td>66 (45.5)</td><td></td></tr><tr><td>Female</td><td>38 (65.5)</td><td>79 (54.5)</td><td></td></tr><tr><td>Tumor location</td><td></td><td></td><td>0.286</td></tr><tr><td>Right colon</td><td>30 (51.7)</td><td>54 (37.2)</td><td></td></tr><tr><td>Transverse colon</td><td>5 (8.6)</td><td>14 (9.7)</td><td></td></tr><tr><td>Left colon</td><td>4 (6.9)</td><td>16 (11.0)</td><td></td></tr><tr><td>Sigmoid colon</td><td>19 (32.8)</td><td>61 (42.1)</td><td></td></tr><tr><td>T category</td><td></td><td></td><td>0.639</td></tr><tr><td>T1</td><td>2 (3.4)</td><td>6 (4.1)</td><td></td></tr><tr><td>T2</td><td>4 (6.9)</td><td>19 (13.1)</td><td></td></tr><tr><td>T3</td><td>23 (39.7)</td><td>53 (36.6)</td><td></td></tr><tr><td>T4</td><td>29 (50.0)</td><td>67 (46.2)</td><td></td></tr><tr><td>N category</td><td></td><td></td><td>0.008*</td></tr><tr><td>N0</td><td>28 (48.3)</td><td>80 (55.2)</td><td></td></tr><tr><td>N1</td><td>13 (22.4)</td><td>48 (33.1)</td><td></td></tr><tr><td>N2</td><td>17 (29.3)</td><td>17 (11.7)</td><td></td></tr><tr><td>M category</td><td></td><td></td><td>0.118</td></tr><tr><td>M0</td><td>50 (86.2)</td><td>135 (93.1)</td><td></td></tr><tr><td>M1</td><td>8 (13.8)</td><td>10 (6.9)</td><td></td></tr><tr><td>Vessin invasion</td><td></td><td></td><td>0.027*</td></tr><tr><td>No</td><td>50 (86.2)</td><td>139 (95.9)</td><td></td></tr><tr><td>Yes</td><td>8 (13.8)</td><td>6 (4.1)</td><td></td></tr><tr><td>Differentiation</td><td></td><td></td><td>0.214</td></tr><tr><td>Well</td><td>29 (50.0)</td><td>70 (48.3)</td><td></td></tr><tr><td>Moderate</td><td>17 (29.3)</td><td>57 (39.3)</td><td></td></tr><tr><td>Poor</td><td>12 (20.7)</td><td>18 (12.4)</td><td></td></tr><tr><td>AJCC stage</td><td></td><td></td><td>0.351</td></tr><tr><td>I-II</td><td>27 (46.6)</td><td>78 (53.8)</td><td></td></tr><tr><td>III-IV</td><td>31 (53.4)</td><td>67 (46.2)</td><td></td></tr><tr><td>Recurrence and metastasis</td><td></td><td></td><td>0.016*</td></tr><tr><td>No</td><td>25 (46.3)</td><td>92 (65.2)</td><td></td></tr><tr><td>Yes</td><td>29 (53.7)</td><td>49 (34.8)</td><td></td></tr><tr><td>Patient survival</td><td></td><td></td><td>0.004*</td></tr><tr><td>No</td><td>30 (51.7)</td><td>44 (30.3)</td><td></td></tr><tr><td>Yes</td><td>28 (48.3)</td><td>101 (69.7)</td><td></td></tr></table>
5ede25c0cbf8c819a42a0a4f772fb52d86c7d17671674ba9d6e3dc0ae8e997a0.png
simple
<table><tr><td>Group of patients</td><td>Survivin positive</td><td>Survivin negative</td><td>Total</td></tr><tr><td>COX-2 positive</td><td>55</td><td>8</td><td>63</td></tr><tr><td>COX-2 negative</td><td>15</td><td>15</td><td>30</td></tr><tr><td>Total</td><td>70</td><td>23</td><td>93</td></tr></table>
37060d0c24564b3173b1b9dbfee58f29edee17dff415510d407f393c9ea7f580.png
simple
<table><tr><td>Characteristic</td><td>Healthy volunteers</td><td>RA patients</td></tr><tr><td></td><td>(N = 7)</td><td>(N = 10)</td></tr><tr><td>Age: mean (range)</td><td>56 (49&#8211;62)</td><td>63 (49&#8211;80)</td></tr><tr><td>Gender (% female)</td><td>43%</td><td>50%</td></tr></table>
ec22d5dc75b0eb1fb2d34c4a067a256f14493f27e0e0fab9a407760cb2c20d66.png
simple
<table><tr><td>Line</td><td>Number of Individuals</td><td>Duplication</td><td>Deletion</td><td>HeR</td><td>Aneuploid</td><td>TOTAL</td></tr><tr><td>ACSRsyn1</td><td>16</td><td>2</td><td>2</td><td>0</td><td>0</td><td>4</td></tr><tr><td>Bronowski</td><td>16</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Daichousen (fuku)</td><td>16</td><td>0</td><td>0</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Maris Haplona</td><td>48</td><td>1</td><td>8</td><td>0</td><td>1</td><td>10</td></tr><tr><td>Surpass 400</td><td>16</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Svalof&#8217;s Gulle</td><td>16</td><td>1</td><td>0</td><td>0</td><td>1</td><td>2</td></tr><tr><td>Tribune</td><td>16</td><td>2</td><td>2</td><td>0</td><td>1</td><td>5</td></tr><tr><td>Topas</td><td>16</td><td>0</td><td>1</td><td>0</td><td>1</td><td>2</td></tr><tr><td>PAK85912</td><td>46</td><td>5</td><td>4</td><td>5</td><td>3</td><td>17</td></tr><tr><td>Zhongyou821</td><td>48</td><td>3</td><td>2</td><td>0</td><td>4</td><td>9</td></tr><tr><td>Rainbow</td><td>254</td><td>12</td><td>22</td><td>30</td><td>13</td><td>77</td></tr></table>
876b1fdc37c3bf2abfc002bb788be614702b140eb7fc7d6b28ababd9ff47f6ef.png
simple
<table><tr><td>Individual Outcome Variables</td><td>Time 1 INTMean (SD)</td><td>Time 2 INTMean (SD)</td><td>Time 1 CONMean (SD)</td><td>Time 2 CONMean (SD)</td></tr><tr><td>Girl's BMI</td><td>20.1 (4.4)</td><td>20.4 (4.5)</td><td>19.1 (2.9)</td><td>19.2 (3.0)</td></tr><tr><td>Girl's BMI percentile</td><td>65.2 (27.0)</td><td>64.8 (26.9)</td><td>64.5 (23.8)</td><td>62.2 (23.2)</td></tr><tr><td>Girl's BMI z-score</td><td>0.57 (0.94)</td><td>0.55 (0.94)</td><td>0.38 (0.75)</td><td>0.36 (0.74)</td></tr><tr><td>Parent BMI<sup>a</sup></td><td>29.1 (6.4)</td><td>29.5 (6.9)</td><td>29.1 (6.7)</td><td>30.0 (7.5)</td></tr><tr><td>Family meals/week<sup>a </sup>(scale 0-21)</td><td>11.2 (4.2)</td><td>10.9 (3.6)</td><td>11.4 (5.0)</td><td>12.1 (4.7)</td></tr><tr><td>Girl days/week of 60 min. MVPA<sup>b </sup>(scale 0-7)</td><td>4.2 (1.8)</td><td>3.9 (1.7)</td><td>4.5 (1.9)</td><td>3.5 (1.8)</td></tr><tr><td>Percent of parents meeting MVPA standard<sup>a</sup></td><td>46.7</td><td>42.0</td><td>33.3*</td><td>36.4</td></tr><tr><td>Girl FV servings/day<sup>b </sup>(scale 0-8)</td><td>5.0 (2.0)</td><td>4.9 (1.7)</td><td>3.7 (1.9)*</td><td>3.7 (1.8)*</td></tr><tr><td>Parent FV Servings/day<sup>a </sup>(scale 0-8)</td><td>3.9 (1.5)</td><td>4.4 (1.6)</td><td>3.7 (1.8)</td><td>4.4 (1.5)</td></tr><tr><td>Girl eating with TV scale<sup>b </sup>(scale 0-4)</td><td>1.1 (0.7)</td><td>0.8 (0.7)</td><td>1.1 (0.8)</td><td>1.1 (0.7)</td></tr><tr><td>Parent eating with TV scale<sup>a </sup>(scale 0-4)</td><td>1.8 (0.7)</td><td>1.7 (0.7)</td><td>2.0 (0.8)</td><td>2.1 (0.7)*</td></tr><tr><td>Girl days/week SSB consumption<sup>b </sup>(scale 0-7)</td><td>3.1 (2.2)</td><td>2.3 (2.4)</td><td>2.6 (2.4)</td><td>2.2 (2.4)</td></tr><tr><td>Parent days/week SSB consumption<sup>a </sup>(scale 0-7)</td><td>1.8 (2.2)</td><td>2.0 (2.6)</td><td>2.7 (2.7)</td><td>2.4 (2.8)</td></tr></table>
eedc88f0a223e44cb223b24650d7d02570b0a3f8abb7bcfa51b064c779203e7b.png
complex
<table><tr><td>Item</td><td> </td><td>Number</td><td>Percent</td><td>Adjusted OR*</td><td colspan="2">95% CI</td></tr><tr><td rowspan="2">A smoke-free hospital would improve the quality of care the patient receives (Agree)</td><td>Admin**</td><td>90</td><td>82.6%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>223</td><td>83.8%</td><td>1.4</td><td>0.63</td><td>3.1</td></tr><tr><td> </td><td>Nurses</td><td>227</td><td>90.4%</td><td>2.2</td><td>0.84</td><td>5.7</td></tr><tr><td rowspan="2">Smoke from someone else's cigarette is unhealthy for non-smokers (Agree)</td><td>Admin</td><td>97</td><td>89.8%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>260</td><td>97.7%</td><td>4.6</td><td>1.41</td><td>15.1</td></tr><tr><td> </td><td>Nurses</td><td>245</td><td>97.2%</td><td>3.6</td><td>1.04</td><td>12.6</td></tr><tr><td rowspan="2">The smoking habits of health professionals influence others (Agree)</td><td>Admin</td><td>100</td><td>91.7%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>258</td><td>97.0%</td><td>3.0</td><td>0.93</td><td>10.0</td></tr><tr><td> </td><td>Nurses</td><td>236</td><td>93.7%</td><td>1.7</td><td>0.51</td><td>5.9</td></tr><tr><td rowspan="2">Cessation programs should be offered to employees (Agree)</td><td>Admin</td><td>101</td><td>92.7%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>254</td><td>95.5%</td><td>6.8</td><td>1.68</td><td>27.3</td></tr><tr><td> </td><td>Nurses</td><td>239</td><td>95.2%</td><td>2.2</td><td>0.60</td><td>7.7</td></tr><tr><td rowspan="2">A hospital should be a smoke-free environment (Agree)</td><td>Admin</td><td>105</td><td>97.2%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>256</td><td>96.2%</td><td>1.2</td><td>0.30</td><td>4.6</td></tr><tr><td> </td><td>Nurses</td><td>246</td><td>97.6%</td><td>1.4</td><td>0.27</td><td>7.4</td></tr><tr><td rowspan="2">Hospital employees who work in offices or areas removed from direct patient care should be allowed to smoke (Disagree)</td><td>Admin</td><td>76</td><td>69.7%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>196</td><td>73.7%</td><td>1.4</td><td>0.77</td><td>2.6</td></tr><tr><td> </td><td>Nurses</td><td>155</td><td>61.3%</td><td>0.7</td><td>0.36</td><td>1.3</td></tr><tr><td rowspan="2">A smoke-free policy is hard to enforce (Disagree)</td><td>Admin</td><td>46</td><td>42.2%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>142</td><td>53.6%</td><td>2.1</td><td>1.28</td><td>3.5</td></tr><tr><td> </td><td>Nurses</td><td>104</td><td>41.6%</td><td>1.2</td><td>0.66</td><td>2.0</td></tr><tr><td rowspan="2">Having a smoke-free policy is unfair to smokers (Disagree)</td><td>Admin</td><td>90</td><td>84.1%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>234</td><td>88.0%</td><td>2.6</td><td>1.08</td><td>6.1</td></tr><tr><td> </td><td>Nurses</td><td>223</td><td>88.8%</td><td>1.2</td><td>0.47</td><td>3.1</td></tr><tr><td rowspan="2">Hospitals with smoke-free policies are likely to lose patients (Disagree)</td><td>Admin</td><td>86</td><td>79.6%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>205</td><td>77.1%</td><td>2.6</td><td>1.24</td><td>5.4</td></tr><tr><td> </td><td>Nurses</td><td>186</td><td>73.5%</td><td>0.9</td><td>0.45</td><td>2.0</td></tr><tr><td rowspan="2">Smoking bans at hospitals would positively influence job performance (Agree)</td><td>Admin</td><td>59</td><td>54.6%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>190</td><td>71.7%</td><td>2.0</td><td>1.21</td><td>3.3</td></tr><tr><td> </td><td>Nurses</td><td>190</td><td>75.7%</td><td>2.1</td><td>1.20</td><td>3.6</td></tr><tr><td rowspan="2">Smoking bans at hospitals would positively affect the public image of the hospital (Agree)</td><td>Admin</td><td>74</td><td>68.5%</td><td>1.0</td><td colspan="2"> </td></tr><tr><td>Physicians</td><td>245</td><td>92.8%</td><td>5.5</td><td>2.79</td><td>10.8</td></tr><tr><td> </td><td>Nurses</td><td>226</td><td>89.7%</td><td>3.3</td><td>1.63</td><td>6.6</td></tr></table>
848465050c9d627e11296d2bab822761cdcac6af04020abf64de5b138ca00d48.png
simple
<table><tr><td>Rhomboid type</td><td>A Strepto</td><td>B Strepto</td><td>C Strepto</td><td>D Strepto</td><td>E Strepto</td><td>E Myco</td><td>AB Myco</td></tr><tr><td>A Strepto</td><td>&#8211;</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>B Strepto</td><td>0.29474</td><td>&#8211;</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>C Strepto</td><td>0.35789</td><td>0.35789</td><td>&#8211;</td><td></td><td></td><td></td><td></td></tr><tr><td>D Strepto</td><td>0.40001</td><td>0.38947</td><td>0.16842</td><td>&#8211;</td><td></td><td></td><td></td></tr><tr><td>E Strepto</td><td>0.43158</td><td>0.38947</td><td>0.40000</td><td>0.42105</td><td>&#8211;</td><td></td><td></td></tr><tr><td>E Myco (Rv1337)</td><td>0.46316</td><td>0.53684</td><td>0.48421</td><td>0.50526</td><td>0.29474</td><td>&#8211;</td><td></td></tr><tr><td>AB Myco (Rv0110)</td><td>0.23158</td><td>0.29500</td><td>0.33684</td><td>0.36842</td><td>0.35789</td><td>0.51579</td><td>&#8211;</td></tr></table>
bbbb71e1583056e83de623a58e73165820493461405f27c5ea339698f65d5eb0.png
simple
<table><tr><td>Cytokine</td><td>Total papers</td><td>Total ratios</td><td>References</td></tr><tr><td>IL-4</td><td>6</td><td>7</td><td>Hensley et al., 2002, 2003; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Audet et al., 2012</td></tr><tr><td>IL-6</td><td>8</td><td>12</td><td>Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Chiu et al., 2008; Audet et al., 2012; Dibaj et al., 2012</td></tr><tr><td>IL-10</td><td>3</td><td>6</td><td>Hensley et al., 2002, 2003; Finkelstein et al., 2011</td></tr><tr><td>IL-1&#945;</td><td>5</td><td>6</td><td>Hensley et al., 2003; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009</td></tr><tr><td>IL-1&#946;</td><td>12</td><td>20</td><td>Hensley et al., 2003; Kang et al., 2003; Xie et al., 2004; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Zhao et al., 2010; Berger et al., 2011; Audet et al., 2012; Valente et al., 2012</td></tr><tr><td>IL-12</td><td>6</td><td>12</td><td>Hensley et al., 2002, 2003, 2006; Kiaei et al., 2006; Kim et al., 2006; Dibaj et al., 2012</td></tr><tr><td>TNF-&#945;</td><td>18</td><td>39</td><td>Yoshihara et al., 2002; Hensley et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kim et al., 2006; Zhang et al., 2008; Cheroni et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Takeuchi et al., 2010; Finkelstein et al., 2011; Pollari et al., 2011; Audet et al., 2012; Valente et al., 2012</td></tr><tr><td>GFAP</td><td>46</td><td>164</td><td>Olsen et al., 2001; Yoshihara et al., 2002; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Tsai et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Zhu and Sheng, 2011; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012</td></tr><tr><td>Type I total</td><td>56</td><td>241</td><td>Olsen et al., 2001; Hensley et al., 2002, 2003, 2006; Yoshihara et al., 2002; Kang et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kiaei et al., 2006; Kim et al., 2006; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Zhang et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Neymotin et al., 2009; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Fang et al., 2010; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Takeuchi et al., 2010; Tsai et al., 2010; Zhao et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Pollari et al., 2011; Audet et al., 2012; Dibaj et al., 2012; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012</td></tr><tr><td>Type II total</td><td>10</td><td>25</td><td>Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Finkelstein et al., 2011; Audet et al., 2012; Dibaj et al., 2012</td></tr></table>
eb0ce2142d4ff4f4f633c9f8d8b211a16a767d5cd55852f6ca79d5dc0a80eb52.png
simple
<table><tr><td>Factor</td><td>Adjusted OR</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>Age</td><td>1.032</td><td>0.991&#8211;1.075</td><td>0.129 (NS)</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>1</td><td> </td><td> </td></tr><tr><td>Male</td><td>0.341</td><td>0.083&#8211;1.402</td><td>0.136 (NS)</td></tr><tr><td>Bedbound</td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>1</td><td> </td><td> </td></tr><tr><td> Yes</td><td>7.332</td><td>0.419&#8211;128.341</td><td>0.173 (NS) </td></tr><tr><td>Albumin</td><td>0.886</td><td>0.774&#8211;1.014</td><td>0.078 (NS)</td></tr><tr><td>Bilirubin</td><td>0.996</td><td>0.984&#8211;1.008</td><td>0.522 (NS) </td></tr><tr><td>Laterality</td><td> </td><td> </td><td> </td></tr><tr><td> Unilateral</td><td>1</td><td> </td><td> </td></tr><tr><td> Bilateral</td><td>8.101</td><td>1.766&#8211;37.156</td><td>0.007</td></tr><tr><td>Complexity</td><td> </td><td> </td><td> </td></tr><tr><td> Simple</td><td>1</td><td> </td><td> </td></tr><tr><td>Complex</td><td>2.050</td><td>0.304&#8211;13.809</td><td>0.555 (NS)</td></tr><tr><td>Stricture</td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>1</td><td> </td><td> </td></tr><tr><td>Yes</td><td>2.564</td><td>0.530&#8211;12.403</td><td>0.242 (NS)</td></tr><tr><td>Ectasia</td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>1</td><td> </td><td> </td></tr><tr><td>Yes</td><td>0.895</td><td>0.184&#8211;4.355</td><td>0.891 (NS)</td></tr><tr><td>Liver atrophy</td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>1</td><td> </td><td> </td></tr><tr><td>Yes</td><td>3.584</td><td>0.594&#8211;21.619</td><td>0.164 (NS)</td></tr><tr><td>Liver abscess</td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>1</td><td> </td><td> </td></tr><tr><td>Yes</td><td>6.058</td><td>0.960&#8211;38.230</td><td>0.055 (NS)</td></tr><tr><td>Extrahepatic stones</td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>1</td><td> </td><td> </td></tr><tr><td>Yes</td><td>1.228</td><td>0.274&#8211;5.509</td><td>0.789 (NS)</td></tr><tr><td>Treatment</td><td> </td><td> </td><td> </td></tr><tr><td> Operative</td><td>1</td><td> </td><td> </td></tr><tr><td> Non-operative</td><td>26.843</td><td>4.856&#8211;148.394</td><td>0.001</td></tr></table>
97f7136b647a387a41745ad46790b3b18e541fcc5db3c09bd232dff1c22e91d9.png
simple
<table><tr><td>Formulation (%)/treatment</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td>TV surimi</td><td>91.25</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>MSTM surimi</td><td>&#8211;</td><td>76.25</td><td>91.25</td></tr><tr><td>Cold water</td><td>&#8211;</td><td>15.00</td><td>&#8211;</td></tr><tr><td>Soybean-concentrated protein</td><td>4.00</td><td>4.00</td><td>4.00</td></tr><tr><td>Cassava starch</td><td>2.00</td><td>2.00</td><td>2.00</td></tr><tr><td>Cure salt</td><td>0.25</td><td>0.25</td><td>0.25</td></tr><tr><td>Global sausage SV 800</td><td>0.80</td><td>0.80</td><td>0.80</td></tr><tr><td>Cochonilha carmim</td><td>0.05</td><td>0.05</td><td>0.05</td></tr><tr><td>Refined salt</td><td>1.65</td><td>1.65</td><td>1.65</td></tr></table>
e33e7286d529a9efdc52c30a30ccefa1ef1d61a88d3d3227f1e8b032cdd58d00.png
simple
<table><tr><td>Dependent variable</td><td>Independent variable</td><td>Beta</td><td>95% CI</td><td>P</td></tr><tr><td>Physical functioning</td><td>Age</td><td>-7.49</td><td>-11.92-3.06</td><td>0.001</td></tr><tr><td></td><td>GHQ-28 score</td><td>-19.28</td><td>-27.21- -11.34</td><td>&lt; 0.001</td></tr><tr><td></td><td>Elbows pain</td><td>-30.53</td><td>-47.94- -13.12</td><td>0.001</td></tr><tr><td></td><td>Low back pain</td><td>-19.87</td><td>-30.25- -9.49</td><td>&lt; 0.001</td></tr><tr><td>Role limitations due to physical health problems</td><td>BMI</td><td>-8.21</td><td>-16.56-0.14</td><td>0.054</td></tr><tr><td></td><td>GHQ-28 score</td><td>-23.33</td><td>-36.89- -9.78</td><td>0.001</td></tr><tr><td></td><td>Hip pain</td><td>-26.70</td><td>-48.34- -5.05</td><td>0.016</td></tr><tr><td>Bodily pain</td><td>Age</td><td>7.21</td><td>1.77-12.64</td><td>0.010</td></tr><tr><td></td><td>GHQ-28 score</td><td>8.71</td><td>0.51-16.91</td><td>0.038</td></tr><tr><td></td><td>Hip pain</td><td>6.58</td><td>5.45-31.51</td><td>0.006</td></tr><tr><td></td><td>Upper back pain</td><td>6.79</td><td>11.68-38.55</td><td>&lt; 0.001</td></tr><tr><td>General health</td><td>Female Gender</td><td>6.38</td><td>2.41-10.35</td><td>0.002</td></tr><tr><td>Vitality</td><td>GHQ-28 score</td><td>-13.07</td><td>-19.39- -8.44</td><td>&lt; 0.001</td></tr><tr><td></td><td>Elbows pain</td><td>-12.56</td><td>-23.49- -1.62</td><td>0.025</td></tr><tr><td>Social functioning</td><td>GHQ-28 score</td><td>--3.71</td><td>-7.33- - 0.09</td><td>0.045</td></tr><tr><td>Role limitations due to emotional health problems</td><td>Female gender</td><td>-11.53</td><td>-23.04- -0.03</td><td>0.049</td></tr><tr><td></td><td>GHQ-28 score</td><td>-19.97</td><td>-32.03 - -7.92</td><td>0.001</td></tr><tr><td></td><td>Upper back pain</td><td>-29.49</td><td>-47.30- -11.68</td><td>0.001</td></tr><tr><td>Mental health</td><td>GHQ-28 score</td><td>-5.06</td><td>-8.91 - -1.208</td><td>&lt; 0.001</td></tr><tr><td>DIMENSION PHYSICAL</td><td>GHQ-28 score</td><td>-9.53</td><td>-13.41- -5.66</td><td>&lt; 0.001</td></tr><tr><td></td><td>Neck pain</td><td>-8.00</td><td>-14.07- -1.93</td><td>0.010</td></tr><tr><td>DIMENSION MENTAL</td><td>GHQ-28 score</td><td>-8.50</td><td>-11.67- -5.32</td><td>&lt; 0.001</td></tr><tr><td></td><td>Upper back pain</td><td>-5.58</td><td>-10.47- -0.68</td><td>0.026</td></tr></table>
1e8ebde72423a6819b100f90301a4d6c34b6a6960fe0511defbf901484bca5b7.png
complex
<table><tr><td rowspan="2">N</td><td colspan="4">Multiplicative Model</td><td colspan="4">Additive Model</td></tr><tr><td>Coefficient</td><td>Value</td><td>SE</td><td>Units</td><td>Coefficient</td><td>Value</td><td>SE</td><td>Units</td></tr><tr><td>389</td><td>b *</td><td>0.0021</td><td>3.4 &#215; 10<sup>&#8722;5</sup></td><td>&#176;C<sup>&#8722;1</sup> d<sup>&#8722;1</sup></td><td>b</td><td>0.0024</td><td>3.8 &#215; 10<sup>&#8722;5</sup></td><td>&#176;C<sup>&#8722;1</sup> d<sup>&#8722;1</sup></td></tr><tr><td>389</td><td>g * (plus)</td><td>9.464</td><td>1.080</td><td>dh<sup>&#8722;1</sup></td><td>g (plus)</td><td>11.40</td><td>0.983</td><td>dh<sup>&#8722;1</sup></td></tr><tr><td>389</td><td>g * (neg)</td><td>&#8722;9.822</td><td>1.078</td><td>dh<sup>&#8722;1</sup></td><td>g (neg)</td><td>&#8722;11.02</td><td>0.921</td><td>dh<sup>&#8722;1</sup></td></tr><tr><td>389</td><td>h *</td><td>0.499</td><td>0.060</td><td>h<sup>&#8722;1</sup></td><td>h</td><td>10.20</td><td>0.438</td><td><sup>O</sup>C h<sup>&#8722;1</sup></td></tr><tr><td>389</td><td>k *</td><td>0.333</td><td>0.066</td><td>d J<sup>&#8722;1</sup></td><td>k</td><td>0.228</td><td>0.023</td><td>d J<sup>&#8722;1</sup></td></tr><tr><td>207</td><td>b *</td><td>0.0021</td><td>4.2 &#215; 10<sup>&#8722;5</sup></td><td>&#176;C<sup>&#8722;1</sup> d<sup>&#8722;1</sup></td><td>b</td><td>0.0025</td><td>3.7 &#215; 10<sup>&#8722;5</sup></td><td>&#176;C<sup>&#8722;1</sup> d<sup>&#8722;1</sup></td></tr><tr><td>207</td><td>g * (plus)</td><td>7.975</td><td>1.461</td><td>dh<sup>&#8722;1</sup></td><td>g (plus)</td><td>12.92</td><td>0.804</td><td>dh<sup>&#8722;1</sup></td></tr><tr><td>207</td><td>g * (neg)</td><td>&#8722;11.62</td><td>1.353</td><td>dh<sup>&#8722;1</sup></td><td>g (neg)</td><td>&#8722;14.64</td><td>0.795</td><td>dh<sup>&#8722;1</sup></td></tr><tr><td>207</td><td>h *</td><td>0.460</td><td>0.050</td><td>h<sup>&#8722;1</sup></td><td>h</td><td>11.94</td><td>0.484</td><td>&#176;C h<sup>&#8722;1</sup></td></tr><tr><td>207</td><td>k *</td><td>0.297</td><td>0.068</td><td>d J<sup>&#8722;1</sup></td><td>k</td><td>0.302</td><td>0.018</td><td>d J<sup>&#8722;1</sup></td></tr></table>
c17d4ac886ed525850cb270065af0b764cbeaf267edced847c0e94d45ecdf811.png
simple
<table><tr><td>Attribute</td><td>Value</td><td>% of Total</td></tr><tr><td>Genome size (bp)</td><td>4,024,382</td><td>100.00%</td></tr><tr><td>DNA coding region (bp)</td><td>3,618,708</td><td>89.92%</td></tr><tr><td>DNA G+C content (bp)</td><td>2,845,385</td><td>70.70%</td></tr><tr><td>Number of replicons</td><td>1</td><td></td></tr><tr><td>Extrachromosomal elements</td><td>0</td><td></td></tr><tr><td>Total genes</td><td>3,710</td><td>100.00%</td></tr><tr><td>RNA genes</td><td>57</td><td>1.54%</td></tr><tr><td>rRNA operons</td><td>2</td><td></td></tr><tr><td>Protein-coding genes</td><td>3,653</td><td>98.46%</td></tr><tr><td>Pseudo genes</td><td>90</td><td>2.43%</td></tr><tr><td>Genes with function prediction</td><td>2,645</td><td>71.29%</td></tr><tr><td>Genes in paralog clusters</td><td>360</td><td>7.70%</td></tr><tr><td>Genes assigned to COGs</td><td>2,674</td><td>72.08%</td></tr><tr><td>Genes assigned Pfam domains</td><td>2,871</td><td>77.39%</td></tr><tr><td>Genes with signal peptides</td><td>1,101</td><td>29.68%</td></tr><tr><td>Genes with transmembrane helices</td><td>860</td><td>23.18%</td></tr><tr><td>CRISPR repeats</td><td>0</td><td></td></tr></table>
cb3627da7b7351e856a608c88ba9089a003bb261d5c9f2bd79af82554ec38398.png
simple
<table><tr><td> Group</td><td>Dose (mg/kg)</td><td>Sleep latency (min)</td><td>Sleeping time (min)</td></tr><tr><td>Normal</td><td>60</td><td>8 &#177; 1</td><td>36 &#177; 3</td></tr><tr><td> DZP</td><td> 3</td><td>6 &#177; 1*</td><td>75 &#177; 3*</td></tr><tr><td> ME</td><td> 800</td><td>12 &#177; 0.5*</td><td>45 &#177; 2*</td></tr><tr><td> ME</td><td> 1000</td><td>6 &#177; 1*</td><td>112 &#177; 3*</td></tr></table>
b8e140322d005a6f929f7851d68c36a37349106b45dc9f73a63ef2db8e95d3ea.png
complex
<table><tr><td></td><td colspan="2">Median (Inter-quartile range) or N (%)</td><td>*<i>p</i>-value</td></tr><tr><td>Variables</td><td>HCC (<i>n</i> = 62)</td><td>Non-HCC (<i>n</i> = 57)</td><td></td></tr><tr><td>Age (years)</td><td>49.5(35&#8211;55)</td><td>36(32&#8211;51)</td><td><i>p</i> = 0.05</td></tr><tr><td>Gender M:F</td><td>48:14</td><td>38:19</td><td><i>p</i> = 0.19</td></tr><tr><td>AST (u/L)</td><td>89(68&#8211;112)</td><td>12(7&#8211;23)</td><td><i>p</i> &lt; 0.001</td></tr><tr><td>ALT (u/L)</td><td>36(22&#8211;54)</td><td>8(5&#8211;16)</td><td><i>p</i> &lt; 0.001</td></tr><tr><td>Total Bilirubin (&#956;mol/l)</td><td>60.3(28&#8211;144)</td><td>18(11.1-29)</td><td><i>p</i> &lt; 0.001</td></tr><tr><td>Albumin (g/l)</td><td>30(26&#8211;35)</td><td>36(34&#8211;39)</td><td><i>p</i> &lt; 0.001</td></tr><tr><td>INR</td><td>1.19(1&#8211;1.4)</td><td>1.1(1&#8211;1.2)</td><td><i>p</i> = 0.22</td></tr><tr><td>Positive for HBsAg</td><td>41(66.1 %)</td><td>42(73.7 %)</td><td><i>p</i> = 0.52</td></tr><tr><td>Positive for Anti-HCV</td><td>0 %)</td><td>1(1.8 %)</td><td><i>p</i> = 0.30</td></tr></table>
4152468bdacc91c1c23edc2e9e096c7bdb3440387ac16182c5ddd66e6893f9e7.png
complex
<table><tr><td rowspan="2">Laboratorial Parameters</td><td colspan="2">Control Group <i>n</i> = 43</td><td colspan="2">SCD Groups <i>n</i> = 72</td><td rowspan="2"><i>p</i> Value</td></tr><tr><td>Median</td><td>IQR (P25&#8211;P75)</td><td>Median</td><td>IQR (P25&#8211;P75)</td></tr><tr><td>Hemoglobin (g/dL)</td><td>13.5</td><td>12.8&#8211;14.7</td><td>8.0</td><td>7.1&#8211;9.3</td><td>&lt;0.001</td></tr><tr><td>Hematocrit (%)</td><td>40.1</td><td>38.7&#8211;44.1</td><td>23.6</td><td>21.4&#8211;28.1</td><td>&lt;0.001</td></tr><tr><td>Leukocytes (&#215;10<sup>3</sup>/mm<sup>3</sup>) </td><td>5.8</td><td>4.9&#8211;6.6 </td><td>10.7</td><td>7.6&#8211;13.9 </td><td>&lt;0.001</td></tr><tr><td>Lymphocytes (%)</td><td>37.1</td><td>33.0&#8211;42.1</td><td>38.4</td><td>30.8&#8211;46.0</td><td>0.676</td></tr><tr><td>Hepcidin (ng/mL)</td><td>7.2</td><td>5.6&#8211;11.6</td><td>5.3</td><td>2.5&#8211;10.9</td><td>0.014</td></tr><tr><td>Ferritin (ng/mL)</td><td>29.8</td><td>17.1&#8211;68.5</td><td>228.7</td><td>69.4&#8211;703.5</td><td>&lt;0.001</td></tr><tr><td>Ferritin/Leukocytes ratio</td><td>6.3</td><td>3.1&#8211;13.2</td><td>27.5</td><td>7.2&#8211;77.0</td><td>&lt;0.001</td></tr><tr><td>Serum iron (&#956;g/dL)</td><td>105.0</td><td>69.0&#8211;129.0</td><td>119.0</td><td>92.0&#8211;158.8</td><td>0.012</td></tr><tr><td>TIBC (&#956;g/dL)</td><td>333.0</td><td>301.0&#8211;383.0</td><td>293.0</td><td>233.3&#8211;347.0</td><td>0.001</td></tr><tr><td>TS (%)</td><td>31.4</td><td>20.5&#8211;41.8</td><td>43.1</td><td>30.1&#8211;62.5</td><td>&lt;0.001</td></tr><tr><td>LDH (U/L)</td><td>349.0</td><td>293.0&#8211;391.0</td><td>818.0</td><td>619.8&#8211;1198.0</td><td>&lt;0.001</td></tr><tr><td>GDF-15 (pg/mL)</td><td>504.8</td><td>396.0&#8211;652.4</td><td>1299.2</td><td>618.4&#8211;1553.1</td><td>&lt;0.001</td></tr><tr><td>IL-6 (pg/mL)</td><td>0.0</td><td>0.0&#8211;2.5</td><td>3.8</td><td>2.4&#8211;8.9</td><td>&lt;0.001</td></tr></table>
b91816ce327c5833c7b59a9e4534686bfd8d01d511576d35dca5f006dabd04e5.png
complex
<table><tr><td>GO.ID</td><td>Term</td><td><i>p</i>-Value</td></tr><tr><td colspan="3">Topic 2</td></tr><tr><td>GO:0001054</td><td>RNA polymerase I activity</td><td>2.5e-07</td></tr><tr><td>GO:0043022</td><td>ribosome binding</td><td>4.8e-06</td></tr><tr><td>GO:0030515</td><td>snoRNA binding</td><td>5.0e-06</td></tr><tr><td>GO:0005524</td><td>ATP binding</td><td>6.1e-06</td></tr><tr><td colspan="3">Topic 3</td></tr><tr><td>GO:0003713</td><td>transcription coactivator activity</td><td>7.6e-07</td></tr><tr><td>GO:0003730</td><td>mRNA 3&#8217;-UTR binding</td><td>4.6e-06</td></tr><tr><td>GO:0004843</td><td>ubiquitin-specific protease activity</td><td>7.7e-06</td></tr><tr><td colspan="3">Topic 4</td></tr><tr><td>GO:0020037</td><td>heme binding</td><td>2.2e-19</td></tr><tr><td>O:0008395</td><td>steroid hydroxylase activity</td><td>5.9e-18</td></tr><tr><td>O:0019825</td><td>oxygen binding</td><td>6.5e-14</td></tr><tr><td>O:0005506</td><td>iron ion binding</td><td>9.2e-13</td></tr><tr><td>O:0004364</td><td>glutathione transferase activity</td><td>1.5e-12</td></tr><tr><td>O:0008392</td><td>arachidonic acid epoxygenase activity</td><td>1.9e-12</td></tr><tr><td>O:0005102</td><td>receptor binding</td><td>4.2e-11</td></tr><tr><td>GO:0004867</td><td>serine-type endopeptidase inhibitor activity</td><td>1.1e-10</td></tr><tr><td>GO:0009055</td><td>electron carrier activity</td><td>1.3e-10</td></tr><tr><td>GO:0070330</td><td>aromatase activity</td><td>2.6e-10</td></tr><tr><td>GO:0042803</td><td>protein homodimerization activity</td><td>7.4e-10</td></tr><tr><td>GO:0008201</td><td>heparin binding</td><td>1.5e-09</td></tr><tr><td>GO:0002020</td><td>protease binding</td><td>2.5e-08</td></tr><tr><td>GO:0051087</td><td>chaperone binding</td><td>6.0e-07</td></tr><tr><td>GO:0003988</td><td>acetyl-CoA C-acyltransferase activity</td><td>8.4e-07</td></tr><tr><td>GO:0016836</td><td>hydro-lyase activity</td><td>1.0e-06</td></tr><tr><td>GO:0004602</td><td>glutathione peroxidase activity</td><td>1.0e-06</td></tr><tr><td>GO:0004601</td><td>peroxidase activity</td><td>1.3e-06</td></tr><tr><td>GO:0030170</td><td>pyridoxal phosphate binding</td><td>1.6e-06</td></tr><tr><td>GO:0004029</td><td>aldehyde dehydrogenase (NAD) activity</td><td>2.4e-06</td></tr><tr><td>GO:0001848</td><td>complement binding</td><td>3.1e-06</td></tr><tr><td>GO:0016616</td><td>oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor</td><td>3.2e-06</td></tr><tr><td>GO:0050660</td><td>flavin adenine dinucleotide binding</td><td>3.8e-06</td></tr><tr><td>GO:0005507</td><td>copper ion binding</td><td>4.1e-06</td></tr><tr><td>GO:0016709</td><td>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</td><td>5.3e-06</td></tr><tr><td>GO:0032403</td><td>protein complex binding</td><td>5.7e-06</td></tr><tr><td>GO:0051537</td><td>2 iron, 2 sulfur cluster binding</td><td>7.8e-06</td></tr></table>
ec66f22823e49abe6469d8e2cda88dced04642fa64aa5fe0f604b5e186cede21.png
simple
<table><tr><td>Characteristics</td><td>Total (n, %)</td></tr><tr><td>Number</td><td>73</td></tr><tr><td>Age (years)</td><td>67.0 (SD 14.1)</td></tr><tr><td>Sex male</td><td>52 (71.2)</td></tr><tr><td>Admission NIHSS score</td><td>9.3 (SD 3.2)</td></tr><tr><td>Admission GCS score</td><td>5.6 (SD 2.0)</td></tr><tr><td>Smoking</td><td>30 (41.1)</td></tr><tr><td>Excess alcohol consumption</td><td>22 (30.1)</td></tr><tr><td>Pre-existing illnesses</td><td></td></tr><tr><td> Hypertension</td><td>53 (72.6)</td></tr><tr><td> Diabetes</td><td>36 (49.3)</td></tr><tr><td> Coronary heart disease</td><td>14 (19.2)</td></tr><tr><td> Liver disease (except for hepatic cirrhosis)</td><td>0 (0)</td></tr><tr><td> Kidney disease</td><td>2 (2.7)</td></tr><tr><td>Chest X ray</td><td>73 (100)</td></tr><tr><td>Chest CT</td><td>58 (79.5)</td></tr><tr><td> GGOs</td><td>40/58 (69.0)</td></tr><tr><td> Consolidation opacities</td><td>31/58 (53.4)</td></tr><tr><td> Pleural effusions</td><td>14/58 (24.1)</td></tr><tr><td> Air bronchogram</td><td>11/58 (19.0)</td></tr><tr><td>Tachypnea (RR &#8805; 25 breaths/min)</td><td>67 (91.8)</td></tr><tr><td>Fever (T &#8805; 37.5 &#176;C)</td><td>43 (58.9)</td></tr><tr><td>PaO<sub>2</sub>/FiO<sub>2</sub> (mmHg)</td><td>143.5 (SD 59.0)</td></tr><tr><td>APACHE II score</td><td>28.2 (SD 10.4)</td></tr><tr><td>pH value</td><td>7.38 (SD 0.57)</td></tr><tr><td>Acidosis (pH &lt; 7.35)</td><td>11 (15.1)</td></tr><tr><td>Albumin (g/L)</td><td>26.1 (SD 9.2)</td></tr><tr><td>Treatment</td><td></td></tr><tr><td>Corticosteroids</td><td>47 (64.4)</td></tr><tr><td> No respiratory response</td><td>16/47 (34.0)</td></tr><tr><td> Respiratory response</td><td>31/47 (66.0)</td></tr><tr><td>Ventilatory support</td><td>63 (86.3)</td></tr><tr><td> Non-invasive ventilation alone</td><td>14/63 (22.2)</td></tr><tr><td> Non-invasive ventilation followed by intubation</td><td>16/63 (25.4)</td></tr><tr><td> First line invasive ventilation</td><td>33/63 (52.4)</td></tr><tr><td>Time from diagnosis to corticosteroids (days)</td><td>6.5 (SD 3.5)</td></tr><tr><td>Outcomes</td><td></td></tr><tr><td> Duration of IMV (days)</td><td>8.5 (SD 5.5)</td></tr><tr><td> Hospital LOS (days)</td><td>23.0 (SD 7.0)</td></tr><tr><td> Hospital mortality</td><td>29 (39.7)</td></tr></table>
9e90d7611b1e3bce9709019a332e43fabadf47dd43f870820d58a19bb1be3809.png
complex
<table><tr><td rowspan="2">Indicator</td><td colspan="4">Baseline</td><td colspan="4">Follow-Up</td><td colspan="2">ATT</td></tr><tr><td>Control</td><td>Treated</td><td>Difference</td><td><i>p</i></td><td>Control</td><td>Treated</td><td>Difference</td><td><i>p</i></td><td>DID <sup>b</sup></td><td><i>p</i></td></tr><tr><td><i>Left-behind</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI_sd <sup>a</sup></td><td>1.011</td><td>0.994</td><td>&#8722;0.017</td><td>0.288</td><td>1.011</td><td>0.986</td><td>&#8722;0.025</td><td>0.223</td><td>&#8722;0.008</td><td>0.756</td></tr><tr><td>Weight_sd</td><td>0.986</td><td>0.928</td><td>&#8722;0.058</td><td>0.006</td><td>0.995</td><td>0.943</td><td>&#8722;0.052</td><td>0.046</td><td>0.006</td><td>0.846</td></tr><tr><td>Height_sd</td><td>1.020</td><td>0.996</td><td>&#8722;0.024</td><td>0.003</td><td>1.032</td><td>1.016</td><td>&#8722;0.016</td><td>0.037</td><td>0.008</td><td>0.415</td></tr><tr><td><i>Father-left</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI_sd</td><td>1.011</td><td>1.000</td><td>&#8722;0.011</td><td>0.563</td><td>1.011</td><td>1.006</td><td>&#8722;0.005</td><td>0.843</td><td>0.006</td><td>0.861</td></tr><tr><td>Weight_sd</td><td>0.986</td><td>0.939</td><td>&#8722;0.047</td><td>0.091</td><td>0.995</td><td>0.950</td><td>&#8722;0.045</td><td>0.209</td><td>0.002</td><td>0.962</td></tr><tr><td>Height_sd</td><td>1.020</td><td>0.998</td><td>&#8722;0.022</td><td>0.034</td><td>1.032</td><td>1.010</td><td>&#8722;0.022</td><td>0.013</td><td>0.000</td><td>0.982</td></tr><tr><td><i>Mother-left</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI_sd</td><td>1.011</td><td>0.986</td><td>&#8722;0.025</td><td>0.241</td><td>1.011</td><td>0.955</td><td>&#8722;0.056</td><td>0.011</td><td>&#8722;0.031</td><td>0.320</td></tr><tr><td>Weight_sd</td><td>0.986</td><td>0.909</td><td>&#8722;0.077</td><td>0.005</td><td>0.995</td><td>0.931</td><td>&#8722;0.064</td><td>0.031</td><td>0.013</td><td>0.735</td></tr><tr><td>Height_sd</td><td>1.020</td><td>0.992</td><td>&#8722;0.028</td><td>0.009</td><td>1.032</td><td>1.027</td><td>&#8722;0.005</td><td>0.656</td><td>0.023</td><td>0.142</td></tr></table>
1ed7d3212d49aa8a1312321b9ef4beab2e290b67a22c4172a5b8f1b2e17830f4.png
simple
<table><tr><td>Hit rate (confirmed hits with selectivity over mammalian cell cytotoxicity)</td><td>G+ve</td><td>G-ve</td><td>Fungi</td></tr><tr><td>CO-ADD academic hit rate</td><td>0.66%</td><td>0.21%</td><td>0.98%</td></tr><tr><td>Commercial hit rate</td><td>0.03%</td><td>0.008%</td><td>ND</td></tr></table>
fbba3d5d5b1d2966526cae14ba86eaa41e091773876983c614dfa33d1f34225b.png
complex
<table><tr><td>Treatment and Age Group<sup>a</sup></td><td>SPR, % (95% CI)</td><td>SCR, % (95% CI)</td><td>GMT, (95% CI)</td></tr><tr><td>LD HA/AS03<sub>B</sub></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;40 y (n = 27)</td><td>96.3 (81.0&#8211;99.9)</td><td>96.3 (81.0&#8211;99.9)</td><td>98.3 (71.8&#8211;134.5)</td></tr><tr><td> 41&#8211;64 y (n = 29)</td><td>86.2 (68.3&#8211;96.1)</td><td>75.9 (56.5&#8211;89.7)</td><td>88.1 (62.0&#8211;125.0)</td></tr><tr><td>LD HA/AS03<sub>A</sub></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;40 y (n = 31)</td><td>100 (88.8&#8211;100)</td><td>100 (88.8&#8211;100)</td><td>202.4 (150.2&#8211;272.6)</td></tr><tr><td> 41&#8211;64 y (n = 25)</td><td>80.0 (59.3&#8211;93.2)</td><td>76.0 (54.9&#8211;90.6)</td><td>72.6 (46.1&#8211;114.3)</td></tr><tr><td>MD HA/AS03<sub>B</sub></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;40 y (n = 27)</td><td>100 (87.2&#8211;100)</td><td>100 (87.2&#8211;100)</td><td>156.1 (110.9&#8211;219.6)</td></tr><tr><td> 41&#8211;64 y (n = 27)</td><td>85.2 (66.3&#8211;95.8)</td><td>77.8 (57.7&#8211;91.4)</td><td>72.2 (50.0&#8211;104.4)</td></tr><tr><td>MD HA/AS03<sub>A</sub></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;40 y (n = 31)<sup>b</sup></td><td>100 (88.8&#8211;100)</td><td>100 (88.4&#8211;100)</td><td>173.0 (137.2&#8211;218.0)</td></tr><tr><td> 41&#8211;64 y (n = 24)</td><td>91.7 (73.0&#8211;99.0)</td><td>91.7 (73.0&#8211;99.0)</td><td>126.9 (85.9&#8211;187.6)</td></tr><tr><td colspan="4">HD HA nonadjuvanted</td></tr><tr><td> 18&#8211;40 y (n = 30)</td><td>43.3 (25.5&#8211;62.6)</td><td>36.7 (19.9&#8211;56.1)</td><td>21.9 (14.9&#8211;32.2)</td></tr><tr><td> 41&#8211;64 y (n = 26)</td><td>11.5 (2.4&#8211;30.2)</td><td>7.7 (.9&#8211;25.1)</td><td>13.0 (9.0&#8211;18.9)</td></tr><tr><td>Placebo</td><td></td><td></td><td></td></tr><tr><td> 18&#8211;40 y (n = 61)</td><td>0.0 (.0&#8211;5.9)</td><td>0.0 (.0&#8211;5.9)</td><td>5.1 (4.9&#8211;5.3)</td></tr><tr><td> 41&#8211;64 y (n = 51)</td><td>0.0 (.0&#8211;7.0)</td><td>0.0 (.0&#8211;7.0)</td><td>5.9 (5.3&#8211;6.6)</td></tr></table>
01bac0ca8f9e874ab2e7bf12c2d34c18b05ad7dabad17b159ed95e65b6cc495b.png
simple
<table><tr><td>Molecular subtypes</td><td>Immunohistochemical characterization</td></tr><tr><td>Luminal A</td><td>ER + and/or PR+, HER2- CK8/18+</td></tr><tr><td>Luminal B</td><td>ER + and/or PR+, HER2+, CK8/18+</td></tr><tr><td>HER2+</td><td>ER-, PR-, HER2+</td></tr><tr><td>basal-like</td><td>ER-, PR-, HER2- and CK 5/6+, HER1+ and/or CK14+</td></tr><tr><td>Unclassified</td><td>ER-, PR-, HER2-, CK 5/6-, HER1- and CK14-</td></tr></table>
b71be187584ac83d3c423da14b5278a0efcfb16fd96be65594ddf964669b7d0e.png
complex
<table><tr><td rowspan="2">DNA adduct levels/HPV infection</td><td colspan="2">Protein expression</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>Negative (%)</td><td>Positive (%)</td></tr><tr><td>XRCC3</td><td></td><td></td><td></td></tr><tr><td> High/+ (n = 24)</td><td>15 (62.5)</td><td>9 (37.5)</td><td></td></tr><tr><td> High/&#8722; (n = 44)</td><td>11 (25.0)</td><td>33 (75.0)</td><td></td></tr><tr><td> Low/+ (n = 6)</td><td>3(50.0)</td><td>3 (50.0)</td><td></td></tr><tr><td> Low/&#8722; (n = 26)</td><td>6 (23.1)</td><td>20 (76.9)</td><td>0.007</td></tr><tr><td>XRCC5</td><td></td><td></td><td></td></tr><tr><td> High/+ (n = 24)</td><td>14 (58.3)</td><td>10 (41.7)</td><td></td></tr><tr><td> High/&#8722; (n = 44)</td><td>6 (13.6)</td><td>38 (86.4)</td><td></td></tr><tr><td> Low/+ (n = 6)</td><td>6 (100.0)</td><td>0 (0.0)</td><td></td></tr><tr><td> Low/&#8722; (n = 26)</td><td>9 (34.6)</td><td>17 (65.4)</td><td>&lt;0.0001</td></tr></table>
839023d39e8b88cc1d8ae5c582b3d5abbcbb7885ef666448be0fd884c9601e11.png
complex
<table><tr><td colspan="4">Control group</td></tr><tr><td>Score</td><td>2 weeks</td><td>14 weeks</td><td>26 weeks</td></tr><tr><td>Total</td><td>-0.06</td><td>-0.05</td><td>+0.01</td></tr><tr><td>Symptom domain</td><td>-0.21</td><td>-0.14</td><td>-0.11</td></tr><tr><td>Mental domain</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Function domain</td><td>+0.05</td><td>+0.02</td><td>+0.14</td></tr></table>
c2bf603ed62aca0c6d56da3508af403a613ff3aad5befaa57e1301a16826af63.png
complex
<table><tr><td rowspan="2">Jurisdiction</td><td rowspan="2">Health policy change in studied period</td><td colspan="2">Cost sharing mechanism</td><td rowspan="2">References</td></tr><tr><td>Outpatient/Inpatient services</td><td>Pharmaceuticals</td></tr><tr><td>1 Czech Rep</td><td>Introduction of formal fees</td><td>Until the end of 2007, outpatient and inpatient services were free of charge. Since 2008, formal OOPs exists; a flat fee of 30 CZK (&#8364;1.2) per doctor visit, 60 CZK (&#8364;2.4) per hospital day as well as spa hotels, 90 CZK (&#8364;3.6) per ambulatory visit outside of working hours. An annual ceiling of CZK 5000 (&#8364;200) for expenses related to doctor visits and drug costs was introduced. Since 2009, a new ceiling of CZK 2500 (&#8364;100) for those below 18 and above 65 was launched. A flat fee per doctor visit for children was eliminated. Since 2012, a flat fee for hospital and spa stay was reduced to 100 CZK per stay (&#8364;3.92 EUR). The dental care is paid by OOPs too. Some groups such as poor, pregnant woman, chronically ill children, patients with infectious diseases are exempted from formal OOPs.(Exchange rate used; 1 EUR = 250 CZK)</td><td>Until 2008, some form of co-payments existed. A prescription fee of 30 CZK (1.18 EUR) per item was introduced in 2008. Since 2009, a difference between actual and reimbursement price is paid out of pocket if it is higher than prescription fee.</td><td>[3, 22]</td></tr><tr><td>2 Estonia</td><td>Introduction of formal fees</td><td>Since 1995, a fee of &#8364;0.30 (EEK 5) per first initial outpatient consultation at public hospitals and/or health centers exists, a free price setting for specialists. Since 2002, no fees for GP visits (except for home GP visit which is &#8364;3.2) but ambulatory specialist care at maximum fee of &#8364;3.20 (EEK 50) unless a referral within the same institution or specialty is granted. Hospital fees are implemented at 1.6 EUR per day, for up to 10 days per episode of illness. Some exemptions for children, pregnant woman and emergency care apply. (Exchange rate used; 1 EUR = 15.6 EEK)</td><td>Co-payment consist of a prescription fee of &#8364;1.30 plus the difference between actual price and reimbursement level. The general reimbursement rate is 50 % of the pharmaceutical price up to a maximum reimbursement of &#8364;12.00 (EEK 200) per prescription. The reimbursement of drugs for chronic disease, children, seniors and disabled is higher, up to 100 % .</td><td>[40, 41]</td></tr><tr><td>3 Hungary</td><td>Introduction of formal fees</td><td>To limited extend, some form of copayments already existed since 1989 (medical devices, spas, specialist treatment outside of standard patient&#8217;s pathway etc.). Since 2007 formal co-payments were introduced; app &#8364;1 per ambulatory visit and per hospital day. After the referendum held in 2008, they were abolished.</td><td>Since 2007 reimbursement rates have been decreased from 50 to 25 %; from 70 to 55 %; and from 90 to 85 %. For drugs with a special reimbursement of 90 %, three levels of coverage was established: 50, 70 and 90 %. For drugs fully reimbursed, a minimum &#8364;1 (300 HUF) fee per prescription was introduced. For special attentionpatients eligible for free of charge drugs, a monthly limit of 40 EUR was established. OOPs apply above that sum. Eligibility for special attention is defined by GP. (Exchange rate used; 1 EUR = 250 HUF)</td><td>[21, 34]</td></tr><tr><td>4 Slovakia</td><td>Introduction of formal fees</td><td>The formal copayments were introduced in 2003. Since then, app. &#8364;0.66 is paid per doctor visit and app. 1.66 EUR per hospital day, app &#8364;1.99 per emergency care visit,&#8364;0.07 per km for ambulance transport and between &#8364;4.98 and 7.30 per food and accommodation in spas. In 2006, user fees for a doctor&#8217;s visit and daily hospital stay were abolished. (Exchange rate used; 1 EUR = 40.03 SKK)</td><td>Until 2003, some form of co-payments existed. Since then &#8364;0.5 EUR prescription fee has to be paid. It was reduced to &#8364;0.17in 2006. If there is a difference between the price of the drug and the reimbursement level, patient has to cover it as well.</td><td>[11, 42]</td></tr></table>
6ee04da386bcad4b5910ab687827d692058d757d9feb75f4b630f205f605e59e.png
simple
<table><tr><td>Data collection</td><td> </td></tr><tr><td>X-ray source</td><td>PF BL-5A</td></tr><tr><td>Wavelength (A&#778;)</td><td>1.0000</td></tr><tr><td>Space group</td><td><i>P</i>4<sub>1</sub>2<sub>1</sub>2</td></tr><tr><td>Unit-cell parameters (A&#778;)</td><td><i>a</i> = <i>b</i> = 91.3, <i>c</i> = 265.4</td></tr><tr><td>Resolution (A&#778;)<sup>a</sup></td><td>20.0-2.20 (2.28-2.20)</td></tr><tr><td>Observed reflections</td><td>689047</td></tr><tr><td>Unique reflections</td><td>55949</td></tr><tr><td>Completeness (%)<sup>a</sup></td><td>96.5 (81.0)</td></tr><tr><td><i>R</i><sub><i>merge</i></sub> (%)<sup>a,b</sup></td><td>9.2 (23.9)</td></tr><tr><td>&lt;I&gt;/&lt;&#963;(I) &gt; <sup>a</sup></td><td>55.6 (11.4)</td></tr><tr><td>Refinement</td><td> </td></tr><tr><td>Resolution range (A&#778;)</td><td>20.0-2.20</td></tr><tr><td>R<sub>factor</sub>(%)<sup>c</sup></td><td>19.2</td></tr><tr><td>R<sub>free</sub>(%)<sup>d</sup></td><td>23.0</td></tr><tr><td>Protein atoms</td><td>8020</td></tr><tr><td>NADPH atoms</td><td>192</td></tr><tr><td>Water molecules</td><td>302</td></tr><tr><td>r.m.s deviaton from ideal</td><td> </td></tr><tr><td>Bond lengths (A&#778;)</td><td>0.011</td></tr><tr><td>Bond angles (deg.)</td><td>1.43</td></tr><tr><td>Ramachandran plot<sup>e</sup></td><td> </td></tr><tr><td>Most favored regions (%)</td><td>91.7</td></tr><tr><td>Allowed regions (%)</td><td>8.3</td></tr></table>
76e2c526f5eab34dccd7f29c7f22acef4108444a174d4a6e2b952052d2f59149.png
complex
<table><tr><td>Step</td><td>Candidate genes</td><td>Wilks&#8217; Lambda</td><td colspan="2">Exact F</td></tr><tr><td></td><td></td><td></td><td>Statistic</td><td>p value</td></tr><tr><td>1</td><td><i>TNFAIP3</i></td><td>0.404</td><td>59.002</td><td>&lt;0.001</td></tr><tr><td>2</td><td><i>IL-21</i></td><td>0.300</td><td>45.521</td><td>&lt;0.001</td></tr><tr><td>3</td><td><i>c-REL</i></td><td>0.261</td><td>35.809</td><td>&lt;0.001</td></tr><tr><td>4</td><td><i>RGS1</i></td><td>0.235</td><td>30.143</td><td>&lt;0.001</td></tr><tr><td>5</td><td><i>LPP</i></td><td>0.222</td><td>25.272</td><td>&lt;0.001</td></tr></table>
0f7cc8e3cfd204f41b7de2de6ad111ce592e9c914e30406f1c12fe52d86c9452.png
simple
<table><tr><td>Parameter</td><td><i>Model LR</i></td><td><i>AR(1)</i></td><td><i>AR(2)</i></td><td><i>AR(3)</i></td><td><i>AR(4)</i></td><td><i>AR(5)</i></td><td><i>Model LME</i></td></tr><tr><td><i>intercept</i></td><td>9.6448</td><td>9.6309</td><td>9.6441</td><td>9.6560</td><td>9.6617</td><td>9.6633</td><td>9.6719</td></tr><tr><td> </td><td>(0.0142)</td><td>(0.0206)</td><td>(0.0231)</td><td>(0.0243)</td><td>(0.0246)</td><td>(0.0247)</td><td>(0.0243)</td></tr><tr><td><i>Age</i></td><td>-0.0045</td><td>-0.0043</td><td>-0.0044</td><td>-0.0045</td><td>-0.0047</td><td>-0.0047</td><td>-0.0049</td></tr><tr><td> </td><td>(0.0003)</td><td>(0.0005)</td><td>(0.0006)</td><td>(0.0006)</td><td>(0.0006)</td><td>(0.0007)</td><td>(0.0006)</td></tr><tr><td><i>Season</i>(<i>Warm</i>)</td><td>-0.0627</td><td>-0.0615</td><td>-0.0681</td><td>-0.0699</td><td>-0.0693</td><td>-0.0694</td><td>-0.0698</td></tr><tr><td> </td><td>(0.0089)</td><td>(0.0074)</td><td>(0.0066)</td><td>(0.0066)</td><td>(0.0067)</td><td>(0.0067)</td><td>(0.0067)</td></tr><tr><td><i>DPV</i></td><td>-0.0610</td><td>-0.0469</td><td>-0.0350</td><td>-0.0385</td><td>-0.0440</td><td>-0.0474</td><td>-0.0636</td></tr><tr><td>(<i>Donation</i>)</td><td>(0.0092)</td><td>(0.0089)</td><td>(0.0079)</td><td>(0.0074)</td><td>(0.0072)</td><td>(0.0072)</td><td>(0.0068)</td></tr><tr><td><i>&#947;</i><sub>1</sub></td><td>&#8212;</td><td>0.5158</td><td>0.3685</td><td>0.3053</td><td>0.2746</td><td>0.2630</td><td>&#8212;</td></tr><tr><td> </td><td>&#8212;</td><td>(0.0061)</td><td>(0.0068)</td><td>(0.0076)</td><td>(0.0082)</td><td>(0.0087)</td><td>&#8212;</td></tr><tr><td><i>&#947;</i><sub>2</sub></td><td>&#8212;</td><td>&#8212;</td><td>0.2888</td><td>0.2080</td><td>0.1766</td><td>0.1621</td><td>&#8212;</td></tr><tr><td> </td><td>&#8212;</td><td>&#8212;</td><td>(0.0078)</td><td>(0.0087)</td><td>(0.0084)</td><td>(0.0091)</td><td>&#8212;</td></tr><tr><td><i>&#947;</i><sub>3</sub></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>0.2207</td><td>0.1730</td><td>0.1581</td><td>&#8212;</td></tr><tr><td> </td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>(0.0095)</td><td>(0.0104)</td><td>(0.0109)</td><td>&#8212;</td></tr><tr><td><i>&#947;</i><sub>4</sub></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>0.1488</td><td>0.1257</td><td>&#8212;</td></tr><tr><td> </td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>(0.0123)</td><td>(0.0129)</td><td>&#8212;</td></tr><tr><td><i>&#947;</i><sub>5</sub></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>0.0829</td><td>&#8212;</td></tr><tr><td> </td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>(0.0167)</td><td>&#8212;</td></tr></table>
ddc474bbfe00e11860ca6d8176b93295c7218040b27851ce09cdadc0144640f1.png
simple
<table><tr><td>Factors</td><td>Concepts</td><td>Health professionals&#8217; experiences, barriers and facilitators &amp; possible improvements with regard to:</td></tr><tr><td>Guideline related factors</td><td>Feasibility of the recommended guideline and the protocol derived from the guideline</td><td>- Guideline- Protocol- EHR- Consults- Collaboration with other continence professionals: Informing the woman&#8217;s GP after the consult by means of a letter, Advices for referrals, diagnostics and treatments</td></tr><tr><td></td><td>Compatibility of the protocol: the extent to which the recommended protocol is practical</td><td>likewise</td></tr><tr><td>Individual health professional factors</td><td>Competences (=skills, attitude and knowledge) needed: the extent to which the targeted health professionals have competences they need</td><td>- Competences needed- Training/educational needs- Learning experiences</td></tr><tr><td></td><td>Health professionals&#8217; engagements and satisfaction with the intervention</td><td>- Involvement &amp; Satisfaction (both rated on a 0&#8211;10 scale)</td></tr><tr><td>Patient factors</td><td>Patient behaviour: patient&#8217;s response to consults</td><td>- Patient&#8217;s response to consults, advices- Factors that influence patient&#8217;s response to nurses&#8217; care, e.g., financial issues</td></tr><tr><td></td><td>Patient motivation: the targeted healthcare professional&#8217;s (perceived) ability to motivate patients to adhere</td><td>- Motivating patients to adhere</td></tr><tr><td></td><td>Patient preferences: the targeted healthcare professional&#8217;s (perceived) ability to pay attention to patient preferences</td><td>- Paying attention to patient preferences</td></tr><tr><td>Professional interactions</td><td>Referral processes: processes for communication between the targeted healthcare professionals and targeted patients</td><td>- Nurse&#8217;s interaction with GPs- Nurse&#8217;s interaction with community pharmacists- Nurse&#8217;s interaction between GPs and community pharmacists</td></tr><tr><td>Incentives and resources</td><td>Financial incentives: the extent to which patients, individual health professionals and organisations have financial incentives or disincentives to adhere</td><td>- Financial issues that influenced adherence among patients, GPs and community pharmacists</td></tr><tr><td></td><td>Information system: the extent to which the EHR facilitates or hinders adherence</td><td>- EHR</td></tr><tr><td>Capacity for organisational change</td><td>Mandate, authority and accountability for making necessary changes</td><td>- Mandate for treatment change in participating women.</td></tr><tr><td></td><td>Regulations, rules, policies: the extent to which organisational regulations, rules or policies facilitate or hinder necessary changes.</td><td>- Regulations, rules and policies.</td></tr><tr><td>Social, political and legal factors</td><td>Payer or funder policies: the extent to which payer or funder policies may affect implementation of necessary changes</td><td>- Payer or funder policies facilitating or hindering implementation of necessary changes</td></tr><tr><td></td><td>Legislation: the extent to which legislation may affect implementation of necessary changes</td><td>- Legislation affecting implementation of necessary changes</td></tr></table>
08b9306c17b1574c3542909fecf2f17aa402f7157201a9fe915d170be70708d4.png
complex
<table><tr><td></td><td colspan="3">10-year breast cancer specific</td><td colspan="3">5-year BDDM</td></tr><tr><td>Variant</td><td><i>P</i>-value</td><td>HR</td><td>95% CI</td><td><i>P</i>-value</td><td>HR</td><td>95% CI</td></tr><tr><td>-903GA</td><td>0.01521</td><td>1.90</td><td>1.13 to 3.20</td><td>0.00201</td><td>2.07</td><td>1.31 to 3.29</td></tr><tr><td>-975GC</td><td>0.00357</td><td>2.68</td><td>1.38 to 5.21</td><td>0.01220</td><td>2.33</td><td>1.20 to 4.52</td></tr><tr><td>-1026CA</td><td>0.01829</td><td>2.06</td><td>1.13 to 3.77</td><td>0.28165</td><td>1.44</td><td>0.74 to 2.79</td></tr><tr><td>any</td><td>0.00002</td><td>2.17</td><td>1.52 to 3.10</td><td>0.00011</td><td>1.97</td><td>1.40 to 2.79</td></tr></table>
9befb659e4f5444ae687ee9b48b2b1898ff0f3b261ed0f952898cb8972832a2c.png
complex
<table><tr><td></td><td>moderate injury (<i>n</i> = 38)</td><td>severe injury (<i>n</i> = 63)</td><td>total (<i>n</i> = 101)</td><td>RTA (<i>n</i> = 68)</td><td>Fall (<i>n</i> = 24)</td></tr><tr><td colspan="6">Gender</td></tr><tr><td> Male (%)</td><td>31(82)</td><td>52(83)</td><td>83(82)</td><td>54(79)</td><td>22(92)</td></tr><tr><td> Female(%)</td><td>7(18)</td><td>11(17)</td><td>18(18)</td><td>14(21)</td><td>2(8)</td></tr><tr><td colspan="6">Age</td></tr><tr><td> Range</td><td>19&#8211;83</td><td>16&#8211;79</td><td>16&#8211;83</td><td>16&#8211;83</td><td>28&#8211;78</td></tr><tr><td> Mean (SD)</td><td>43.86(16.85)</td><td>40.46(17.56)</td><td>41.67(17.47)</td><td>38.23(17.54)</td><td>49.92(15.47)</td></tr><tr><td colspan="6">Marital status</td></tr><tr><td> Married(%)</td><td>31(82)</td><td>39(62)</td><td>70(69)</td><td>42(62)</td><td>21(88)</td></tr><tr><td> Unmarried(%)</td><td>5(13)</td><td>19(30)</td><td>24(24)</td><td>21(31)</td><td>1(4)</td></tr><tr><td> Divorced(%)</td><td>1(2)</td><td>3(4)</td><td>4(4)</td><td>3(4)</td><td>1(4)</td></tr><tr><td> Widowed(%)</td><td>1(2)</td><td>2(3)</td><td>3(3)</td><td>2(3)</td><td>1(4)</td></tr><tr><td colspan="6">Education level</td></tr><tr><td> No formal education</td><td>3(8)</td><td>2(3)</td><td>5(5)</td><td>1(1)</td><td>3(13)</td></tr><tr><td> Primary education</td><td>5(13)</td><td>5(8)</td><td>10(10)</td><td>7(10)</td><td>2(8)</td></tr><tr><td> Secondary Education</td><td>28(74)</td><td>54(86)</td><td>82(81)</td><td>57(84)</td><td>18(75)</td></tr><tr><td> Degree</td><td>(0)</td><td>2(3)</td><td>2(2)</td><td>2(3)</td><td>0(0)</td></tr><tr><td colspan="6">ASCOT score (%)</td></tr><tr><td> ASCOT Mean(SD)</td><td>0.90(0.06)</td><td>0.61(0.22)</td><td>0.72(0.23)</td><td>0.72(0.22)</td><td>0.67(0.25)</td></tr><tr><td> TRISS Mean(SD)</td><td>0.97(0.02)</td><td>0.86(0.14)</td><td>0.90(0.12)</td><td>0.91(0.11)</td><td>0.86(0.16)</td></tr><tr><td> RTS Mean(SD)</td><td>6.81(0.24)</td><td>4.53(0.84)</td><td>5.39(1.30)</td><td>5.34(1.30)</td><td>5.30(1.37)</td></tr><tr><td> ISS Mean(SD)</td><td>6.87(4.41)</td><td>5.57(4.69)</td><td>6.06(4.61)</td><td>6.09(4.02)</td><td>6.00(5.08)</td></tr><tr><td colspan="6">GCS</td></tr><tr><td>&lt; 9</td><td>0(0)</td><td>63(100)</td><td>63(62)</td><td>44(65)</td><td>15(63)</td></tr><tr><td> 9&#8211;12 score</td><td>38(100)</td><td>0(0)</td><td>38(38)</td><td>24(35)</td><td>9(38)</td></tr><tr><td colspan="6">Mechanism of injury</td></tr><tr><td> RTA</td><td>24(63)</td><td>44(70)</td><td>68(67)</td><td>68(100)</td><td>0(0)</td></tr><tr><td> Fall</td><td>9(24)</td><td>15(24)</td><td>24(24)</td><td>0(0)</td><td>24(100)</td></tr><tr><td> Other</td><td>5(13)</td><td>4(6)</td><td>9(9)</td><td>0(0)</td><td>0(0)</td></tr><tr><td colspan="6">Length of ICU stay(days)</td></tr><tr><td> Median(IQR)</td><td>6(8)</td><td>5(6)</td><td>6 (8.75)</td><td>6(8)</td><td>5.5(24)</td></tr><tr><td> Range</td><td>1&#8211;91</td><td>0&#8211;122</td><td>0&#8211;122</td><td>1&#8211;95</td><td>0&#8211;122</td></tr></table>
1f0910bae552d8b93687e379f0a76aacda38b7f5a52a61b08c90099807ad3f1c.png
simple
<table><tr><td>DT sensitivity, <i>&#968;</i></td><td>DT duration (days)</td><td>Total radiation (Gy)</td><td>TCP</td></tr><tr><td>5</td><td>238</td><td>76.84*</td><td>0.499</td></tr><tr><td></td><td>247</td><td>72.32*</td><td>0.505</td></tr><tr><td>50</td><td>204</td><td>74.58*</td><td>0.503</td></tr><tr><td></td><td>222</td><td>63.28</td><td>0.500</td></tr></table>
7b8305c270fe13ca141d052443e7ae0bce08c8e860eddda3c4abc1987f2f3551.png
simple
<table><tr><td>Variable</td><td>Group APioglitazone(n = 42)</td><td>Group BOther treatment(n = 39)</td><td>Pvalue</td></tr><tr><td>Age, years (range)</td><td>64.3 &#177; 8.1 (44-77)</td><td>64.8 &#177; 7.5 (48-81)</td><td>0.78</td></tr><tr><td>Female gender, n (%)</td><td>27 (64)</td><td>28 (72)</td><td>0.49</td></tr><tr><td>Hypertensives, n (%)</td><td>31 (74)</td><td>32 (82)</td><td>0.27</td></tr><tr><td>Hyperlipidaemics, n (%)</td><td>26 (62)</td><td>27 (69)</td><td>0.64</td></tr><tr><td>Ever smokers, n (%)</td><td>14 (33)</td><td>10 (26)</td><td>0.48</td></tr><tr><td>Family history of CAD</td><td>23 (55)</td><td>24 (62)</td><td>0.35</td></tr><tr><td>Duration of diabetes, years</td><td>10.2 &#177; 6.6</td><td>9.0 &#177; 6.9</td><td>0.41</td></tr><tr><td>Metformin</td><td>31 (74)</td><td>26 (67)</td><td>0.63</td></tr><tr><td>Sulfonylurea</td><td>31 (74)</td><td>27 (69)</td><td>0.81</td></tr><tr><td>Metformin &amp; Sulfonylurea</td><td>20 (48)</td><td>15 (38)</td><td>0.50</td></tr><tr><td>Antihypertensives, n (%)</td><td>27 (64)</td><td>27 (69)</td><td>0.81</td></tr><tr><td>Diuretics, n (%)</td><td>6 (14)</td><td>8 (21)</td><td>0.56</td></tr><tr><td>ACE or AT-II inhibitors, n (%)</td><td>22 (52)</td><td>22 (56)</td><td>0.82</td></tr><tr><td>&#946;-blockers, n (%)</td><td>1 (2)</td><td>3 (8)</td><td>0.35</td></tr><tr><td>Calcium channel blockers, n (%)</td><td>12 (29)</td><td>11 (28)</td><td>1.00</td></tr><tr><td>Statin, n (%)</td><td>18 (43)</td><td>17 (44)</td><td>1.00</td></tr><tr><td>Antiplatelets, n (%)</td><td>5 (12)</td><td>4 (10)</td><td>1.00</td></tr></table>
c48a9a079f4739c2a21f3545fe72c57cba4050ff9c49eac90a179a4864f9a5ad.png
simple
<table><tr><td> </td><td>Clonidine group </td><td>Clonidine and Dextromethorphan group</td><td><i>P</i> value</td></tr><tr><td>Number of patients </td><td>30</td><td>30</td><td>&#8212;</td></tr><tr><td>Initial symptoms score </td><td>2.7 &#177; 1.9</td><td>3.4 &#177; 2.6</td><td>0.17</td></tr><tr><td>Age </td><td>29.3 &#177; 3.5</td><td>28.9 &#177; 4.3</td><td>0.56</td></tr><tr><td>Systolic blood pressure </td><td>125.2 &#177; 13.6</td><td>125.4 &#177; 12.5</td><td>0.67</td></tr><tr><td>Diastolic blood pressure</td><td>75.4 &#177; 10.1</td><td>74.9 &#177; 10.1</td><td>0.98</td></tr></table>
5afef5bc49b610bcfcc0ac3805b81db28ef66e9f04c8f314e7176473bfca59c6.png
simple
<table><tr><td> </td><td>FBP-OSEM</td><td>FBP-TOF</td><td>FBP-TPSF</td><td>OSEM-TOF</td><td>OSEM-TPSF</td><td>TOF-TPSF</td></tr><tr><td>2 min</td><td>0.40</td><td>0.74</td><td>0.64</td><td>0.53</td><td>0.64</td><td>0.87</td></tr><tr><td>5 min</td><td>0.34</td><td>0.66</td><td>0.55</td><td>0.59</td><td>0.71</td><td>0.87</td></tr><tr><td>10 min</td><td>0.86</td><td>0.98</td><td>0.73</td><td>0.87</td><td>0.86</td><td>0.85</td></tr><tr><td>30 min</td><td>0.91</td><td>0.94</td><td>0.80</td><td>0.85</td><td>0.90</td><td>0.94</td></tr></table>
ada5289422910ccc10af80923c345b991a42e6f2ea9dfb1905b3df22bd024154.png
complex
<table><tr><td></td><td>Active Synchronous</td><td>Passive Synchronous</td><td>Active Synchronous</td><td>Active Asynchronous</td></tr><tr><td></td><td>Congruent</td><td>Congruent</td><td>Incongruent</td><td>Congruent</td></tr><tr><td colspan="5">FMD group</td></tr><tr><td>Ownership statements vs. Ownership controls</td><td>Z = -3.757; <i>p</i> &lt; 0.001</td><td>Z = -3.427; <i>p</i> = 0.001</td><td>Z = -2.379; <i>p</i> = 0.017</td><td>Z = -0.880; <i>p</i> = 0.379</td></tr><tr><td>Agency statements Vs. Agency controls</td><td>Z = -3.542; <i>p</i> &lt; 0.001</td><td>Z = -1.700; <i>p</i> = 0.089</td><td>Z = -4.019; <i>p</i> &lt; 0.001</td><td>Z = -0.916; <i>p</i> = 0.360</td></tr><tr><td>Ownership statements vs. Agency statements</td><td>Z = -2.534; <i>p</i> = 0.011</td><td>Z = -3.082; <i>p</i> = 0.002</td><td>Z = -3.827; <i>p</i> &lt; 0.001</td><td>Z = -2.508; <i>p</i> = 0.012</td></tr><tr><td colspan="5">HC group</td></tr><tr><td>Ownership statements vs. Ownership controls</td><td>Z = -3.666; <i>p</i> &lt; 0.001</td><td>Z = -3.626; <i>p</i> &lt; 0.001</td><td>Z = -3.163; <i>p</i> = 0.002</td><td>Z = -0.427; <i>p</i> = 0.669</td></tr><tr><td>Agency statements vs. Agency controls</td><td>Z = -3.925; <i>p</i> &lt; 0.001</td><td>Z = -0.987; <i>p</i> = 0.324</td><td>Z = -3.927; <i>p</i> &lt; 0.001</td><td>Z = -1.442; <i>p</i> = 0.149</td></tr><tr><td>Ownership statements vs. Agency statements</td><td>Z = -3.341; <i>p</i> = 0.001</td><td>Z = -2.834; <i>p</i> = 0.005</td><td>Z = -3.788; <i>p</i> &lt; 0.001</td><td>Z = -1.661; <i>p</i> = 0.097</td></tr></table>
2323a74239287f162092eb3b49322d3c5a23a0b3c0dfe03e0f42ee1d75359ee9.png
complex
<table><tr><td rowspan="2">Storage Condition (&#8722;80 &#176;C)</td><td colspan="3">Fucoxanthin</td><td colspan="3">Fucoxanthinol</td></tr><tr><td>Concentration (ng/mL)</td><td>Accuracy (%)</td><td>RSD (%)</td><td>Concentration (ng/mL)</td><td>Accuracy (%)</td><td>RSD (%)</td></tr><tr><td rowspan="3">1 freeze-thaw cycle</td><td>12.25</td><td>82.55</td><td>4.03</td><td>9.4</td><td>99.60</td><td>4.83</td></tr><tr><td>90.0</td><td>87.40</td><td>1.78</td><td>75</td><td>89.05</td><td>5.00</td></tr><tr><td>360</td><td>80.35</td><td>3.78</td><td>300</td><td>89.45</td><td>4.03</td></tr><tr><td rowspan="3">2 freeze-thaw cycles</td><td>12.25</td><td>102.20</td><td>6.64</td><td>9.4</td><td>101.90</td><td>12.63</td></tr><tr><td>90.0</td><td>80.35</td><td>0.44</td><td>75</td><td>91.30</td><td>8.83</td></tr><tr><td>360</td><td>86.75</td><td>3.67</td><td>300</td><td>91.75</td><td>8.25</td></tr><tr><td rowspan="3">3 freeze-thaw cycles</td><td>12.25</td><td>113.0</td><td>7.51</td><td>9.4</td><td>118.0</td><td>5.52</td></tr><tr><td>90.0</td><td>90.55</td><td>3.36</td><td>75</td><td>99.70</td><td>6.10</td></tr><tr><td>360</td><td>85.95</td><td>1.89</td><td>300</td><td>98.60</td><td>0.14</td></tr></table>
79674d533fb8935f5b1355442473d297eb09350653091c764a1221c565145873.png
complex
<table><tr><td>Characteristic</td><td>Frequency</td><td>Percent</td><td>M (SD)</td><td>Range</td></tr><tr><td>Age</td><td></td><td></td><td>51.50 (14.56)</td><td>18&#8211;89</td></tr><tr><td>Duration of RD symptoms in years</td><td></td><td></td><td>18.84 (16.49)</td><td>0&#8211;75</td></tr><tr><td>Years since RD diagnosis</td><td></td><td></td><td>9.76 (11.46)</td><td>0&#8211;70</td></tr><tr><td colspan="5">Number of RDs perparticipant</td></tr><tr><td> 1</td><td>1058</td><td>87%</td><td></td><td></td></tr><tr><td> 2</td><td>130</td><td>11%</td><td></td><td></td></tr><tr><td> 3</td><td>22</td><td>2%</td><td></td><td></td></tr><tr><td> 4</td><td>4</td><td>&lt;1%</td><td></td><td></td></tr><tr><td> 5</td><td>4</td><td>&lt;1%</td><td></td><td></td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Female</td><td>935</td><td>77%</td><td></td><td></td></tr><tr><td> Male</td><td>279</td><td>23%</td><td></td><td></td></tr><tr><td> Other</td><td>4</td><td>&lt;1%</td><td></td><td></td></tr><tr><td colspan="5">Income</td></tr><tr><td> under $10,000</td><td>58</td><td>5%</td><td></td><td></td></tr><tr><td> $10,000&#8211;20,000</td><td>95</td><td>8%</td><td></td><td></td></tr><tr><td> $20,001&#8211;30,000</td><td>118</td><td>10%</td><td></td><td></td></tr><tr><td> $30,001&#8211;45,000</td><td>127</td><td>11%</td><td></td><td></td></tr><tr><td> $45,001&#8211;60,000</td><td>161</td><td>14%</td><td></td><td></td></tr><tr><td> $60,001&#8211;75,000</td><td>128</td><td>11%</td><td></td><td></td></tr><tr><td> $75,001&#8211;90,000</td><td>107</td><td>9%</td><td></td><td></td></tr><tr><td> $90,001 and above</td><td>376</td><td>32%</td><td></td><td></td></tr><tr><td colspan="5">Race/ethnicity</td></tr><tr><td> American Indian orAlaska native</td><td>11</td><td>1%</td><td></td><td></td></tr><tr><td> Asian</td><td>23</td><td>2%</td><td></td><td></td></tr><tr><td> Black or African American</td><td>13</td><td>1%</td><td></td><td></td></tr><tr><td> Hispanic or Latino/a</td><td>31</td><td>3%</td><td></td><td></td></tr><tr><td> Native Hawaiian orPacific Islander</td><td>2</td><td>6%</td><td></td><td></td></tr><tr><td> White</td><td>1149</td><td>94%</td><td></td><td></td></tr><tr><td> Other</td><td>31</td><td>3%</td><td></td><td></td></tr></table>
ee5d94776d6a6c2ea2ddf3aad8222d83064a19de617cc163df26bde844f9c431.png
simple
<table><tr><td> </td><td>Tumbi hospital (%)</td><td>Dodoma hospital (%)</td><td>All (%)</td></tr><tr><td>Occupational injury</td><td> </td><td> </td><td> </td></tr><tr><td>Needle stick (used needle)</td><td>64 (37.4)*</td><td>41 (17.8)</td><td>105 (26.2)</td></tr><tr><td>Blood stained sharp objects</td><td>64 (37.4)*</td><td>37 (16.1)</td><td>101 (25.2)</td></tr><tr><td>Blood or body fluid splash</td><td>81 (47.4)*</td><td>73 (31.7)</td><td>154 (38.4)</td></tr><tr><td>Blood or body fluid contact with ulcerated or abraded skin</td><td>63 (36.8)*</td><td>38 (16.5)</td><td>101 (25.2)</td></tr><tr><td>Human bite</td><td>45 (26.3)*</td><td>21 (9.1)</td><td>66 (16.5)</td></tr><tr><td>At least one occupational injury</td><td>98 (57.3)*</td><td>94 (40.9)</td><td>192 (47.9)</td></tr><tr><td>Managing occupational exposure</td><td> </td><td> </td><td> </td></tr><tr><td>Good practice</td><td>118 (69.0)</td><td>158 (68.7)</td><td>276 (68.8)</td></tr></table>
06a7337dfe205cd42db4ca8020c4f76715abe975d6250ba3c3decde8e3c911c5.png
simple
<table><tr><td>Year</td><td>2010</td><td>2010</td></tr><tr><td>Group</td><td>BFM</td><td>Japanese Childhood AML Cooperative Study</td></tr><tr><td>Induction Therapy</td><td>ATRA+IDA+VP/CA+VP+DNR</td><td>ATRA+IDA+CA</td></tr><tr><td>No. of Pts</td><td>81</td><td>58</td></tr><tr><td>Consolidation Therapy</td><td>CA+IDA+HD-CA+VP16</td><td>HD-CA+MTZ+ATRA+PIRARUBI CIN+ACLARUBICIN</td></tr><tr><td>EFS (%)</td><td>73 (5 years)</td><td>91 (7 years)</td></tr><tr><td>OS (%)</td><td>89 (5 years)</td><td>93 (7 years)</td></tr></table>
2f6727286b8ea44c6df2062d865c8b28daa7652404cddac9a367ddc2eac8d7f7.png
complex
<table><tr><td rowspan="2">Size of facial image</td><td colspan="3">Size of LBP operator</td></tr><tr><td>3 &#215; 3 operator</td><td>5 &#215; 5 operator</td><td>7 &#215; 7 operator</td></tr><tr><td>64 &#215; 64</td><td>16.617</td><td>14.656</td><td>13.966</td></tr><tr><td>96 &#215; 96</td><td>15.584</td><td>13.503</td><td>13.612</td></tr><tr><td>128 &#215; 128</td><td>16.784</td><td>12.878</td><td>12.693</td></tr><tr><td>160 &#215; 160</td><td>16.803</td><td>13.376</td><td>12.730</td></tr><tr><td>192 &#215; 192</td><td>17.711</td><td>13.809</td><td>13.119</td></tr><tr><td>220 &#215; 250</td><td>18.365</td><td>13.460</td><td>12.813</td></tr></table>
bbd7cbf39e0157bf7618d42a3b5af5562d592a71a48eac660426147fc31c7753.png
simple
<table><tr><td>Variables</td><td>Group C (<i>n</i> = 35)</td><td>Group T (n = 35)</td><td><i>P</i> value</td></tr><tr><td>Time from TAP to incision(min)</td><td>47.0(44.3&#8211;50.2)</td><td>46.9(43.5&#8211;47.8)</td><td>0.626</td></tr><tr><td>Incision length(cm)</td><td>30.0(23.8&#8211;35.0)</td><td>25.0(20.0&#8211;35.0)</td><td>0.703</td></tr><tr><td>Operation time(min)</td><td>193.9(172.7&#8211;287.1)</td><td>193.8(159.7&#8211;261.9)</td><td>0.377</td></tr><tr><td>Intraoperative intravenous crystalloids</td><td>2250(1750&#8211;3030)</td><td>2250(1750&#8211;3120)</td><td>0.872</td></tr><tr><td>Estimated blood loss (mL)</td><td>200.0(100.00&#8211;350.0)</td><td>200.0(100.0&#8211;400.0)</td><td>0.345</td></tr><tr><td>Urine output(mL)</td><td>200.0(150.0&#8211;400.0)</td><td>200.0(140.0&#8211;400.0)</td><td>0.894</td></tr><tr><td>Intraoperative Propofol(mg)</td><td>1168.7(986.0&#8211;1681.1)</td><td>1121.7(866.1&#8211;1291.2)</td><td>0.276</td></tr><tr><td>Extubation time(min)</td><td>59.9(51.7&#8211;85.0)</td><td>45.35(39.9&#8211;61.25)*</td><td>0.022</td></tr><tr><td>Surgeon</td><td></td><td></td><td>0.097</td></tr><tr><td> Group 1</td><td>10</td><td>10</td><td></td></tr><tr><td> Group 2</td><td>3</td><td>0</td><td></td></tr><tr><td> Group 3</td><td>11</td><td>5</td><td></td></tr><tr><td> Group 4</td><td>7</td><td>13</td><td></td></tr><tr><td> Group 5</td><td>4</td><td>7</td><td></td></tr><tr><td>Anesthetist</td><td></td><td></td><td>0.632</td></tr><tr><td> Group 1</td><td>19</td><td>17</td><td></td></tr><tr><td> Group 2</td><td>16</td><td>18</td><td></td></tr><tr><td>Intraoperative ephedrine use</td><td></td><td></td><td>1.000</td></tr><tr><td> yes(n)</td><td>4</td><td>5</td><td></td></tr><tr><td> No(n)</td><td>31</td><td>30</td><td></td></tr><tr><td>Intraoperative antihypertensives</td><td></td><td></td><td>0.002</td></tr><tr><td> yes(n)</td><td>24</td><td>10*</td><td></td></tr><tr><td> No(n)</td><td>11</td><td>25</td><td></td></tr></table>
39e0023309ba90b5c9bedce1bc13e19f85e3d160a54d75aa60a05633d3e73ad7.png
complex
<table><tr><td rowspan="2">Fraction or COMBI</td><td colspan="3">Primary (% activity)</td><td colspan="4">Secondary (EC<sub>50</sub>, &#956;g/mL)</td></tr><tr><td>&#956;g/mL</td><td>MAR3D7<sup>a</sup></td><td>MARK1<sup>b</sup></td><td>HEK293<sup>c</sup></td><td>BJ<sup>d</sup></td><td>MAR3D7<sup>a</sup></td><td>MARK1<sup>b</sup></td></tr><tr><td>f8/c9</td><td>23.68</td><td>43.4</td><td>37</td><td>2.15</td><td>&#8722;0.85</td><td></td><td></td></tr><tr><td>f9/c8</td><td>35.75</td><td>95.2</td><td>80.2</td><td>2.52</td><td>6.63</td><td>8.15</td><td>7.57</td></tr><tr><td>f10/c7</td><td>23.68</td><td>97.4</td><td>95</td><td>8.13</td><td>4.91</td><td>0.53</td><td>0.63</td></tr><tr><td>f11/c6</td><td>14.39</td><td>96.9</td><td>96.5</td><td>5.29</td><td>0</td><td>2.02</td><td>3.6</td></tr><tr><td>f12/c5</td><td>8.37</td><td>92.8</td><td>93.4</td><td>7.42</td><td>0.7</td><td>0.61</td><td>0.81</td></tr><tr><td>f13/c5</td><td>5.57</td><td>92</td><td>92.4</td><td>3.59</td><td>0.45</td><td>0.39</td><td>0.45</td></tr><tr><td>f14/c4</td><td>5.11</td><td>89.9</td><td>96</td><td>5.05</td><td>&#8722;0.48</td><td>0.86</td><td>2.07</td></tr><tr><td>f15/c4</td><td>7.43</td><td>84.9</td><td>97.6</td><td>6.94</td><td>0.56</td><td>1.11</td><td>10.61</td></tr><tr><td>f16/c3</td><td>11.14</td><td>84.4</td><td>93.7</td><td>10.1</td><td>1.13</td><td>0.21</td><td>4.77</td></tr><tr><td>f17/c2</td><td>6.96</td><td>95.7</td><td>94.6</td><td>1.09</td><td>1.48</td><td>1.66</td><td>1.7</td></tr><tr><td>f18/c2</td><td>5.11</td><td>76.9</td><td>39</td><td>3.12</td><td>&#8722;0.94</td><td></td><td></td></tr><tr><td>f19/c1</td><td>4.18</td><td>35.6</td><td>21.2</td><td>1.29</td><td>0.64</td><td></td><td></td></tr></table>
bb6747a6e8055e892746d51f04fdfe963f84ece34e447ee932b035db82e7e425.png
simple
<table><tr><td>Characteristic</td><td>mean &#177; SD, or N(%)</td></tr><tr><td>Gender</td><td> </td></tr><tr><td>Male</td><td>85 (38.3)</td></tr><tr><td>Female</td><td>137(61.7)</td></tr><tr><td>Marital status</td><td> </td></tr><tr><td>Married</td><td>205 (92.3)</td></tr><tr><td>Not married</td><td>17 (7.7)</td></tr><tr><td>Mean age (years)</td><td>64.5 &#177; 6.4</td></tr><tr><td>Age categories</td><td> </td></tr><tr><td>&lt;60</td><td>48 (21.6)</td></tr><tr><td>60-69</td><td>119 (53.6)</td></tr><tr><td>&#8805;70</td><td>55 (24.8)</td></tr><tr><td>Education</td><td> </td></tr><tr><td>Illiteracy or elementary school</td><td>21 (9.5)</td></tr><tr><td>Junior high school</td><td>85 (38.3)</td></tr><tr><td>Senior high school</td><td>64 (28.8)</td></tr><tr><td>Technical school or college</td><td>52 (23.4)</td></tr><tr><td>Family per capita month income (RMB)</td><td> </td></tr><tr><td>&lt;2000</td><td>102 (45.9)</td></tr><tr><td>&#8805;2000</td><td>120 (54.1)</td></tr><tr><td>Family history of diabetes</td><td> </td></tr><tr><td>Yes</td><td>86 (38.7)</td></tr><tr><td>No</td><td>136 (61.3)</td></tr><tr><td>Clinical symptoms</td><td> </td></tr><tr><td>Yes</td><td>96 (43.2)</td></tr><tr><td>No</td><td>126 (56.8)</td></tr><tr><td>Complications</td><td> </td></tr><tr><td>Yes</td><td>155 (69.8)</td></tr><tr><td>No</td><td>67 (30.2)</td></tr><tr><td>Duration of diabetes (years)</td><td> </td></tr><tr><td>&lt;4</td><td>64 (28.8)</td></tr><tr><td>5-9</td><td>72 (32.4)</td></tr><tr><td>10-14</td><td>56 (25.2)</td></tr><tr><td>&#8805;15</td><td>30 (13.5)</td></tr><tr><td>Mean BMI (kg/m<sup>2</sup>)</td><td>24.9 &#177; 3.4</td></tr><tr><td>BMI categories*</td><td> </td></tr><tr><td>&lt;24</td><td>91 (41.0)</td></tr><tr><td>&#8805;24</td><td>131 (59.0)</td></tr></table>
813a43a82740c248777ece55eb64604c1e815879099c247fb129e92855edf10d.png
complex
<table><tr><td rowspan="2">Adsorbent</td><td rowspan="2">Concentration (mg/L)</td><td rowspan="2">q<sub>e(exp)</sub> (mg/g)</td><td colspan="3">Pseudo first order values</td><td colspan="4">Pseudo second order values</td></tr><tr><td>q<sub>e(Calc)</sub> (mg/g)</td><td>k<sub>1</sub> (min<sup>&#8722;1</sup>)</td><td>R<sup>2</sup></td><td>q<sub>e(Calc)</sub> (mg g<sup>&#8722;1</sup>)</td><td>k<sub>2</sub> (g mg<sup>&#8722;1</sup> min<sup>&#8722;1</sup>)</td><td>h (mg g<sup>&#8722;1</sup>min<sup>&#8722;1</sup>)</td><td>R<sup>2</sup></td></tr><tr><td>CS</td><td>260</td><td>133.71</td><td>123.19</td><td>7.83 &#215; 10<sup>&#8722;2</sup></td><td>0.9959</td><td>142.85</td><td>7.96 &#215; 10<sup>&#8722;4</sup></td><td>16.24</td><td>0.9980</td></tr><tr><td></td><td>300</td><td>169.23</td><td>127.84</td><td>7.18 &#215; 10<sup>&#8722;2</sup></td><td>0.9950</td><td>169.49</td><td>8.27 &#215; 10<sup>&#8722;4</sup></td><td>23.75</td><td>0.9983</td></tr><tr><td></td><td>340</td><td>191.29</td><td>125.14</td><td>6.52 &#215; 10<sup>&#8722;2</sup></td><td>0.9915</td><td>196.07</td><td>8.42 &#215; 10<sup>&#8722;4</sup></td><td>32.37</td><td>0.9973</td></tr><tr><td></td><td>380</td><td>185.93</td><td>151.01</td><td>6.70 &#215; 10<sup>&#8722;2</sup></td><td>0.9953</td><td>199.60</td><td>5.74 &#215; 10<sup>&#8722;4</sup></td><td>22.87</td><td>0.9979</td></tr><tr><td>TS</td><td>260</td><td>133.71</td><td>74.03</td><td>10.13 &#215; 10<sup>&#8722;2</sup></td><td>0.9904</td><td>140.84</td><td>2.14 &#215; 10<sup>&#8722;3</sup></td><td>42.45</td><td>0.9985</td></tr><tr><td></td><td>300</td><td>145.91</td><td>92.44</td><td>9.70 &#215; 10<sup>&#8722;2</sup></td><td>0.9968</td><td>147.05</td><td>1.69 &#215; 10<sup>&#8722;3</sup></td><td>36.54</td><td>0.9985</td></tr><tr><td></td><td>340</td><td>167.81</td><td>104.47</td><td>9.44 &#215; 10<sup>&#8722;2</sup></td><td>0.9952</td><td>172.41</td><td>1.38 &#215; 10<sup>&#8722;3</sup></td><td>41.02</td><td>0.9978</td></tr><tr><td></td><td>380</td><td>149.19</td><td>73.65</td><td>9.05 &#215; 10<sup>&#8722;2</sup></td><td>0.9961</td><td>153.84</td><td>2.00 &#215; 10<sup>&#8722;3</sup></td><td>47.33</td><td>0.9980</td></tr></table>
da964f1fcb6465bac93732b3c471f1a198e40aefcdc5ca9f91cca5ab873cc2b3.png
simple
<table><tr><td>Item</td><td>X<sub>1</sub> (h)</td><td>X<sub>2</sub> (&#176;C)</td><td>X<sub>3</sub> (Ac:Al) a</td><td>X<sub>4</sub> (%)</td><td>Predicted yield (%)</td><td>Experimental yield (%)</td></tr><tr><td>Lipozyme<sup>&#174;</sup> RMIM</td><td>4.00</td><td>57.51</td><td>2.12</td><td>46.41</td><td>97.56 &#177; 3.61</td><td>94.21 &#177; 1.56</td></tr><tr><td>Novozym<sup>&#174;</sup> 435</td><td>3.65</td><td>57.84</td><td>2.35</td><td>34.38</td><td>98.39 &#177; 1.61</td><td>98.24 &#177; 0.11</td></tr></table>
a5649e5b1140cf6c25be4d68eb701ba537ddcdac9b6b0d1bb085e85310a68acd.png
complex
<table><tr><td>General recommendations</td><td>Rehabilitation should be undertaken by individuals with relevant skills and knowledge communication between teams and professionals over the rehabilitation pathway should occur</td></tr><tr><td>Pathway-specific recommendations</td><td> </td></tr><tr><td rowspan="5">During critical care stay</td><td>Assess risk of post-ICU disability</td></tr><tr><td>Commence goal-oriented rehabilitation early</td></tr><tr><td>Involve families and carers</td></tr><tr><td>Provide illness-related information to patient and family</td></tr><tr><td>Optimise provision of nutrition</td></tr><tr><td rowspan="3">At ICU discharge</td><td>Screen patient for physical and psychological issues</td></tr><tr><td>Plan individualised rehabilitation programme with defined goals</td></tr><tr><td>Provide information to patients and families about rehabilitation pathway, likely morbidity, ICU stay, and transition to general ward environment</td></tr><tr><td rowspan="4">During ward based care</td><td>Repeat screening for physical and psychological issues</td></tr><tr><td>Offer individualised rehabilitation programme with defined goals, provided by a multidisciplinary team</td></tr><tr><td>Regularly update rehabilitation programme and goals, making specialist referral where appropriate</td></tr><tr><td>Offer structured self-directed and supported rehabilitation manual for at least 6 weeks to appropriate patients</td></tr><tr><td rowspan="3">Prior to hospital discharge</td><td>Perform a functional assessment including physical and psychological elements, evaluating the impact on patient activities of daily living and participation</td></tr><tr><td>Ensure support for outstanding issues are arranged, including ongoing rehabilitation by community services</td></tr><tr><td>Provide patient and family with relevant information, including information about their ICU stay</td></tr><tr><td rowspan="2">At 2&#8211;3 months post-ICU discharge</td><td>Review patient as outpatient and perform functional assessment</td></tr><tr><td>Refer for ongoing rehabilitation and/or specialist support according to individual need</td></tr><tr><td colspan="2">Adapted from [36]</td></tr></table>
9534b6be11a8fe65016d58865f427986757de9dbb8abccc54ccea0ee16598428.png
simple
<table><tr><td>SNP-candidates</td><td>Morph</td><td>Uni</td><td>Rep</td><td>Total</td></tr><tr><td>Total</td><td></td><td>96231</td><td>74341</td><td>165790</td></tr><tr><td>Filter coverage</td><td></td><td>66569</td><td>57009</td><td>113776</td></tr><tr><td>Diff. Bwn. samples</td><td></td><td>21417</td><td>22252</td><td>42869</td></tr><tr><td>Diff. Bwn. morphs</td><td></td><td>11385</td><td>12953</td><td>23974</td></tr><tr><td>Delta &gt; 0.5</td><td>AC</td><td>396</td><td>285</td><td>672</td></tr><tr><td>Delta &gt; 0.5</td><td>SB</td><td>526</td><td>353</td><td>872</td></tr><tr><td>Delta &gt; 0.75</td><td>AC</td><td>95</td><td>68</td><td>159</td></tr><tr><td>Delta &gt; 0.75</td><td>SB</td><td>155</td><td>95</td><td>248</td></tr><tr><td>Delta &gt; 0.95</td><td>AC</td><td>17</td><td>13</td><td>30</td></tr><tr><td>Delta &gt; 0.95</td><td>SB</td><td>29</td><td>4</td><td>33</td></tr></table>
379b56c813922c1d3bc473188602b83215574eec46d4fdbed4b0ea262c848ccf.png
complex
<table><tr><td colspan="2">Variables</td><td>Frequency (percentage)</td></tr><tr><td colspan="2">Gender (females)</td><td>212 (58.1)</td></tr><tr><td colspan="2">Age at diagnosis (years):</td><td> </td></tr><tr><td> </td><td>&#8804; 5</td><td>24 (6.6)</td></tr><tr><td> </td><td>6&#8211;10</td><td>170 (46.6)</td></tr><tr><td> </td><td>11-15</td><td>171 (46.8)</td></tr><tr><td colspan="2">Residence (urban or semi-urban):</td><td>178 (48.8)</td></tr><tr><td colspan="2">Mitral valve disease</td><td>359 (98.4)</td></tr><tr><td colspan="2">Pure mitral stenosis (all grades)</td><td>35 (10.0)</td></tr><tr><td colspan="2">Mitral stenosis with regurgitation (all grades)</td><td>91 (24.9)</td></tr><tr><td colspan="2">Mitral regurgitation, no stenosis (all grades)</td><td>233 (63.8)</td></tr><tr><td colspan="2">Multi-valvular involvement (mitral valve disease included):</td><td> </td></tr><tr><td colspan="2">Aortic valve disease (regurgitation and/or stenosis)</td><td>257 (70.4)</td></tr><tr><td colspan="2">Tricuspid valve disease (regurgitation and/or stenosis)</td><td>299 (81.9)</td></tr><tr><td colspan="2">Mean transmitral diastolic pressure gradient (n = 108):</td><td> </td></tr><tr><td> </td><td>&lt;10 mmHg</td><td>4 (3.5)</td></tr><tr><td> </td><td>10 &#8211; 20 mmHg</td><td>40 (35.7)</td></tr><tr><td> </td><td>21 &#8211; 30 mmHg</td><td>61 (54.5)</td></tr><tr><td> </td><td>&gt;30 mmHg</td><td>3 (2.7)</td></tr><tr><td colspan="2">Mitral valve score for severe mitral stenosis (n = 19)</td><td> </td></tr><tr><td> </td><td>&#8804;8</td><td>2 (10.5)</td></tr><tr><td> </td><td>&gt;8</td><td>17 (89.5)</td></tr><tr><td colspan="2">Functional class (New York Heart Association):</td><td> </td></tr><tr><td> </td><td>I</td><td>10 (2.7)</td></tr><tr><td> </td><td>II</td><td>276 (75.6)</td></tr><tr><td> </td><td>III</td><td>27 (7.4)</td></tr><tr><td> </td><td>IV</td><td>52 (14.2)</td></tr><tr><td colspan="2">On secondary prophylaxis against recurrence of rheumatic fever (at the time of referral)</td><td>272 (74.5)</td></tr></table>
0a7ad8b253b3a58b450c7b0142c33968d6dcc4876605c8248382f147ad4274f7.png
complex
<table><tr><td>Variable</td><td>Odds ratio</td><td colspan="2">95% confidence interval</td><td>Coefficient</td><td>S.E.</td><td>Significance</td></tr><tr><td colspan="7"><i>Predisposing</i></td></tr><tr><td colspan="7">Race/ethnicity (ref. = non-Hispanic White)</td></tr><tr><td> Black</td><td>1.738</td><td>1.371</td><td>2.203</td><td>0.552</td><td>0.120</td><td>***</td></tr><tr><td> Hispanic/Latina</td><td>1.799</td><td>1.126</td><td>2.875</td><td>0.587</td><td>0.239</td><td>**</td></tr><tr><td> Other race</td><td>0.726</td><td>0.444</td><td>1.187</td><td>&#8722;0.319</td><td>0.250</td><td></td></tr><tr><td>Age</td><td>1.000</td><td>0.992</td><td>1.009</td><td>0.001</td><td>0.004</td><td></td></tr><tr><td colspan="7">Educational attainment (ref. = no high school diploma)</td></tr><tr><td> High school</td><td>1.092</td><td>0.781</td><td>1.529</td><td>0.088</td><td>0.171</td><td></td></tr><tr><td> Some college</td><td>1.068</td><td>0.743</td><td>1.535</td><td>0.065</td><td>0.185</td><td></td></tr><tr><td> College or greater</td><td>1.349</td><td>0.941</td><td>1.935</td><td>0.299</td><td>0.184</td><td></td></tr><tr><td>Married</td><td>1.304</td><td>1.094</td><td>1.554</td><td>0.265</td><td>0.089</td><td>**</td></tr><tr><td colspan="7"><i>Enabling</i></td></tr><tr><td>Poverty status (1 = poor, 0 = non-poor)</td><td>0.979</td><td>0.714</td><td>1.341</td><td>&#8722;0.021</td><td>0.160</td><td></td></tr><tr><td>Employment status (1 = employed, others = 0)</td><td>1.206</td><td>0.994</td><td>1.463</td><td>0.186</td><td>0.098</td><td>*</td></tr><tr><td>Insured (1 = having health insurance, 0 = no health insurance)</td><td>3.857</td><td>2.616</td><td>5.687</td><td>1.349</td><td>0.198</td><td>***</td></tr><tr><td colspan="7">Source of healthcare</td></tr><tr><td> Community health center</td><td>2.728</td><td>1.449</td><td>5.138</td><td>1.003</td><td>0.322</td><td>**</td></tr><tr><td> Private practice</td><td>2.053</td><td>1.228</td><td>3.432</td><td>0.719</td><td>0.262</td><td>**</td></tr><tr><td> Outpatient clinic</td><td>1.671</td><td>0.882</td><td>3.166</td><td>0.513</td><td>0.326</td><td></td></tr><tr><td>Experienced medical discrimination</td><td>0.784</td><td>0.563</td><td>1.092</td><td>&#8722;0.243</td><td>0.168</td><td></td></tr><tr><td>Community connection</td><td>1.056</td><td>0.988</td><td>1.130</td><td>0.054</td><td>0.034</td><td></td></tr><tr><td>Group membership</td><td>1.060</td><td>0.996</td><td>1.128</td><td>0.058</td><td>0.031</td><td>*</td></tr><tr><td>Respondent residence&#8212;city (ref = suburban)</td><td>1.026</td><td>0.849</td><td>1.240</td><td>0.025</td><td>0.096</td><td></td></tr><tr><td colspan="7"><i>Need</i></td></tr><tr><td>Poor or fair self-rated health</td><td>0.700</td><td>0.570</td><td>0.861</td><td>&#8722;0.356</td><td>0.105</td><td>***</td></tr><tr><td>Constant</td><td></td><td></td><td></td><td>&#8722;1.475</td><td>0.462</td><td>***</td></tr><tr><td>N</td><td>3261</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Akaike Inf. Crit.</td><td>3613.910</td><td></td><td></td><td></td><td></td><td></td></tr></table>
2c4304bf21d681fde93952ffa07856f71c210489d1be3e3f6a250bfdc3f3ce2c.png
complex
<table><tr><td colspan="4">Method: 95% LSD</td></tr><tr><td>Pass</td><td>Count</td><td>LS Mean</td><td>Homogeneous Groups</td></tr><tr><td>0</td><td>21</td><td>1135.93</td><td>X</td></tr><tr><td>1</td><td>21</td><td>1245.32</td><td>X</td></tr><tr><td>2</td><td>21</td><td>1285.31</td><td>X</td></tr><tr><td>3</td><td>21</td><td>1287.18</td><td>X</td></tr><tr><td>4</td><td>21</td><td>1307.01</td><td>X</td></tr><tr><td>5</td><td>21</td><td>1320.83</td><td>X</td></tr></table>
b775f59626bd9ee98137c946d1f2dcd84e40c50941e355305d20fa52817db472.png
complex
<table><tr><td>Transgene</td><td>Description</td><td>Efficacy</td><td>Promoter</td><td>Assay</td><td>Publication</td></tr><tr><td>R2</td><td>SIV <i>rev</i> + <i>env</i> shRNA</td><td>68%&#8211;80% inhibition of viral replication</td><td>U6</td><td>SIV challenge, CEMx174 cell line</td><td>Park<i>et al</i>. 2005 [77]</td></tr><tr><td>L2R</td><td>HIV LTR + <i>rev</i> miRNA cassette</td><td>&gt;98% inhibition of viral replication</td><td>CMV</td><td rowspan="4">HIV challenge, U87.CD4.CXCR4 cell line</td><td rowspan="4">Park<i>et al</i>. 2009 [78]</td></tr><tr><td>TAR + L2R</td><td>Tat inducible HIV LTR + <i>rev</i> miRNA cassette + TAR</td><td>&gt;98% inhibition of viral replication</td><td>Tat inducible LTR-Hsp fusion</td></tr><tr><td>TAR + R</td><td>Tat inducible <i>rev</i> miRNA cassette + TAR</td><td>&gt;98% inhibition of viral replication</td><td>Tat-inducible LTR-Hsp fusion</td></tr><tr><td>TAR</td><td>TAR</td><td>&gt;98% inhibition of viral replication</td><td>LTR</td></tr><tr><td>Sh1</td><td>anti <i>tat</i>/<i>rev</i> shRNA</td><td>4 log reduction of viral replication</td><td>U6</td><td rowspan="2">HIV challenge, CD34-derived macrophages</td><td rowspan="4">Taylor<i>et al</i>. 2008 [79]</td></tr><tr><td>C46</td><td>membrane associated fusion inhibitor</td><td>4 log reduction of viral replication</td><td>MSCV</td></tr><tr><td>Sh1 + C46 + RevM10</td><td><i>tat</i>/<i>rev</i> shRNA + membrane-associated fusion inhibitor + dominant negative Rev</td><td>significantly increased relative to C46 alone</td><td>U6, MSCV, PGK</td><td rowspan="2">HIV challenge of protected and unprotected cells in CEMx174 cell line</td></tr><tr><td rowspan="3">C46</td><td rowspan="3">membrane associated fusion inhibitor</td><td>5.2-fold increase in cell survival +3.1-fold decrease in HIV p24/cell</td><td>MSCV</td></tr><tr><td>4 log reduction of viral replication</td><td>SFFV</td><td>SHIV challenge, CEM.NKR-CCR5 lymphocytes</td><td rowspan="7">Kiem<i>et al</i>. 2010 [27]</td></tr><tr><td>15&#8211;20 fold reduction of viral replication</td><td>SFFV</td><td rowspan="3">SHIV or HIV single viral cycle challenge, MAGI-CCR5 cell line</td></tr><tr><td>SI + C46</td><td><i>tat</i>/<i>rev</i> shRNA + membrane associated fusion inhibitor</td><td>5 fold reduction of viral replication</td><td>U6, SFFV</td></tr><tr><td rowspan="2">SII + SI + R5 + C46</td><td rowspan="2">two <i>tat</i>/<i>rev</i> shRNAs + CCR5 shRNA + membrane associated fusion inhibitor</td><td>23 fold reduction of viral replication</td><td rowspan="2">H1, SFFV</td></tr><tr><td>4 log reduction of viral replication</td><td rowspan="3">SHIV challenge, CEM.NKR-CCR5 lymphocytes</td></tr><tr><td>SI + C46</td><td><i>tat</i>/<i>rev</i> shRNA + C46</td><td>4 log reduction of viral replication</td><td>U6, SFFV</td></tr><tr><td>SII + SI + R5</td><td>two <i>tat</i>/<i>rev</i> shRNAs + CCR5 shRNA</td><td>180 fold reduction of viral replication</td><td>H1</td></tr></table>
665b222e5ce29ce8d06153ebb98450a337a05f0b6b032198767475a59e556cd6.png
complex
<table><tr><td>Characteristic*</td><td>Type 2 diabetes cases (n=1775)</td><td>Controls (n=1295)</td><td><i>p </i>value<sup>&#8224;</sup></td></tr><tr><td>Age (years)</td><td>65.8 (9.2)</td><td>65.7 (9.1)</td><td>0.93</td></tr><tr><td>Female, n (%)</td><td>1,014 (57)</td><td>731 (56)</td><td>0.71</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>30.6 (5.6)</td><td>28.9 (5.4)</td><td>&lt;0.0001</td></tr><tr><td colspan="3">Race/ethnicity, n (%)</td><td>0.15</td></tr><tr><td>Caucasian</td><td>608 (34)</td><td>493 (38)</td><td> </td></tr><tr><td>Hispanic</td><td>937 (53)</td><td>642 (50)</td><td> </td></tr><tr><td>African American</td><td>216 (12)</td><td>153 (12)</td><td> </td></tr><tr><td colspan="4">Blood pressure (mm Hg)</td></tr><tr><td>Systolic</td><td>149 (19)</td><td>148 (18)</td><td>0.32</td></tr><tr><td>Diastolic</td><td>85 (11)</td><td>86 (10)</td><td>0.0008</td></tr><tr><td>Hypercholesterolemia, n (%)<sup>&#8225;</sup></td><td>1,017 (57)</td><td>673 (52)</td><td>0.003</td></tr><tr><td>History of LVH, n (%)</td><td>319 (18)</td><td>174 (13)</td><td>0.0007</td></tr><tr><td>History of CHF, n (%)**</td><td>84 (5)</td><td>25 (2)</td><td>&lt;0.0001</td></tr><tr><td>History of smoking, n (%)</td><td>706 (40)</td><td>507 (39)</td><td>0.73</td></tr></table>
8ac3c8856e73c997c6ac63e310bef0551b44b150792408e81759db3308fbc2fa.png
simple
<table><tr><td></td><td>ARVC Total (<i>N</i> = 155)</td><td>ECG-positive ARVC (<i>N</i> = 89)</td><td>ECG-negative ARVC (<i>N</i> = 66)</td><td><i>p</i>-valueECG-positive vs ECG-negative</td></tr><tr><td>Age</td><td>42.1 &#177; 17.3</td><td>42.0 &#177; 17.4</td><td>41.7 &#177; 17.6</td><td>0.861</td></tr><tr><td>Sex (% male)</td><td>106 (68.4%)</td><td>63 (70.8%)</td><td>43 (65.2%)</td><td>0.488</td></tr><tr><td>Proband (%)</td><td>111 (71.6%)</td><td>71 (79.8%)</td><td>30 (45.5%)</td><td>0.012</td></tr><tr><td>I. Imaging</td><td>155 (100%)</td><td>89 (100%)</td><td>66 (100%)</td><td>1.000</td></tr><tr><td> major, %</td><td>111 (71.6%)</td><td>68 (76.4%)</td><td>43 (65.2%)</td><td>0.082</td></tr><tr><td> minor, %</td><td>89 (57.4%)</td><td>60 (67.4%)</td><td>29 (43.9%)</td><td>0.005</td></tr><tr><td>II. Tissue characterization of the wall, biopsies performed (% of patients)</td><td>70 (45.2%)</td><td>39 (43.8%)</td><td>31 (47.0%)</td><td>0.745</td></tr><tr><td> major, %</td><td>53 (75.7%)</td><td>31 (79.1%)</td><td>22 (71.0%)</td><td>0.576</td></tr><tr><td> minor, %</td><td>63 (90.0%)</td><td>36 (92.3%)</td><td>27 (87.1%)</td><td>0.454</td></tr><tr><td>III. Repolarization abnormality</td><td></td><td></td><td></td><td></td></tr><tr><td> major, %</td><td>54 (34.8%)</td><td>54 (60.7%)</td><td>0 (0.0%)</td><td>&lt;0.001</td></tr><tr><td> minor, %</td><td>20 (12.9%)</td><td>20 (22.5%)</td><td>0 (0.0%)</td><td>&lt;0.001</td></tr><tr><td>IV. Depolarization abnormality</td><td></td><td></td><td></td><td></td></tr><tr><td> major, %</td><td>13 (8.4%)</td><td>13 (14.6%)</td><td>0 (0.0%)</td><td>&lt;0.001</td></tr><tr><td> minor, %</td><td>17 (11.0%)</td><td>17 (19.1%)</td><td>0 (0.0%)</td><td>&lt;0.001</td></tr><tr><td>V. Arrhythmia</td><td></td><td></td><td></td><td></td></tr><tr><td> major, %</td><td>44 (28.4%)</td><td>26 (29.2%)</td><td>18 (27.3%)</td><td>0.858</td></tr><tr><td> minor, %</td><td>64 (41.3%)</td><td>42 (47.2%)</td><td>22 (33.3%)</td><td>0.1000</td></tr><tr><td>VI. Family history</td><td></td><td></td><td></td><td></td></tr><tr><td> major, %</td><td>84 (54.2%)</td><td>48 (53.9%)</td><td>35 (53.0%)</td><td>1.000</td></tr><tr><td>VII. Genotype positive</td><td>48 (31.0%)</td><td>29 (32.6%)</td><td>19 (28.8%)</td><td>0.726</td></tr><tr><td> PLN (% genotype positive)</td><td>1 (2.1%)</td><td>0 (0.0%)</td><td>1 (5.3%)</td><td>0.396</td></tr><tr><td> TTN (% genotype positive)</td><td>11 (22.9%)</td><td>8 (27.6%)</td><td>3 (15.8%)</td><td>0.488</td></tr><tr><td> PKP2 (% genotype positive)</td><td>23 (47.9%)</td><td>17 (58.6%)</td><td>6 (31.2%)</td><td>0.083</td></tr><tr><td> DSC2 (% genotype positive)</td><td>2 (4.2%)</td><td>1 (3.5%)</td><td>1 (5.3%)</td><td>1.000</td></tr><tr><td> DSG2 (% genotype positive)</td><td>12 (25.0%)</td><td>6 (20.7%)</td><td>6 (31.5%)</td><td>0.501</td></tr><tr><td> DSG3 (% genotype positive)</td><td>2 (4.2%)</td><td>1 (3.5%)</td><td>1 (5.30%)</td><td>1.000</td></tr><tr><td> DSP (% genotype positive)</td><td>8 (16.7%)</td><td>6 (20.7%)</td><td>2 (10.56%)</td><td>0.4510</td></tr></table>
584eb2a2a249dc3ddcf492f1361499cfa17e4035852b7a4287c4daade5fd9633.png
simple
<table><tr><td>Residue</td><td>W</td><td>Ac(%)</td><td>Sn(%)</td><td>Sp(%)</td><td>Mcc</td><td>FPR</td></tr><tr><td></td><td>7</td><td>74.94</td><td>51.80</td><td>87.33</td><td>0.43</td><td>0.13</td></tr><tr><td></td><td>9</td><td>75.02</td><td>52.17</td><td>87.26</td><td>0.44</td><td>0.13</td></tr><tr><td>S</td><td>11</td><td>75.54</td><td>53.00</td><td>87.61</td><td>0.45</td><td>0.12</td></tr><tr><td></td><td>13</td><td>75.78</td><td>53.46</td><td>87.73</td><td>0.45</td><td>0.12</td></tr><tr><td></td><td>15</td><td>76.15</td><td>54.53</td><td>87.74</td><td>0.46</td><td>0.12</td></tr><tr><td></td><td>7</td><td>72.44</td><td>46.76</td><td>89.11</td><td>0.41</td><td>0.11</td></tr><tr><td></td><td>9</td><td>72.47</td><td>48.14</td><td>88.26</td><td>0.41</td><td>0.12</td></tr><tr><td>T</td><td>11</td><td>72.39</td><td>50.35</td><td>86.70</td><td>0.41</td><td>0.13</td></tr><tr><td></td><td>13</td><td>72.70</td><td>50.47</td><td>87.13</td><td>0.42</td><td>0.13</td></tr><tr><td></td><td>15</td><td>72.63</td><td>50.12</td><td>87.24</td><td>0.41</td><td>0.13</td></tr><tr><td></td><td>7</td><td>70.38</td><td>36.69</td><td>91.60</td><td>0.36</td><td>0.08</td></tr><tr><td></td><td>9</td><td>71.76</td><td>41.45</td><td>90.84</td><td>0.39</td><td>0.09</td></tr><tr><td>Y</td><td>11</td><td>71.84</td><td>41.12</td><td>91.19</td><td>0.39</td><td>0.09</td></tr><tr><td></td><td>13</td><td>72.31</td><td>42.11</td><td>91.33</td><td>0.40</td><td>0.09</td></tr><tr><td></td><td>15</td><td>72.12</td><td>40.74</td><td>91.88</td><td>0.39</td><td>0.08</td></tr></table>
79b854b71aae67297a9ef957ea4f20205bf0172f5a2940f40719e7472933923f.png
simple
<table><tr><td>Lesion</td><td>Age</td><td>Site</td><td>Cytomorphology</td><td>IHQ</td></tr><tr><td>Ganglioneuroma</td><td>80% &lt; 10 years</td><td>Retroperitoneum, posterior mediastinum, pelvis, head and neck</td><td>Mature ganglion cells, myxoid stroma, schwann cells, neurites</td><td>NSE, Syp, PS-100 (+)CK, Actin (-)</td></tr><tr><td>Ganglioneuroblastoma</td><td>90% &lt; 5 years</td><td>Retroperitoneum, posterior mediastinum</td><td>Neuroblasts, rosettes, neuropil, mature ganglion cells, myxoid stroma, schwann cells, neurites</td><td>NSE, Syp, PS-100 (+)CK, Actin (-)</td></tr><tr><td>Neuroblastoma</td><td>90% &lt; 5 years</td><td>Retroperitoneum, posterior mediastinum</td><td>Neuroblasts, rosettes, neuropil, necrosis</td><td>NSE, Syp, PS-100, NbP (+)CK, Actin (-)</td></tr><tr><td>Nerve Sheath Tumors</td><td>30&#8211;50 years</td><td>Posterior mediastinum, retroperitoneum, limbs</td><td>Cohesive aggregates of spindle cells, myxoid background</td><td>NSE, PS-100 (+)CK, Actin (-)</td></tr><tr><td>Proliferative fasciitis, Proliferative myositis</td><td>All ages</td><td>Limbs, head and neck, chest wall</td><td>Spindle cells, plump cells ganglion cell-like cells, lack of myxoid background</td><td>Vimentin, Actin, PS-100, SMA (+)Syp, CK, NSE (-)</td></tr></table>
698fb31bd5a0e096bbd02c7605fd281d6386dbb02131369091e6b2395faa7bd0.png
simple
<table><tr><td>Professional category</td><td>Grade</td><td>Experience/ service</td><td>Annual salary prior to OSD</td><td>Annual salary as at 1 July 2009</td><td>Total annual salary package as at 1 July 2009*</td><td>% Increase Year 1</td><td>% Accumulative increase Year 2</td></tr><tr><td>Medical intern</td><td> </td><td> </td><td>R117 501 ($13873)<sup>^</sup></td><td>R228 828 ($27016)</td><td>R314 023 ($37075)</td><td>31 % - 53%</td><td> </td></tr><tr><td>Medical officer (Community service)</td><td> </td><td> </td><td>R174 243 ($20572)</td><td>R286 086 ($33776)</td><td>R392 599 ($46352)</td><td>9.8 % - 18.9%</td><td>6.1%</td></tr><tr><td>Medical officer</td><td>Grade 1</td><td>0 &#8211; 4 years</td><td>R174 243 ($20572)</td><td>R332 016 ($39199)</td><td>R365 217 ($43119)</td><td>9 % - 25%</td><td>12%</td></tr><tr><td> </td><td>Grade 2</td><td>5 &#8211; 9 years</td><td>R247 512 ($29222)</td><td>R385 314 ($45492)</td><td>R423 846 ($50041)</td><td>26 % - 44%</td><td>14%</td></tr><tr><td> </td><td>Grade 3</td><td>&gt; 10 years</td><td>R391 026 ($46166)</td><td>R447 174 ($52795)</td><td>R491 892 ($58075)</td><td>46 % - 68%</td><td>20%</td></tr><tr><td>Medical specialist</td><td>Grade 1</td><td>0 &#8211; 4 years</td><td> </td><td> </td><td>R491 892 ($58075)</td><td>1.8 % - 18%</td><td>13%</td></tr><tr><td> </td><td>Grade 2</td><td>5 &#8211; 9 years</td><td> </td><td> </td><td>R554 109 ($65420)</td><td>14.7 % - 32.9%</td><td>20%</td></tr><tr><td> </td><td>Grade 3</td><td>&gt; 10 years</td><td> </td><td> </td><td>R624 198 ($73695)</td><td>29.2 % - 49.8%</td><td>26%</td></tr><tr><td>Principal specialist</td><td> </td><td> </td><td>R769 271 - R962 174 ($90823-113598)</td><td> </td><td>R932 399 ($110083)</td><td>4.6 % - 25.1%</td><td> </td></tr><tr><td>Chief specialist</td><td> </td><td> </td><td>R932 399 ($110083)</td><td> </td><td>R1.2 million ($141677)</td><td>7.9 % - 29%</td><td> </td></tr></table>
b484c319c77770aa1360ac177667ea6f8af97513ad77364808da0095613b270b.png
simple
<table><tr><td>Time (week)</td><td>Body weight (kg)</td><td>TEE (kcal/day)</td><td>Mean energy intake (kcal/day)</td><td>Net energy intake (kcal/day)</td></tr><tr><td>0</td><td>69.39</td><td>1934.33</td><td>3538.72</td><td>1604.39</td></tr><tr><td>S1</td><td>68.35</td><td>1884.53</td><td>1658</td><td>&#8722;226.53</td></tr><tr><td>S2</td><td>66.8</td><td>1835.21</td><td>1658</td><td>&#8722;177.21</td></tr><tr><td>S3</td><td>65.76</td><td>1786.36</td><td>1648.88</td><td>&#8722;137.48</td></tr><tr><td>S4</td><td>64.29</td><td>1737.6</td><td>1610.88</td><td>&#8722;126.72</td></tr><tr><td>S5</td><td>63.33</td><td>1691.55</td><td>1645.94</td><td>&#8722;45.61</td></tr><tr><td>S6</td><td>62.16</td><td>1643.45</td><td>1639.16</td><td>&#8722;4.29</td></tr><tr><td>S7</td><td>61.11</td><td>1595.75</td><td>1639.03</td><td>43.28</td></tr><tr><td>S8</td><td>60.31</td><td>1548.28</td><td>1634.84</td><td>86.56</td></tr><tr><td>S9</td><td>59.56</td><td>1500.8</td><td>1620.41</td><td>119.61</td></tr><tr><td>S10</td><td>58.71</td><td>1453.31</td><td>1595.31</td><td>142</td></tr><tr><td>S11</td><td>58.14</td><td>1405.63</td><td>1578.72</td><td>173.09</td></tr><tr><td>S12</td><td>57.28</td><td>1357.94</td><td>1525.16</td><td>167.22</td></tr><tr><td>S13</td><td>56.6</td><td>1346.8</td><td>1515.69</td><td>168.89</td></tr><tr><td>S14</td><td>56.16</td><td>1335.67</td><td>1492.84</td><td>157.17</td></tr><tr><td>S15</td><td>55.69</td><td>1324.54</td><td>1459.94</td><td>135.4</td></tr><tr><td>S16</td><td>54.7</td><td>1313.39</td><td>1430.5</td><td>117.11</td></tr><tr><td>S17</td><td>54.28</td><td>1302.28</td><td>1488.81</td><td>186.53</td></tr><tr><td>S18</td><td>54.08</td><td>1291.1</td><td>1486.44</td><td>195.34</td></tr><tr><td>S19</td><td>53.51</td><td>1281.22</td><td>1519.72</td><td>238.5</td></tr><tr><td>S20</td><td>53.18</td><td>1271.34</td><td>1515.47</td><td>244.13</td></tr><tr><td>S21</td><td>52.99</td><td>1261.46</td><td>1538.75</td><td>277.29</td></tr><tr><td>S22</td><td>52.9</td><td>1251.58</td><td>1554.06</td><td>302.48</td></tr><tr><td>S23</td><td>52.83</td><td>1241.7</td><td>1581.19</td><td>339.49</td></tr><tr><td>S24</td><td>52.57</td><td>1231.83</td><td>1641.63</td><td>409.8</td></tr></table>
282744cb84a1be8f7fbda241ac95872ff597f6b9d23c8020b8f2fda4ee79dde8.png
complex
<table><tr><td rowspan="2" colspan="2">Sliding window (SW)</td><td colspan="4">Most significant result</td></tr><tr><td colspan="4">HCV Genotype</td></tr><tr><td> </td><td> </td><td>1</td><td>2</td><td>1</td><td>2</td></tr><tr><td>SNPs/SW</td><td>No. of SW</td><td>SW</td><td>SW</td><td><i>P</i>value</td><td><i>P</i>value</td></tr><tr><td>1</td><td>4</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>2</td><td>3</td><td>S1.S2</td><td>S3.S4</td><td>0.0208*</td><td>0.0546</td></tr><tr><td>3</td><td>2</td><td>S2.S4</td><td>S2.S4</td><td>0.0540</td><td>0.1099</td></tr><tr><td>4</td><td>1</td><td>S1.S4</td><td>S1.S4</td><td>0.0397*</td><td>0.1585</td></tr></table>
95beac5f4d9ea484a4d8081533b327189338ba363e9da06f724e0065fb8478eb.png
simple
<table><tr><td></td><td>AP group</td><td>EP group</td></tr><tr><td>Number of patients</td><td>149</td><td>150</td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td> Male</td><td>114 (76.5 %)</td><td>113 (75.3 %)</td></tr><tr><td> Female</td><td>35 (23.5 %)</td><td>37 (24.7 %)</td></tr><tr><td>Median age, years (SD)<sup>a</sup></td><td>58.0 (13.0)</td><td>59.0 (13.0)</td></tr><tr><td>ECOG PS</td><td></td><td></td></tr><tr><td> 0</td><td>42 (28.2 %)</td><td>32 (21.3 %)</td></tr><tr><td> 1</td><td>107 (71.8 %)</td><td>118 (78.7 %)</td></tr><tr><td>Stage</td><td></td><td></td></tr><tr><td> IIIB</td><td>3 (2.0 %)</td><td>9 (6.0 %)</td></tr><tr><td> IV</td><td>146 (98.0 %)</td><td>141 (94.0 %)</td></tr><tr><td>Metastasis<sup>b</sup></td><td>148 (99.3 %)</td><td>144(96.0 %)</td></tr><tr><td> Lung</td><td>18 (12.1 %)</td><td>22 (14.7 %)</td></tr><tr><td> Bone</td><td>60 (40.3 %)</td><td>65 (43.3 %)</td></tr><tr><td> Brain</td><td>30 (20.1 %)</td><td>17 (11.3 %)</td></tr><tr><td> Liver</td><td>37 (24.8 %)</td><td>41 (27.3 %)</td></tr><tr><td> Other</td><td>82 (55.0 %)</td><td>78 (52.0 %)</td></tr></table>
9270382416c13f914e3b852045dff07e1a69fd460280055e84f0adb7ffc368b6.png
simple
<table><tr><td><i>MicroRNA</i></td><td><i>No. of brain-expressed target genes</i></td><td><i>No. of brain-expressed target genes</i>, P<i>&lt;0.05</i></td><td><i>P enrichment</i></td><td><i>No. of significant targets (corr)</i></td><td><i>No. of significant pathways</i></td></tr><tr><td><i>miR-499-5p</i></td><td>286</td><td>59</td><td>0.7172</td><td>4</td><td>12</td></tr><tr><td><i>miR-708-5p</i></td><td>174</td><td>37</td><td>0.9265</td><td>2</td><td>1</td></tr><tr><td><i>miR-1908-5p</i></td><td>56</td><td>17</td><td>0.1422</td><td>1</td><td>5</td></tr></table>
ca9ac49a9a452888ca67da675e15ab60228634c4a8f6eb2d673b114cd1fce550.png
simple
<table><tr><td> </td><td>FEV1 loss &lt; 15% (n = 28)</td><td>FEV1 loss &#8805;15% (n = 7)</td><td>p-value</td></tr><tr><td>Age</td><td>37 &#177; 13</td><td>45 &#177; 10</td><td>0.11</td></tr><tr><td>FEV1% pred.at T0</td><td>90 &#177; 17</td><td>98 &#177; 13</td><td>0.25</td></tr><tr><td>FEV1/FVC at T0</td><td>77 &#177; 9</td><td>72 &#177; 7</td><td>0.25</td></tr><tr><td>Current smoking</td><td>8 (29%)</td><td>2 (29%)</td><td>1.0</td></tr><tr><td>Pack years*</td><td>11 (17)</td><td>11 (17)</td><td>0.42</td></tr><tr><td>Total exposure time (months)</td><td>46 (91)</td><td>62 (169)</td><td>0.32</td></tr><tr><td>Symptomatic exposure time (months)</td><td>11 (19)</td><td>19 (49)</td><td>0.40</td></tr></table>
f47eb13dde6b7be0eabcc647474ddc80860306b61516b8cd94e30a49971605a6.png
simple
<table><tr><td>Antigen</td><td>Labeled cells</td><td>Clone</td><td>Conjugate</td><td>Source<sup>a</sup></td></tr><tr><td>CD45</td><td>Pan-leukocyte</td><td>YKIX716.13</td><td>PE</td><td>AbD Serotec</td></tr><tr><td>CD18</td><td>Pan-leukocyte</td><td>CA1.4E9</td><td>AF647</td><td>AbD Serotec</td></tr><tr><td>CD3</td><td>T cells</td><td>CA17.2A12</td><td>FITC</td><td>AbD Serotec</td></tr><tr><td>CD5</td><td>T cells</td><td>YKIX322.2</td><td>PE</td><td>AbD Serotec</td></tr><tr><td>CD4</td><td>T helper/regulatory cells, neutrophils, activated monocytes</td><td>YKIX302.9</td><td>FITC</td><td>AbD Serotec</td></tr><tr><td>CD8&#945;</td><td>Cytotoxic T cell</td><td>YCATE55.9</td><td>PE</td><td>AbD Serotec</td></tr><tr><td>TCR&#945;&#946;</td><td>T cells</td><td>CA15.8G7</td><td>None</td><td>UC-Davis</td></tr><tr><td>CD21</td><td>B cells</td><td>B-ly4</td><td>PE</td><td>BD-Biosciences</td></tr><tr><td>CD22</td><td>B cells</td><td>RFB4</td><td>PE</td><td>Abcam</td></tr><tr><td>CD14</td><td>Monocytes</td><td>Tu&#776;k4</td><td>PE</td><td>Dako</td></tr><tr><td>CD34</td><td>Stem cell</td><td>1H6</td><td>PE</td><td>BD-Biosciences</td></tr><tr><td>MHCII</td><td>Lymphocytes, monocytes</td><td>YKIX334.2</td><td>FITC</td><td>AbD Serotec</td></tr><tr><td>CD11b</td><td>Neutrophils, monocytes</td><td>CA16.3E10</td><td>None</td><td>AbD Serotec</td></tr><tr><td>CD11c</td><td>Monocytes, neutrophils,</td><td>CA11.6A1</td><td>None</td><td>AbD Serotec</td></tr><tr><td>CD11d</td><td>T subset, some monocytes</td><td>CA11.8H2</td><td>None</td><td>AbD Serotec</td></tr><tr><td>CD1c</td><td>T subset, B subset, monocytes</td><td>CA13.9H11</td><td>None</td><td>UC-Davis</td></tr><tr><td>Anti-pmn</td><td>Neutrophil</td><td>CAD048A</td><td>None</td><td>VMRD</td></tr><tr><td>CD90 (Thy-1)</td><td>Lymphocytes, monocytes, stem cells, eosinophils</td><td>CA1.4G8</td><td>None</td><td>UC-Davis</td></tr><tr><td>CD61</td><td>Platelets</td><td>SZ21</td><td>PE</td><td>Beckman-Coulter</td></tr></table>
44f6489546cca9d7418574b6be576d3b055854b503154b1f3e07f9a5651f2b5e.png
complex
<table><tr><td></td><td></td><td colspan="2">Results of conventional RT-PCR</td><td>Total</td></tr><tr><td></td><td></td><td>Positive</td><td>Negative</td><td></td></tr><tr><td>Results of NanoSign<sup>&#174; </sup>Influenza A/B antigen kit</td><td>Positive</td><td>158</td><td>23</td><td>181</td></tr><tr><td></td><td>Negative</td><td>41</td><td>801</td><td>842</td></tr><tr><td colspan="2">Total</td><td>199</td><td>824</td><td>1,023</td></tr></table>